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Abstract  
Histone deacetylases (HDACS) are a class of enzymes responsible for deacetylating the 
lysine residues of histones in chromatin. Inhibitors of these enzymes have shown promise in 
the treatment of a number of diseases including neurodegenerative diseases such as 
Alzheimer’s and Huntingdon’s disease, various cancers and most recently as a treatment for 
acute myocardial infarction. There are 11 zinc-dependent isoforms of HDACs present in 
humans but to date the majority of inhibitors of these enzymes have shown broad 
inhibition across all isoforms. This makes determination of the function of individual 
isoforms via chemical means very difficult. This thesis outlines three chemical methods; 
namely protein-ligand engineering, isoform-selective inhibitor discovery and activity based 
protein profiling that have been developed towards dissecting the function of individual 
histone deacetylase isoforms. A histone deacetylase 1 (HDAC1) mutant protein-ligand pair 
was designed with the aid of a computational docking program and site-directed 
mutagenesis used to introduce the mutation into HDAC1, which was expressed in Sf9 cells. 
A set of potentially selective inhibitors was then synthesised and tested for selectivity 
compared to the wild-type histone deacetylase 1. A novel series of potential isoform-
selective inhibitors were designed based around a cyclotetrapeptide capping group and a 2-
phenylamide zinc-binding group and joined together via a ruthenium catalysed cross-
metathesis reaction. These were then tested for selectivity against HDAC1 and HDAC2 in a 
fluorimetric assay. Finally, an activity-based protein profiling probe specific to HDACs was 
designed and synthesised. The probe was designed to have a reactive chloromethyl ketone 
head group that would irreversibly bind to HDACs as well as an alkyne group to allow 
attachment of a fluorescent tag via the copper mediated alkyne-azide ‘click’ reaction. The 
probe was then tested for its ability to label HDACs in vitro and an in vivo system expressing 
HDAC1.  
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Abbreviations 
aa  amino acids 
ABP  activity based probe 
AcNPV   Autographa calfornica nuclear polyhedrosis virus 
AfBP  affinity based probe  
AFU  Arbitrary fluorescence units 
Ar  Aryl 
aq  aqueous 
Bn  Benzyl 
bp  base pair(s) 
CHAP   cyclic hydroxamic acid peptide 
CM  cross-methathesis 
CMK  chloromethyl ketone 
CTCL  Cutaneous T-Cell Lymphoma            
d  doublet  
DCC  N,N’-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DMAP  N-dimethylaminopyridine 
δ  chemical shift 
ES  Electron Spray Ionisation 
eq  equivalent 
GST  glutathione-S-transferase 
h  hour(s) 
HAT  histone acetyltransferase 
HDAC  histone deacetylase 
HDACI  histone deacetylase inhibitor 
HDLP  histone deacetylase-like protein 
His  histidine protein purification tag 
HRP  horseradish peroxidase 
Hz  Hertz 
IC50  50% inhibition activity 
IR   Infrared (spectroscopy) 
J   coupling constant 
HDAC  lysine deacetylase 
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HDACI  lysine deacetylase inhibitor 
IP  Immuno-precipitation 
LB  Luria broth 
m   multiplet  
MCS  multiple cloning site 
Me  methyl 
Water  HPLC grade distilled water 
min  minute(s) 
mmol  millimole 
m.p.  melting point 
MS   Mass Spectrometry 
νmax  vibrational frequency 
NMR   Nuclear Magnetic Resonance 
PAGE  polacrylamide gel electrophoresis 
PE  petroleum ether 
Ph  Phenyl 
PLE  Protein-ligand engineering 
ppm  parts per million 
q   quartet  
quin  quintet 
ROS  reactive oxygen species 
rt  room temperature 
s   singlet  
SAHA  suberoylanilide hydroxamic acid 
SDS  sodium dodecylsulphate 
t   triplet 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
Triton X-100 polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether 
TSA  trichostatin A 
UV  Ultraviolet 
w/t  wild type 
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1 Introduction  
1.1  Aims and Objectives 
Histone deacetylase enzymes (HDACs) have been of great interest in recent years due to 
their potential as therapeutic targets and a large amount of research effort has been 
dedicated to finding out their precise biological role. The overarching aim of this project 
was to facilitate the dissection of the function of HDACs via a number of chemical biology 
approaches. The initial approach, pursued at the start of the project, was protein-ligand 
engineering which is described in Section 2.1. The second approach pursued was the more 
traditional isoform-selective inhibitor design (Section 2.2) and the final approach, pursued 
towards the end of the project, was activity based protein profiling (ABPP) which is 
described in Section 2.3. This introduction provides an overview of HDACs, including the 
challenges to dissecting their function, as well introducing the chemical biology approaches 
outlined above.  
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1.2 Epigenetics 
For a long time heritable changes were thought to be solely due to the combination of 
genes arising from the DNA sequence passed from parent to child with genetic variation a 
result of spontaneous and/or artificial mutation[1],[2]. This took precedence over the 
Lamarckian theory of the 19th century that attributed heritable changes to environmental 
interactions[3]. Since then evidence has emerged that environmental influences can lead to 
heritable traits on the macro scale such as acquired epigenetic modifications influencing not 
only the phenotypic development of mice but also the development of their offspring[4]. The 
field of epigenetics attempts to explain these heritable traits by looking at the various ways 
DNA and the surrounding proteins can be modified and how this affects DNA transcription. 
DNA itself can be modified by methylation while the surrounding proteins (histones) can be 
chemically modified in a number of ways to contribute to epigenetic control[5]. 
DNA methylation occurs mainly at the 5’ ring of CpG dinucleotides[6] (Fig. 1) although 
methylation at other sites has been found to occur in embryonic stem cells[7]. The primary 
consequence of DNA methylation is gene silencing[8], which ultimately impacts on cell 
differentiation. One recent example showed that insulin gene expression is regulated by 
DNA methylation in pancreatic islet cells[9].  
 
 
Fig. 1 – Methylation occurs on the 5’ ring of the cytosine in cytosine-phospho-guanine pairing. 
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Methylation of the DNA enhances transcriptional repression by assembling specialised 
nucleosomal structures specific to methylated DNA that act as repressors[10]. 
While examples such as this demonstrate the ways in which DNA transcription can be 
controlled by certain specific modifications, there is evidence to suggest that both DNA 
methylation and histone modification are cooperatively involved in gene silencing with one 
example being the reversal of DNA-methylation induced gene silencing by inhibition of 
HDACs[11]. This intrinsic link between DNA-methylation and control of chromatin 
modification demonstrates the complexity of the various layers of epigenetic control and 
identifies the DNA binding proteins - histones - as not just essential to the packaging of DNA 
but also its transcription.  
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1.3  Histones  
Histones are the major proteins responsible for the tight packing of DNA in chromatin and 
can be split into 6 major classes[12]. These are H1, H2A, H2B, H3, H4 and the archaeal 
histones. In addition to these there is also the minor H5 histone which is closely related to 
H1[13]. In the histone-DNA complexes (also known as nucleosomes) DNA is wrapped around 
octamers of histone proteins termed the core histones with the H1 histones acting as 
linkers between each core holding the DNA in place and stabilising the overall structure Fig. 
2[14]. The core histones comprise two of each of the H2A, H2B, H3 and H4 histones and each 
core accommodates approximately 147 base pairs of DNA[15]. The nucleosomes are bound 
together into a tightly packed structure and form part of a much bigger chromatin super 
structure Fig. 3.  
  
 
 Fig. 2 – Binding of the core histones to form an octamer comprising of a H3-H4 tetramer bound to two 
H2A-H2B dimers
[14]
. 
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Initial studies of histones suggested that they were responsible for transcriptional 
repression and that it was the role of transcriptional activators to overcome this 
repression[16]. Subsequent studies have shown histones to be involved in transcriptional 
activation as well as repression[17] and have led to the concept of a histone code that is 
responsible for regulated control of transcription[18].  
 
 
Fig. 3 – Histones are vital in allowing billions of base pairs of DNA to be packed tightly into the 
chromosome
[19]
. 
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1.4  Modification of Histones  
The modification of histones is essential for gene regulation with a large number of 
modifications discovered to date including lysine acetylation, lysine mono, di and tri 
methylation, arginine mono-methylation and di-methylation, serine and tyrosine 
phosphorylation, lysine ubiquitination and biotinylation, arginine citrullination and 
deimination, and proline isomerisation[20]. These modifications have been shown to be 
essential for the control of cellular mechanisms in a number of ways including 
transcriptional activation, chromatin decondensation, transcriptional silencing, mitosis, 
chromatin assembly, transcriptional repression, DNA repair, spermatogenesis, apoptosis, 
meiosis, histone deposition, genomic imprinting, DNA methylation and DNA damage 
response[21]. The majority of histone modifications occur in the N-terminal or C-terminal 
domains although there are some examples of modifications occurring in the central 
domain[22].  
Histone acetylation is catalysed by histone acetyl transferases (HATs)[23] and deacetylation 
by histone deacetylases (HDACs). It is therefore not surprising that both HATs and HDACs 
are closely involved in gene transcription activation and repression and have been shown to 
act widely across the genome[24]. The mechanism by which lysine acetylation and 
deacetylation affects transcription in nucleosomes is often described as via the control of 
charge on the residue leading to variation in the binding to the negatively charged DNA 
phosphate backbone (Fig. 4)[25]. However, chromatin signalling such as the association of 
acetylated lysine with the N-terminal domains of bromodomain proteins also plays a role[26]. 
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Fig. 4 – Deacetylated lysine residues on core histones bind the phosphate backbone of DNA more tightly 
leading to transcriptional repression
[25]
.  
 
Hypoacetylation or hyperacetylation due to the loss of epigenetic control is associated with 
a number of disease states and this effect can be attributed to malfunctions in both HATs 
and HDACs (Table 1). 
 
Disease Alteration Comments 
Rubinstein-Taybi 
syndrome 
Hypoacetylation Mutation in gene encoding 
CBP, a known HAT 
Diabetes Hyperacetylation at promoters of 
inflammatory genes 
Increased HAT activity and 
decreased HDAC activity 
Asthma Hyperacetylation Increased HAT activity and 
decreased HDAC activity 
Cancer H4K16 acetylation loss Hypomethylation of DNA 
repetitive sequences 
 
Table 1 –Disease states associated with a loss of epigenetic control can be attributed to aberrant activity 
in the histone modifying enzymes.
[27]
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1.5  Histone Deacetylases 
1.5.1  Structure and Classification 
Histone deacetylases (HDACs) are the enzyme responsible for deacetylating lysine residues 
of histones and they are also responsible for the deacetylation of a large number of non 
histone proteins[28]. Indeed one study has shown the acetylation of lysine residues to be 
almost as prevalent as phosphorylation with 1750 proteins identified as being acetylated at 
a total of 3600 sites in 3 different cell lines[29].  
18 unique HDACs have been identified in humans and these have been split into 4 classes 
based on homology to yeast HDAC proteins. The class III HDACs or Sirtuins are NAD+ 
dependent while Classes I, II and IV have one or more metal cation species in their active 
site/s (Fig. 5).  
 Fig. 5 – Phylogenetic tree of the 11 zinc-dependent HDACs. 
The Class I HDACs can be divided into 3 sub classes; HDAC1 and 2 are in class Ia, HDAC3 in Ib 
and HDAC8 in Ic. All class I HDACs are homologous to yeast RD3 deacetylase[30] while the 
class II HDACs based on yeast Hda1 are divided into two subgroups with HDACs 4, 5, 7 and 9 
in group IIa and HDACs 6 and 10 which both contain two active sites in group IIb[31],[32]. Class 
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III contains the sirtuins as previously mentioned and the only class IV HDAC is HDAC11 
based on phylogenetic analyses[33],[34].  
Class I HDACs are 350-500 amino acids (aa) long while class II enzymes are usually about 
1000aa. Both classes share a homologous region of about 320aa in which the catalytic site 
resides. The extra amino acids in the class II enzymes comprise additional structural 
features including an elongated N-terminal sequence[35]. Class I HDACs tend to be found in 
all tissue types but Class II HDACs are generally found in specific tissues suggesting that they 
may be involved in cell differentiation and development[36]. Within Class I, HDACs 1 and 2 
primarily reside in the nucleus while due to the presence of a nuclear export signal (NES) 
HDAC3 can be found in the cytoplasm. Class II HDACs are generally found in the cytoplasm 
although may be chaperoned to the nucleus[37],[38]. HDAC6 is unique in that it is the only 
HDAC that deacetylates tubulin and it is the only HDAC with two active catalytic sites 
(HDAC10 has two sites but only one is active). In addition to this both sites have been 
shown to be independent and have different sets of substrates with tubulin deacetylation 
occurring at the C-terminal catalytic site[39],[40].  
To control substrate specificity in vivo HDACs exist as multi-protein complexes with the 
exception of HDAC6. Class IIa HDACs are inactive when expressed as recombinant proteins 
but can be activated by co-expression with SMRT/N-CoR/HDAC3 while HDACs 1 and 2 often 
exist in complexes such as the Nucleosome Remodeling and Deacetylase complex (NuRD) 
and the Sin3 complex[38]. (Fig. 6). 
 
Fig. 6 – Illustration of part of the Sin3 complex in vivo featuring the Sin3 co-repressor as well as cofactors 
SAP18, SAP30, RbAp46 and RbAp48.    
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In vivo SMRT and NCoR are thought to recruit HDACs to transcriptional repressors as well as 
activate the HDACs via a deacetylase activating domain (DAD)[41]. 
Crystal structures of HDAC2[42], HDAC7[43], HDAC8[44] (Fig. 7) and the catalytic domain of 
HDAC4[45] have been reported in the literature as well as three HDAC-related bacterial 
deacetylases including the histone deacetylase like protein (HDLP) from Aquifex 
Thermophillus[46]., 
 
 
Fig. 7 – Crystal structure of HDAC8 complexed to TSA (shown in purple and blue)
[47]
. 
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1.5.2  HDACs and Disease 
The over-expression specifically of Class I and II HDACs has been seen in certain cancers 
including prostate (HDAC1)[48] gastric (HDAC2)[49], ovarian (HDAC1-3)[50] and lung cancers 
(HDAC1 and 3)[51]. This has led to the identification of HDAC inhibitors (HDACIs) as potential 
therapeutic targets for the treatment of cancer with several HDACIs at various stages of 
clinical development (Table 2).   
 
Disease HDAC Inhibitor Clinical Trial Phase 
Cutaneous T-Cell Lymphoma Vorinostat 
Romidepsin 
Panobinostat 
Belinostat 
Approved 
Approved 
Phase III 
Phase II 
Ovarian Cancer Valproic acid 
Belinostat 
Phase III 
Phase II 
Hodgkin Lymphoma Mocetinostat 
Entinostat 
Resminostat 
Phase II 
Phase II 
Phase II 
Sarcoma Abexinostat Phase II 
Metastatic Prostate Cancer SB939 Phase II 
Multiple myeloma 
 
AR-42 
ACY-1215 
Phase I 
Phase I 
 
Table 2 – Current progress of some HDACIs in clinical trials for a number of cancers.
[52]
 
Complementary DNA (cDNA) studies have shown that inhibition of HDACs can lead to 
changes in gene expression (7 – 10%) of certain cancer cell lines including leukaemia, 
multiple myeloma and carcinomas of the colon, kidney, bladder, prostate and 
breast[53],[54],[55],[56]. The anticancer activity of HDACIs has also been linked to a number of 
anti-proliferative processes including cell cycle arrest induction, intrinsic and extrinsic 
apoptotic pathway activation, mitotic and autophagic cell death induction, activation of 
senescence phenotypes, accumulation of reactive oxygen species (ROS), ROS scavenger 
inhibition, angiogenesis inhibition and disruption of various other pathways leading to 
tumour progression[57]. Of particular note with regards to HDAC inhibitor-induced cancer 
cell death is that both proliferating and non-proliferating cancer cells can be killed giving a 
distinct advantage over chemotherapeutic drugs that solely target proliferating cells[58].  
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As well as cancer, HDACIs are potential drug targets for the treatment of neurodegenerative 
diseases such as Alzheimer’s, Parkinson’s, Rubinstein–Taybi syndrome, Rett syndrome, 
Friedreich's ataxia, Huntington's disease and multiple sclerosis[59],[57],[60],[61]. Recent studies 
have also highlighted the possible use of HDACIs in preventing heart failure[62].   
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1.5.3  Mechanism of Deacetylation 
The mechanism of lysine deacetylation was first proposed after the publication of the 
crystal structure of HDLP complexed to TSA[46].  
 
 
Fig. 8 – First proposed mechanism of lysine deacetylation via catalytic acetamide hydrolysis with residues 
labelled from the crystal structure of HDLP with the HDAC1 equivalent in brackets
[46]
.   
 
Fig. 8 shows an illustration of this mechanism. In the catalytic site of HDAC1 the zinc centre 
acts as a Lewis acid to the carbonyl of the N-acetyl group activating it towards nucleophilic 
attack from a molecule of water which is activated by the imidazole ring of the H140 
histidine side chain. The tetrahedral intermediate is stabilised by the zinc centre and by 
hydrogen bonding interactions with the Tyr303 residue. Elimination of the lysine residue is 
accomplished via protonation of the amine by the His141 residue leaving behind the 
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acetate anion. This is the most widely accepted mechanism although others have been 
proposed including inverse protonation of H140 and H141[63]. 
While the crystal structures for all human HDACs have not been solved it is thought that this 
mechanism is similar for all HDACs due to conservation of amino acids in the active site and 
the fact that many inhibitors act on all HDACs with roughly equal potency. This similarity is 
useful when designing pan-HDAC inhibitors but presents itself as a challenge when trying to 
inhibit select HDAC isoforms.  
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1.5.4  Function of Specific Isoforms 
As previously discussed, over-expression of specific HDAC isoforms has been associated 
with the development of disease and as a result dissecting the function of specific HDACs 
has the potential to allow not only a better understanding of the mechanisms of epigenetic 
control, but also lead to potential therapeutic intervention.  
Biological studies to dissect the function of HDACs range from in vitro short interference 
RNA (siRNA) studies to gene knockout studies with mice. For example, siRNA studies have 
shown the effects of inhibiting the production of HDAC1, HDAC3, HDAC4 and HDAC7 in 
carcinoma cells[64]. These demonstrated the role of HDAC1 and HDAC3 in controlling cancer 
cell proliferation, highlighting these enzymes and targets for cancer therapy. Growth of 
HDAC1 knockout mice showed embryonic lethality at an early stage mainly due the arrest of 
cell growth that resulted from the upregulation of p21[65]. Class II HDAC knockout mice are 
generally viable possibly due to the restricted expression of these enzymes or other 
compensating factors and this has allowed certain HDACs to be associated with specific 
function. For example HDAC9 knockout mice exhibit hypertrophic growth of 
cardiomyocytes due to the loss of their interaction with the cardio hypertrophy regulator 
MEF2[66]. HDAC4 knockout mice exhibit chondrocyte hypertrophy during skeletogenesis due 
to its interaction with the transcription factor RUNX2[67] and HDAC6 knockout mice, despite 
exhibiting tubulin hyperacetylation, show normal growth with slight reductions in immune 
response and bone density[68]. 
While the biological studies described can give a good overview of the relationship between 
expression and function there are limitations with regards to dissecting the function of 
active enzymes. To begin with, the timescales of catalysis are relatively short when 
compared with the timescales of gene expression and also depend on a number of 
additional factors including post-translational modification, allosteric control and substrate 
co-localisation. In addition, dynamic mRNA processing means that the amount of gene 
expressed does not necessarily match the amount of enzyme expressed and this in turn 
PhD Thesis – Robert Felstead September 26, 2012 
 
24 
 
does not necessarily represent the amount of active enzyme that is in the vicinity of 
substrates. Chemical tools offer a solution to this problem by directly interacting with or 
altering the action of enzymes in situ. This allows the function of active enzymes to be 
monitored as well as observing the effects of inhibition of these enzymes and subsequently 
revealing their potential as therapeutic targets.  
The next sections introduce three methodologies that have the potential to dissect HDAC 
function; namely isoform-selective inhibition, protein-ligand engineering (PLE) and activity 
based protein profiling (ABPP). The PLE approach has not yet been applied to HDACs while 
whether the ABPP approach has been applied is dependent upon the definitions used 
(summarised in Section 1.8). Many attempts to discover isoform-selective inhibitors have 
been reported and these show varying degrees of success. Current progress towards the 
discovery of these inhibitors is outlined in the next section.  
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1.6  Isoform-selective inhibitors  
1.6.1  HDAC Inhibitors 
The first HDAC inhibitor (HDACI) to be discovered was the natural product TSA[69]. Since 
then many classes of HDAC inhibitors (HDACIs) have been discovered including hydroxamic 
acids such as SAHA[70], aniline derivatives such as MS-275[71], thiols or thiol precursors such 
as FK-228[72], carboxylic acids such as phenylbutyrate[73] and cyclic tetrapeptides such as 
chlamydocin[74] (Fig. 9). 
 
 
Fig. 9 – A wide range of HDACIs have been discovered. 
 
The vast majority of HDACIs discovered exhibit broad range inhibition across all or most of 
the 11 metal-dependent HDAC isoforms found in humans. This is due to conservation in the 
HDAC active site and it is this conservation that has posed the greatest challenge to the 
discovery of isoform-selective inhibitors.  
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1.6.2  HDAC Isoform Selectivity 
An array of isoform-selective inhibitors would be a useful tool for dissecting the specific 
function of the various isoforms as well as leading to the discovery of new drug targets. 
Therefore the quest for isoform-selective inhibitors has been a highly active area of 
research with varying success. The main challenge in designing isoform-selective inhibitors 
lies in the fact that the active site channel is highly conserved (Fig. 10). Despite this difficulty 
there has been some success in the discovery of HDAC inhibitors that show selectivity for 
specific classes of HDACs and within classes.   
 
Fig. 10 – Image of the HDAC active site channel. Conservation of amino acids across the HDAC family is a 
significant barrier to isoform-selective inhibitor design
[75]
.  
 
To aid the design of isoform-selective inhibitors HDACIs are often divided into three parts: 
capping group, linker and zinc-binding group (Fig. 11). The zinc-binding group (ZBG) is 
thought to sit in the active site and co-ordinate to the central metal species. The linker 
region sits in the active site channel and joins the ZBG to the capping group which interacts 
with the surface of the protein. In the quest for isoform selectivity all three parts have been 
varied to confer selectivity on various types of inhibitor.  
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Fig. 11 – HDACIs can be described as consisting of three parts as shown in this example with the HDACI 
MS-275. 
 
The ZBG is essential to inhibitor activity and as a result a number of well defined classes 
have been developed including hydroxamic acids, carboxylic acids, thiols, 2-amino-phenyl 
benzamides and mercaptoacetamides[76],[77],[78],[79],[80]. The most potent ZBG is the 
hydroxamic acid, which binds very well to the zinc ion as well as participating in hydrogen-
bonding to other residues within the active site. Simple hydroxamic acids such as SAHA are 
roughly equipotent inhibitors of all isoforms suggesting that while highly potent, selectivity 
would not be obtained from the hydroxamic acid group itself. Another highly potent ZBG is 
the epoxy-ketone group as seen in chlamydocin (Fig. 9). Inhibitors with this group show 
modest selectivity for Class I HDACs but bind irreversibly thus restricting the practical use of 
this class[81]. Of particular selective interest is the 2 amino-phenyl amide ZBG as seen in MS-
275 (Fig. 9) showing selectivity for HDACs 1-3 (EC50 181 nM, 1155 nM, 2311 nM 
respectively) over HDAC8 and Class II HDACs (EC50 > 10,000 nM)
[82]. Crystal structure data 
have revealed this to be due to a steric clash with the bulky Trp141 in the active site of 
HDAC8 which is a Leu residue only in HDACs 1-3 (Fig. 12). The cause of inactivity against the 
class II isoforms is also thought to be due to steric interactions within the active site based 
on studies using the HDAC6 homologue FB188 HDAH[35].  
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Fig. 12 – The HDAC 1-3 selectivity of the benzamide inhibitor class is thought to be due to the smaller Leu 
residues on the active site (corresponding to Met130 in HDLP) accommodating the large benzamide 
group as opposed to the bulkier Trp141 in HDAC8
[35]
.     
 
Small molecule studies have been performed using substituted phenylanilines to confer 
selectivity for HDACs 1 and 2 over 3[83],[84]. Introduction of a phenyl group or thiophene para 
to the NH2 group (Table 3) appears to give selectivity for HDACs 1 and 2. 
Inhibitor R group HDAC1 IC50 HDAC2 IC50 HDAC3 IC50 
 
H 2.4 µM 3.3 µM 2.8 µM 
 
0.048 µM 0.36 µM 11 µM 
 
0.060 µM 0.78 µM 11 µM 
 
Table 3 – Effect of the thiophene group on selectivity for HDAC1 and 2 over 3
[83]
.  
This effect opens the door to enhanced selectivity from compounds containing this ZBG 
although it could be that the small size of inhibitors showing this selectivity allows them to 
adopt conformations that would otherwise not be possible in larger, more conformationally 
restricted compounds.  
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Carboxylic acid HDACIs such as valproic acid (Fig. 9) (EC50 HDAC1-4, 6-8; 1.5 – 7.4 mM)
[85] 
are generally much weaker at binding compared to their hydroxamic acid counterparts. 
That said the cyclic tetrapeptide carboxylic acid azumamide E (Fig. 13) shows nanomolar 
potency and selectivity for HDACs 1-3 (IC50 0.050, 0.100 and 0.080 µM respectively vs. 12.0 
µM for HDAC6 and 28.0 µM for HDAC9) although this selectivity is likely to be due to the 
cyclic tetrapeptide capping group as opposed to the carboxylic acid[86].  Another potent ZBG 
is the thiol group with one SAHA equivalent 1 (Fig. 13), showing equal potency to that of the 
hydroxamic acid (IC50 0.21µM vs. 0.28 µM for SAHA)
[78]. Due to the reactive nature of thiols 
they are often prepared as disulfide prodrugs. So far selective thiols have been cyclic 
tetrapeptide based inhibitors such as 3 with similar selectivity profiles to other cyclic 
tetrapeptides (IC50 0.142 µM for HDAC1, 0.145 µM for HDAC4 and >500 µM for HDAC6 and 
HDAC8) although one example using thioether 4 did indeed change the selectivity profile 
(IC50 0.119, 0.405, 0.191 and 0.284 µM for HDAC1, 4, 6 and 8 respectively) suggesting that 
the binding was altered in such a way as to distort the peptide conformation[87].  
Mercaptoacetamides on the other hand appear to show selectivity for HDAC6 over HDAC1. 
This is thought to be a specific effect of the ZBG as mercaptoacetamide based SAHA 
analogues such as 2 (Fig. 13) (IC50 2010 nM for HDAC6 vs. 10800 nM for HDAC1) still show 
this selectivity while SAHA does not[88]. 
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Fig. 13 – Thiol and mercaptoacetamide SAHA analogues, the cyclotetrapeptide Azumamide E and two 
cyclic hydroxamic acid peptides (CHAPs).  
 
Due to conservation between HDAC isoforms in the active site channel the majority of 
efforts have been made to exploit differences in the surface residues surrounding the 
channel which show much less conservation (Fig. 10)[89]. The potential for variation of the 
capping group is much higher than that of the ZBG as this portion of the molecule is 
designed to interact with the enzyme surface as opposed to specifically bind the central 
metal atom and accompanying residues. Available crystal structures reveal multiple grooves 
in the HDAC surface surrounding the active site introducing the possibility for multiple 
capping groups to selectively bind specific isoforms[90]. The cyclic tetrapeptides are of 
particular interest when it comes to selectivity as they contain large capping moieties that 
have a chance to interact with a higher proportion of the enzyme surface when compared 
with simpler HDACIs such as SAHA. A series of cyclic tetrapeptide hydroxamic acids (CHAPS) 
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was developed which explored this idea. The synthetic CHAP 1 (Fig. 13) showed 10-fold 
selectivity for HDAC1 (IC50 1.9 nM) over HDAC6 (IC50 19 nM) while the chlamydocin 
analogue CHAP 15 showed 86-fold selectivity (IC50 0.44 nM for HDAC1 vs. 38 nM for HDAC6) 
despite only differing by one amino acid[91]. Further investigation into the effect of altering 
the amino acids in cyclic tetrapeptides have shown that as well as needing at least one 
aromatic group to be active, the position of the aromatic group can affect selectivity as well 
as potency[81],[92]. Despite these differences, one general trend with cyclic tetrapeptides is 
preferred inhibition of class I enzymes as seen with the thiol precursor FK228, azumamide E 
(Fig. 13), chlamydocin and apicidin (Table 4)[91],[93] ,[94],[86].  
 
Inhibitor Class I Inhibition Class II Inhibition 
FK288 IC50 HDAC1 36 nM IC50 HDAC4 510 nM, HDAC6 14 µM 
Azumamide E IC50 HDAC1 50 nM, HDAC2 100 
nM, HDAC3 80 nM  
IC50 HDAC5 10 µM, HDAC6 12 µM, 
HDAC7 9.7 µM, HDAC9 28 µM   
Chlamydocin IC50 HDAC1 0.15 nM IC50 HDAC6 1,100 nM 
Apicidin IC50 HDAC1 44 nM, HDAC2 120 
nM, HDAC3 43 nM, HDAC8 575 
nM 
IC50 HDAC4, 6 and 7 >10,000 nM 
Table 4 – Examples of the Class I selectivity of cyclic tetrapeptide HDACIs
[91], [86],[94],[93]. 
In the quest for HDAC6 selective inhibitors a series of compounds have been developed 
based on selective substrate deacetylation studies (Fig. 14). These compounds such as 6 use 
an NHBoc group alpha to an amide to produce two capping groups with the N-Boc group 
found to be essential for the selectivity (IC50 29 nM for HDAC6 vs. 1210 nM for HDAC1 and 
1030 nM for HDAC4)[95],[96]. A range of inhibitors that use a uracil moiety to link to the 
capping group have demonstrated selectivity for HDAC1 over HDAC4 with one example 7 
(Fig. 15). (94% inhibition of HDAC1 at 5µM vs. 20% inhibition of HDAC4) suggesting they 
could be useful as class I inhibitors[97].  
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Fig. 14 – Selective substrates such as 5 have been used to design selective inhibitors, in this case 6
[96]
. 
 
Fig. 15 – Selective inhibitors 7 and 8. 
A range of benzamide inhibitors has been made based on MS-275 (Fig. 9) and these 
generally show a similar HDAC1:2:3 selectivity profile. A typical example is benzamide 8 
(Fig. 15) which, while Class I selective inhibits HDAC1 with potency approximately 10 times 
higher than HDAC2 and HDAC3 (IC50 HDAC1 36 nM, HDAC2 313 nM, HDAC3 697 nM, HDAC6 
and 8 >10,000 nM) [98].  
Due to conservation in the active site channel varying the linker of HDACIs does not 
generally confer selectivity with the notable exception of HDAC8 which due to flexibility in 
the binding pocket can be inhibited by compounds that are “linkerless”[47],[99]. Recent work 
varying substituents on the linker near the ZBG of SAHA showed some HDAC6 selectivity 
although this greatly reduced the potency of the compound[100].   
Despite progress and interest in developing isoform-selective inhibitors there are still 
questions as to whether isoform-selective inhibitors would be more or less effective than 
pan HDAC inhibitors as therapeutic agents[101]. However, a comprehensive suite of 
inhibitors that inhibit each isoform with good selectivity is still yet to be developed and may 
still have as yet unknown clinical benefits as well as enabling the dissection of HDAC 
function.  
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1.7  Protein-Ligand Engineering 
As well as potential drug targets isoform-selective inhibitors would be valuable tools for 
dissecting the various functions and substrates of HDACs. Protein-ligand engineering (PLE) 
has found application in dissecting the function of protein kinases which itself is a daunting 
task given the vast number of kinases in the proteome[102]. PLE involves the design of a 
synthetic ligand that binds selectively to a mutant protein over the wild type thus bypassing 
the need to discover isoform-selective ligands.  
 One of the most basic approaches to protein-ligand engineering is the bump-hole 
approach. A protein is mutated such that one or more amino acid residues around a binding 
site are replaced with smaller residues to create a pocket in the active site. The idea is that 
a ligand may then be synthesised with a bump to fill that hole (Fig. 16)[103]. The selective 
ligand binds preferentially to the mutated protein and not the wild type while the natural 
ligand binds to both the wild type and the mutated protein.  
 
 
Fig. 16 – Illustration of the bump-hole approach showing a ligand that specifically binds to a genetically 
engineered receptor while not inhibiting natural ligands. 
 
This approach was first applied to kinases using inhibitors based on the 4-amino-1-tert-
butyl-3-phenylpyrazolo[3,4-d]pyrimidine (PP1) scaffold[104] inhibiting Src family tyrosine 
kinases. In this case the naphthyl derivative was shown to preferentially inhibit the 
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Ile338Gly mutant over the w/t due to steric clashes with the naphthyl group preventing H-
bonding and other binding interactions essential to inhibitor activity (Fig. 17). 
 
Fig. 17 – Introduction of the Ile338Gly mutation allows the naphthyl derivative (11) to bind to the mutant 
of the Src family tyrosine kinase Hck
[104]
.  
 
Inhibitor 11 has been used alongside complementary mutations to determine the genetic 
function of Pho85 and APG1 in yeast and GRK2 in HEK293 cells[105],[106],[107]. Similar inhibitors 
based on the PP1 scaffold including cell-permeable inhibitors have been used to evaluate 
the function of a number of enzyme targets[102].  
As these examples show the bump-hole approach has been highly useful in uncovering the 
function of kinases. The main potential limitation of this approach is that for it to work a 
suitable mutation must be available that does not significantly affect the activity of the 
enzyme under investigation. A way round this problem is to engineer specifically a novel 
interaction between the target protein and a synthetic ligand that does not interrupt this 
activity by, for example, being located away from the active site. This way any necessary 
inherent features of the enzyme can be retained while ligand selectivity can be introduced. 
When designing a novel protein-ligand interaction it is hoped that the synthetic ligand will 
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interact more strongly with the engineered target protein than the wild-type allowing 
selective inhibition to be simulated (Fig. 18).  
 
 
Fig. 18 – Novel interactions can be created by engineering protein-ligand interactions not seen in w/t 
enzymes
[103]
.  
 
A number of PLE approaches to engineering selectivity are possible including H-bond and 
ion pair reversal[108],[109], salt bridge reversal[110] and ion pair elimination[111]. H-bond 
reversal, for example, has been applied to the GTPase EF-Tu where the Asp138 residue 
(with two hydrogen-bond acceptors) was mutated to an asparagine (a hydrogen-bond 
donor) resulting in the mutant enzyme being inhibited by a xanthine-nucleoside 
triphosphate (XTP)[108] (Fig. 19).    All of these approaches have their advantages and 
disadvantages and the method used is likely to depend on the protein-ligand system and 
the desired selectivity. 
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Fig. 19 – Hydrogen-bond reversal by inducing the A138Q mutation in GTP/EF-Tu results in the enzyme 
binding XTP with an affinity to the wt affinity for GTP
[108]
.  
The application of PLE to biological problems has been extended as far as introducing 
mutant enzymes into mice[112]. In one example a mouse strain was created which over-
expressed the mutant kinase calmodulin-dependent protein kinase II CAMKII. The mice 
were subsequently fed a PP1 based inhibitor and the effects on long term memory 
assessed. The results showed that CMKII reactivation is essential to long term memory 
consolidation in the first post-learning week as determined by switching the kinase on or off 
using the selective PP1 inhibitor. 
While there are biological limitations to the application of PLE, the ability to imitate drug-
like behaviour in vivo gives it a distinct advantage over biological approaches such as siRNA. 
Thus, as described in Section 2.1, it was hoped that PLE could be successfully applied to 
HDACs.  
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1.8  Activity Based Protein Profiling 
Dissecting the function of proteins is one of the key aims of proteomics and a fast growing 
area within this field involves the profiling of proteins using chemical probes[113]. This area 
can be split into two categories based on the mode of action in the active site. These are 
affinity based protein profiling (AfBPP) and activity based protein profiling (ABPP)[114]. It 
should be noted that while ABPP probes for HDACs have been reported by Cravatt[115] the 
definitions used here would classify those as AfBPP probes.   
 AfBPP involves incubating cells or cell lysates with a chemical probe that has an affinity for 
a particular substrate and then activating a reactive group such as a photoactivatable 
moiety attached to the group which then combines covalently with that substrate (Fig. 20). 
The affinity for the protein of interest can be at the active site or other parts of the 
molecule but as long as the reactive moiety is in the vicinity of the protein or associated 
proteins then it will covalently bind allowing identification.  
 
Fig. 20 – Affinity based probing relies on activation of a reactive group in the vicinity of the target enzyme. 
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After the covalent linkage is formed a fluorescent marker or affinity tag can be attached to 
the protein-bound probe via a chemical reaction. In Fig. 20 this is done via  the copper(I) 
catalysed Huisgen [3+2] azide-alkyne cycloaddition or Click reaction to form a 1,2,3-
triazole[116]. The Click reaction is commonly used in vivo and in vitro profiling reactions due 
to its orthogonality to biochemical reactions within the cell[117].      
Activity based protein profiling (ABPP) involves incubating cells or cell lysates with a 
chemical probe that can react with an enzyme leading to covalent binding to that enzyme 
followed by subsequent identification (Fig. 21). What sets ABPP apart from AfBPP is that 
covalent linkage to the protein of interest can occur without the need to activate a reactive 
moiety. This is because the reactivity comes from the enzyme’s catalytic activity, which is 
exploited in the labelling. One advantage of this is that one can, for example, avoid exposing 
live cell systems to UV light for extended periods of time such as in the case of UV activated 
reactive moieties. Another advantage is that it allows the identification of active enzymes. 
This is important because some enzymes are only active when bound to activating cofactors 
and so ABPP has the potential to target specifically active enzymes while AfBPP will in 
theory target all forms of an enzyme whether catalytically active or not.  
 
Fig. 21 – Activity based probing allows targeting of active enzymes in vivo.  
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The reactive group on most activity based probes (ABPs) usually possesses two properties. 
These are affinity for the active site and an electrophilic group to undergo covalent bond 
formation with an amino acid within the active site. This bond formation is promoted by 
interactions with the active catalytic site and hence the probe is said to be activity based as 
this activity is necessary for bond formation.  A variety of reactive groups has been used in 
ABPs including fluorophosphonates, sulfonates, vinyl sulfones, epoxides, phenyl acetylenes, 
and diazomethyl, acyloxymethyl and halomethyl ketones (Table 5).  
 
Reactive Group Target  
 
Serine hydrolases e.g. [118] 
 
Serine hydrolases e.g.[119] 
 
Cysteine and threonine 
proteases e.g.[120] 
 
Cysteine proteases e.g.[121] 
 
Cytochrome p450 e.g. [122] 
 
Cysteine proteases [123] 
 
Cysteine proteases e.g. [124] 
 
Serine and cysteine 
proteases e.g. [125]  
 
Table 5 – Reactive groups of common ABPs also known as ‘warheads’. 
 
The chloromethyl ketone (CMK) based probes were among the first class to be use as ABPs 
and their mode of action has been extensively studied using a variety of methods[123]. This 
led to the discovery that this type of ABP forms an irreversible linkage with the nitrogen on 
the histidine ring within the active site of serine proteases (Fig. 22).  
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Fig. 22 – Proposed mechanism for the binding of CMKs with serine proteases.  
In this mechanism the serine is thought to undergo nucleophilic addition to the ketone 12 
forming the tetrahedral intermediate 13, which then displaces the chloride leaving a 
reactive epoxy-hemiketal intermediate 14. This intermediate then undergoes attack from 
the nitrogen of the histidine forming an irreversible linkage which exists as either the serine 
bound 15 or non serine bound form 16. Evidence for formation of the epoxy-hemiketal 
intermediate comes from a study hydrolysing the S-isomer of Ac-Ala-Phe-CHCl-CH3 17
[126] 
where the non-enzymatic hydrolysis led to inversion of configuration while the enzymatic 
hydrolysis led to retention suggesting a double inversion mechanism facilitated by the 
formation of the epoxy-hemiketal intermediate (Fig. 23). In addition to this - determination 
of the crystal structure of γ-chymotrypsin inhibited by 17 has shown that the inhibitor 
alkylates the His 57 with retention of configuration (Fig. 23) 
[126]. 
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Fig. 23 – Enzymatic and non-enzymatic hydrolysis of (2S)-Ac-Ala-Phe-CHCl-CH3 as well as the crystal 
structure of the inhibitor bound to γ-chymotrypsin provide evidence for a double-inversion mechanism. 
 
Applying ABPP to biological systems can potentially yield a large amount of information 
including de novo enzyme discovery, location of enzyme activity in vivo via fluorescence 
microscopy and in vivo competitive inhibitor activity. For example, a cellular assay showing 
protein binding to an ABP that mimics a substrate would allow comparison of profiles with 
and without inhibitor thus identifying the inhibitor hits in a cellular system. This could 
potentially allow the mode of action of clinically relevant inhibitors to be understood as well 
as facilitate the identification of new ones.   
The vast majority of activity based probes (ABPs) have been used to target hydrolase 
enzymes although the technique has been expanded to study other enzymes including 
cytochrome P450s as well as polyketide and non ribosomal peptide synthases[127],[128]. As 
mentioned at the beginning of this section AfBPs have been applied to HDACs[129] but ABPs 
as defined here have not. The progress of this work is briefly described in the introduction 
to Section 2.3.  
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2 Results and Discussion       
2.1  Chemical genetic simulation of isoform-selective inhibition 
Successful application of a protein-ligand engineering (PLE) approach to simulating isoform-
selective inhibition of HDACs has not been reported in the literature. However, the work 
described herein followed on from previous work involving a set of computational dockings 
using AutoDock 3.0.5 which modelled the interactions of several HDAC mutants with a 
selection of putative inhibitors[130]. In particular these studies led to the identification of two 
mutants, F150A and L271A selected for their potential as engineered holes to interact with 
inhibitors. The inhibitors themselves were designed to create a complementary bump-hole 
interaction. These inhibitors (Fig. 24) showed some selectivity towards the F150A and 
L271A mutants of hHDAC1 over the wild-type[131].  
 
Fig. 24 – Potential selective bump-hole inhibitors as determined by analysis with AutoDock 3.0.5
[131]
. 
Five of these inhibitors (Scheme 1) were then synthesised and work towards expressing the 
wt, F150A and L271A mutant took place. This involved successful baculovirus expression 
(see below) of the HDAC1-Strep-tag II wt and L271A mutant and the F150A mutant was in 
the process of being amplified ready for expression[132].  
 
Scheme 1 – a) DCC, DMAP, DCM; b) (COCl)2, 
i
PrNEt2, DCM; c) NHOH.HCl, NaOMe, MeOH. 
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For reasons outlined below the preferred method of expression chosen was baculovirus 
mediated expression of protein in Sf9 cells (Fig. 25)[133].  
 
Fig. 25 – Illustration of the BaculoGold® expression system.  
This method involves sub-cloning the protein-coding DNA sequence into a recombinant 
plasmid vector which can then combine with linearized baculovirus DNA in vivo to form the 
protein expressing virus in Sf9 cells. The virus can then be amplified in the cells before being 
used to express large amounts of protein.  
Expression of HDAC fusion proteins tagged with a histidine, FLAG and GST tag in Sf9 cells 
have been reported in the literature[88],[134],[82] as well as in mammalian systems while 
bacterial expression was not considered as bacterially expressed HDACs (apart from HDAC8) 
are not catalytically active[135],[136]. All 11 human zinc-dependent HDAC isoforms are also 
commercially available as recombinant enzymes expressed in both Sf9 and mammalian 
systems. The Strep-tag II is an 8 amino acid peptide used to mimic the biotin-streptavidin 
interaction and was chosen in this case as it is known to afford good separation while at the 
same time being a small tag so as to not interfere with binding[137]. 
PhD Thesis – Robert Felstead September 26, 2012 
 
44 
 
A range of lysis conditions were initially tried to solubilise the w/t fusion protein for assay, 
varying detergent concentration (Fig. 26), lysis volume and sonication (Table 6). Despite 
some signs of the desired protein in the soluble fraction initially, these results were not 
reproducible. 
 
 
Fig. 26 – Anti-Strep-tag II Western blot of control and infected Sf9 cells lysed in buffer A and then 
immediately lysed in 2x SDS buffer (first three lanes). The remaining cells were then lysed for 10min on 
ice before being centrifuged at 14k at 4 
o
C. 
 
Detergent Sonication Lysis Volume Protein Solubility 
0.5 % No 200 μL Trace solubility 
0.5 % Yes 200 μL Trace solubility with degradation 
0.5 % Yes 200 μL Insoluble 
1.0% No 200 μL Insoluble 
2.0% No 200 μL Insoluble 
0.5 % No 100 μL Insoluble 
0.5% No 50 uL Insoluble 
 
Table 6 –  Range of conditions explored in attempt to solubilise HDAC1-Strep.  
Varying the time between viral infection and lysis was also attempted in case extended 
occlusion body formation was interrupting the solubility via formation of protein 
aggregates. Infection to lysis times of 24, 36, 48 and 60 hours were attempted but this was 
again unsuccessful.  
PhD Thesis – Robert Felstead September 26, 2012 
 
45 
 
One advantage of the Strep-tag II tag is that it is small and thus less likely to interfere with 
post translational modifications and cofactor binding. However, the larger GST-tag protein 
is known to enhance protein solubility[138] and so it was decided to change the approach to 
allow solubilisation of the expressed proteins.  
The idea of changing the purification tag also coincided with a change in PLE strategy due to 
the publication of a study by the Pflum group at Wayne State University, USA[75]. This study 
involved systematic mutation of the active site of HDAC1 and demonstrated that even 
simple alterations in the active site channel have a detrimental effect on catalytic activity. A 
selection of amino acids identified by crystal structure analysis as being in the HDAC active 
site were systematically mutated to alanine and the effect on catalytic activity measured 
(Fig. 27). Enzyme activity dropped to between control levels and 20% of wild-type HDAC1 
with the exception of Y204A, which showed an enzyme activity of 40% and E98A, which 
showed activity comparable to the wild-type levels. Other mutations were explored 
including F205Y, which showed c. 60% activity compared to the wild-type suggesting the 
hydrophobic interaction of the phenyl ring to be important to the catalytic activity[75].  
 
Fig. 27 – Mutations of amino acids in the 11Å active site channel of HDAC1. The E98A mutant shows 
activity in line with the w/t with the Y204A mutant showing c.40% of w/t activity
[75]
.  
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The new PLE strategy involved the introduction of a de novo binding site into the entrance 
of the active site channel. The residue chosen corresponds to glutamate E98 in HDAC1 and 
is not widely conserved among the HDAC isoforms (Fig. 28) suggesting that mutating it 
would not be detrimental to catalytic activity. Additional evidence for this is that 
engineering the E98A mutant of HDAC1 showed activity comparable to that of the w/t (Fig. 
27)[75].  
 
 
Fig. 28 – The E98 position in HDAC1 is not widely conserved across the species suggesting that a number 
of amino acids could be placed here without being too detrimental to deacetylase activity
[75]
.  
Despite variation at this site it was noted that all the natural amino acids were either 
neutral or negatively charged so it was decided that introduction of a positive charge would 
potentially allow a negatively charged inhibitor to bind selectively to this residue. Arginine-
carboxylate interactions have been previously exploited to change the selectivity of an 
enzyme where introduction of an arginine residue allowed a lactate dehydrogenase to be 
converted to a malate dehydrogenase[139].  
It was therefore decided that the possibility of engineering an arginine-carboxylate 
interaction would be investigated by computational modelling using AutoDock 4.0[140]. 
Mutated versions of the HDLP from rcsb.org[141] were created and minimised with Y91E and 
Y91R mutations (equivalent to wt and E98R in HDAC1) using Chimera[142] and 
AutoDockTools (ADT). These were then docked with a variety of ligand structures (Table 7). 
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The AutoDock program uses a semi-empirical free energy force field, which has been 
calibrated on a set of 188 diverse protein-ligand complexes of known structure and binding 
energy to determine the binding energy of protein-bound molecules[143].  During the 
docking calculation the binding energy is calculated by evaluating the intramolecular 
energies of both the ligand and protein in their bound and unbound states and then it 
evaluates the intermolecular energetics of the protein and ligand in their bound states. 
AutoDock 4.0 allows for flexible residues and so it was decided that E91 (w/t) or R91 
(mutant) would be allowed flexibility with the rest of the molecule modelled as a rigid 
electronic surface. The advantages of this model are that it would allow exploitation of any 
arginine-carboxylate interaction to be visualised. One key disadvantage is that changes to 
the active site induced by the mutation could not be accounted for but it was hoped that 
with the mutated residue location being largely external this effect would be minimal.       
The structures were chosen with a hydroxamic acid ZBG to bind in the active site and a 
carboxylic acid to interact with the arginine group on the surface of the enzyme. To explore 
a range of chemical space three chain lengths were selected which were either the same 
length as SAHA or one carbon shorter or longer than SAHA. The R group was also varied to 
include a number of moieties ranging in size and aromaticity with both R and S enantiomers 
investigated. The hope was that in some of the structures preferential binding to the E98R 
mutant would be observed over the wild-type with visualisation of a favourable COOH-Arg 
binding interaction. Docked structures were assessed for hydroxamic acid-zinc binding and 
in the case of the Y91R mutant assessed for Arg-COOH binding (Table 7).   
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R n R/S 
HDLP Y91R Binding 
Energy kcal mol-1 
HDLP Y91E Binding 
Energy kcal mol-1 
SAHA (not R) - - -7.64 -7.80 
H 2 - 4 - * * 
Me 3 S,R * * 
 
2 
R -8.37 -6.70 
S -8.14 -7.52 
3 
R -8.72 -8.14 
S -7.84 -7.62 
4 
R -8.67 -8.24 
S -8.21 -7.66 
 
3 
R -8.44 -8.93 
S -7.80 -8.34 
 
2 
R * * 
S -6.88 -7.55 
3 
R * * 
S -7.48 -7.78 
4 
R -8.11 -7.90 
S -7.31 -8.69 
Table 7 – Docked structures and the accompanying binding energies for structures that displayed the 
Arginine-COOH interaction. * No favourable binding free energies greater than 6.00 kcal mol-1. 
Docking with the structures containing R = H and R = Me showed no favourable binding free 
energies greater than 6.00 kcal mol-1 regardless of chain length while all structures with R = 
Bn showed preferential binding to the Y91R mutant over the wt mimic Y91E. The best of 
these was the n = 2 R enantiomer (-8.37 kcal mol-1 for the mutant vs. -6.70 kcal mol-1 for the 
wt mimic). Docking with R = naphthyl showed preferential binding to the w/t mimic over 
the mutant and R = phenylamide showed no binding for the structures with (R) 
stereochemistry and n = 2 or 3. The R = amide structure with n = 4 showed a slight 
preference for binding the mutant (-8.11 vs. -7.90 kcal mol-1) while all the (S) enantiomers 
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of R = phenylamide showed preferential binding to the w/t mimic over the mutant. SAHA 
docked to the mutant with an energy of -7.64 kcal mol-1 and the w/t mimic with an energy 
of -7.80 kcal mol-1 which is in good agreement with other studies that have shown SAHA to 
have a binding energy of -7.48 kcal mol-1 with HDAC1[144]. Visual inspection of potential 
binders also showed the possibility of favourable interactions with the arginine residue (Fig. 
29).  
 
 
Fig. 29 – Snapshot from the docking of the (R)-enantiomer of the benzyl derivative with n = 3. The 
arginine-carboxylic acid interaction is clearly visible with the phenyl group residing in one of the grooves 
on the surface. 
With the docking studies suggesting that engineering a favourable selective protein-
inhibitor interaction was possible it was decided that HDAC1 E98R as well as the E98A and 
L271A mutants as positive and negative controls respectively would be expressed to 
determine activity of the E98R mutant vs. the wild-type and validate the HDAC1 expression 
system.  
To solve the solubility problem with previous recombinant proteins the use of GST tags was 
also implemented due to their ability to enhance protein solubility[138].  
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Vectors to express GST-fusion proteins of the w/t, L271A, E98A and E98R hHDAC1 were 
then prepared and co-transfected with linearized AcNPV into Sf9 cells. Attempts to amplify 
the virus were then made with w/t, L271A and E98R viruses showing good amplification. 
The E98A mutant transfected virus did not amplify well however and it was decided to 
continue investigation with the other three using w/t HDAC1 as the sole positive control. 
Initially a time course experiment was conducted to assess protein expression after 
infection of 5.8 x 105 cells in a six-well plate with cell lysis at 24, 36, 48 and 60 hours (Fig. 
30).  
 
 
Fig. 30 – Western Blot with anti-GST antibody shows GST tagged HDAC1 expressed in Sf9 cells at c. 
100kDa for w/t and two mutant proteins. Control cells infected with baculovirus expressing GST-cdk2. 
 
The results showed some protein expression 24 hours post infection with greater 
expression from 36 hours onwards as expected with baculovirus systems. With the protein 
expressing well, it was decided to attempt GST purification followed by an assay for HDAC 
activity. Large scale infections (1.3 x 107 cells) were carried out for all three enzymes and 
the cells lysed after 48 hours and subjected to purification on GST-Sepharose beads (Fig. 31)   
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Fig. 31 – Coomassie gel of 5 and 20µL samples of the beads confirms the presence of HDAC as well as free 
GST.  
With the HDACs successfully attached to the beads and purified they were then assayed for 
catalytic activity with a fluorimetric assay (Fig. 33)[145]. The deacetylase assay consists of an 
acetylated substrate that when deacetylated forms a fluorophore complex with a 
developer. Thus, the acetylated substrate is incubated with the HDAC (with or without 
inhibitor) and then a developer is added to identify the amount of deacetylated substrate 
present (Fig. 32).  
 
Fig. 32 – Illustration of the deacetylated lysine sensitive substrate
[145]
.  
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The assay showed the purified enzymes to possess the same deacetylase activity as the 
control expression (without HDAC). HeLa cell extract was also assayed alongside and 
showed activity significantly higher than that of the control and HDAC levels showing that 
the low activity was due to the expression and/or purification as opposed to the assay. 
 
 
Fig. 33 - Fluorescence activity of a 5 µL sample of beads with the GST-HDAC1 w/t, L271A and E98R 
attached with control values for beads without protein and measured against a sample of HeLa nuclear 
extract measured in arbitrary fluorescence units (AFU). Error is the standard error for three separate 
measurements. 
 
With the enzyme inactive on the beads a number of attempts were then made to isolate 
the active HDAC (summarised in Table 8).  
Despite being able to isolate reproducibly GST-HDAC enzyme, none showed activity above 
background levels despite a range of lysis and purification protocols. Further experiments 
varying the amount of virus added to cells before infection were also carried out but no 
improvement in activity beyond control levels could be detected. 
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Scale of 
Infection 
Protocol HDAC  
Present?1 
Deacetylase 
Activity2 
1.3 x 107 cells Lysis, incubation with GST-sepharose, 
washing, store at -20 Co, assay on 
beads 
Yes Same as 
control levels 
1.3 x 107 cells Lysis, incubation with GST-sepharose, 
washing, store at -20 Co, elution with 
glutathione, concentration, assay 
No N/A 
1.3 x 107 cells Lysis, incubation with GST-sepharose, 
washing, immediate elution with 
glutathione, concentration, assay 
No (enzyme 
lost during 
concentration) 
N/A 
5.8 x 106 cells Lysis, incubation with GST-sepharose, 
washing, elution with glutathione, 
assay 
Yes Same as 
control levels 
5.8 x 105 cells Lysis in GST buffer, assay Yes Same as 
control levels 
5.8 x 105 cells Lysis via sonication in assay buffer, 
assay 
Yes Same as 
control levels 
5.8 x 105 cells Lysis via sonication, incubation with 
GST-sepharose, washing, assay 
Yes Same as 
control levels 
Table 8 – Range of conditions tried to obtain deacetylase activity. 1) Presence of HDAC was tested via 
Anti-GST Western Blot of sample. Samples tested were either a portion of the eluent or beads for 
experiments performed without elution. 2) Fluorescence was measured as described in Fig. 33.   
 
Active HDAC1 with an N-terminal GST fusion tag expressed in Sf9 cells has been reported in 
the literature[82] but the expression of active HDACs in Sf9 cells is known to be 
problematic[146]. In addition, specific co-expression of HDAC1 with three cofactors (Rb46, 
Rb48 and MTA2) expressed in Sf9 cells has been shown to improve dramatically Sf9 
expressed HDAC activity[134]. This improvement in activity suggests that association with 
these cofactors is either essential or in some way enhances the catalytic activity of HDAC1 
expressed in Sf9 cells (Fig. 34). While there is evidence that HDAC3 expressed in Sf9 cells is 
activated by co-expression with the cofactor SMRT via binding to a deacetylase activating 
domain (DAD)[41] the extent to, and the mechanism by which, HDAC1 catalytically is 
enhanced by these cofactors is less clear in this system. 
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Fig. 34 – Putative complex likely to be involved in the activation of HDAC in Sf9 cells.   
 
In the continuing pursuit of catalytic activation it was then decided that HDAC1 should be 
co-expressed with RBAp46, RbAp48 and MTA2. Viral stocks of RbAp46, RbAp48, MTA2-Flag, 
HDAC1-Flag, and HDAC2 were then obtained[147] and amplified.  
Before testing the HDAC activity the viral stocks were first tested for protein expression (Fig. 
35). 
 
Fig. 35 – 1 Control, 2 RbAp46, 3 RbAp48, 4 MTA2, 5 HDAC1, 6 Co-Expression of HDAC1-Flag, RbAp46, 
RbAp48 and MTA2-Flag, 7 control, 8 HDAC2. Cells were lysed in 200 µL 2x SDS buffer and boiled at 100 
o
C 
for 10 min before being run on a gel and stained with Coomassie.  
 
Proteins of the appropriate molecular weight for HDAC1-Flag and HDAC2 (55 kDa) were 
visible by Coomassie but RbAp46 (46 kDa), RbAp48 (48 kDa) and MTA2-Flag (70 kDa) were 
not obviously expressed over background staining. Expression of the MTA2-Flag was 
subsequently determined via Western Blot (Fig. 36). 
 
Fig. 36 – Anti-flag Western Blot of Sf9 cells expressing in lanes: 1 - (MTA2-Flag, HDAC1-Flag, RbAp46 and 
RbAp48);2 – control; 3 – HDAC1-Flag; 4 – MTA2-Flag. 
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RbAp46, RbAp48, MTA2-Flag, HDAC1-Flag, GST-HDAC1, HDAC1 co-expressed with RbAp46, 
RbAp48 and MTA2 and GST-HDAC1 co-expressed with RbAp46, RbAp48 and MTA2 were 
then expressed in Sf9 cells and the cells lysed and assayed for activity (Fig. 37). 
All assay readings showed some deacetylase activity but this was in line with control levels 
suggesting that the catalytic activity was being dominated by endogenous Sf9 HDACs. To 
overcome this problem GST purification of GST-HDAC1 co-expressed with RbAp46, RbAp48 
and MTA2-Flag was undertaken followed by assay. 
 
 
Fig. 37 – Sf9 cells were harvested and lysed via sonication for 3 s in assay buffer (150 µL). 25 µL of lysates 
were then incubated with HDAC fluorimetric substrate (50 µM) for 30 min at room temperature. Error is 
the Standard Error of 3 fluorescence measurements.   
 
The assay showed increased activity in the HDAC vs. control levels but this was very low in 
absolute terms (Fig. 38). One reason for this was the possibility that the large GST tag (c. 
25KDa) was interfering with binding to the cofactors. To negate this problem it was decided 
to use the Flag affinity tag on the MTA2-Flag protein to purify the active enzyme complex. 
Immunoprecipitation (IP) of the co-expressed MTA2-Flag bound to RbAp46, RbAp48 and the 
HDACs would then allow isolation of the active HDAC complex. HDAC1-Flag and HDAC2 
were co-expressed with RbAp46; RbAp48 and MTA2, purified by IP and assayed for activity 
(Fig. 39).  
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Fig. 38 - Sf9 cells were lysed as before but mixed with GST-sepharose beads for 1 h at 4 
o
C and the assays 
performed by mixing the HDAC substrate with the washed beads on the wheel for 30 min at room 
temperature. Error is the Standard Error of 3 fluorescence measurements. 
 
 
Fig. 39 – Fluorescence from on bead assays (described above). RbAp48, MTA2-Flag, HDAC1-Flag and 
HDAC2 in the first four lanes were expressed as controls. HDAC1-Flag (co-expressed with MTA2-Flag, 
RbAp46 and RbAp48) and HDAC2-Flag (co-expressed with MTA2-Flag, RbAp46 and RbAp48) were 
expressed in the last two lanes. All proteins were expressed in Sf9 cells, harvested after 72 h and subject 
to IP with 2 µL anti-flag on 25 µL protein G-Sepharose beads. The beads were washed and then HDAC 
assays performed directly on the beads. Error is the Standard Error of 3 fluorescence measurements. 
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The assay results showed that the HDAC1 and HDAC2 co-expressed with the three cofactors 
had activity levels of 23.5 ± 0.5 AFU and 26.7 ± 0.15 AFU respectively. This was significantly 
higher than the control levels of HDAC1-Flag, HDAC2 and RbAp48 (between 1.0 and 1.5 
AFU) and MTA2, which displayed an activity of 7.5 ± 0.1 AFU. This was slightly higher than 
the other controls possibly due to attachment of endogenous Sf9 HDAC complexes to the 
MTA2-Flag.  
Work was then done to express the HDAC1 E98R mutant in Sf9 cells as a free protein for co-
expression. Attempts were made to subclone the HDAC E98R fragment into the baculovirus 
transfection vector pAcC4[148] but these were unsuccessful despite repeated attempts. It 
was then decided that an improved baculovirus expression system would be used to 
facilitate expression of the mutant (Fig. 40).  
 
 
Fig. 40 – The FastBac expression system
[149]
.  
PhD Thesis – Robert Felstead September 26, 2012 
 
58 
 
This improved system utilises a piece of DNA called a “bacmid”. This bacmid can be grown 
up in bacteria and infect Sf9 cells. Large amounts of bacmid DNA can then be produced in 
bacteria very quickly and subsequently used to create large amounts of virus in the insect 
cells reducing the rounds of amplification required. 
HDAC1 w/t and HDAC1 E98R were successfully subcloned into the pfastbac1 vector and 
transformed into bacteria. White colony selection allowed identification of bacteria 
containing the desired bacmid, which were subsequently cultured and the bacmid DNA 
isolated. This was then transfected into Sf9 cells and the resulting baculovirus amplified.    
W/t and E98R HDAC1 were then co-expressed with RbAp46, RbAp48 and MTA2-Flag, 
purified via IP and assayed for activity (Fig. 41). 
 
 
Fig. 41 – CoEx = Co-expression with RbAp46, RbAp48 and MTA2-Flag. Deacetylase activity was measured 
relative to CoEx only (RbAp46, RbAp48 and MTA2-Flag). Errors are the standard errors from three 
separate experiments.  
 
W/t and E98R HDAC1 showed activity above the cofactor only control suggesting that the 
HDAC complex was responsible for the activity. When expressed on their own the cofactors 
are likely to bind endogenous Sf9 HDACs and this was thought to be responsible for the 
displayed activity. However, it was hoped that this endogenous activity would be 
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suppressed when in the presence of expressed HDACs as they are expressed at much higher 
levels than endogenous HDACs in the system.   
With the wild-type and E98R mutant HDAC1 being expressed as purified active complexes, 
the design and synthesis of viable selective inhibitors could take place. While potential 
structures for selective binding had been assessed previously, it was decided to propose 12 
new potential inhibitor structures. These new structures were designed to have four key 
features; the first being a hydroxamic acid based Zn-binding group; the second being an 
aromatic moiety and peptide bond in the capping region, which is present in the vast 
majority of HDACIs; the third being an aliphatic carbon chain to occupy the active site 
channel and fourthly, a carboxylic acid group to bind to the arginine group.   
 (Fig. 42). 
 
 
Fig. 42 – Ligands that were docked with HDLP Y91E and HDLP Y91R and analysed. 
AutoDock 4.0 was used to assess the 12 structures, which were docked against HDLPY91E (a 
homologue for HDAC1) and HDLPY91R (a homologue for HDAC1 E98R) and their docking 
interactions and binding energies analysed for selective inhibitor potential (Table 9). A 
number of the structures showed promising selectivity (Table 10) with both phenylalanine 
derivatives 27 and 28 showing a slight energetic preference for the mutant (28 -8.24 vs. -
7.55 kcal mol-1 , 27 -7.71 vs. -6.90 kcal mol-1) and the carboxyl derivative 31 showing the 
best energetic selectivity (-7.97 vs. -6.68 kcal mol-1). 
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Structure n R/S 
HDLP Y91R Binding 
Energy kcal mol-1 
HDLP Y91E Binding 
Energy kcal mol-1 
SAHA  - - -7.64 -7.80 
 
1 
R -6.66 * 
S -7.27 -7.31 
2 
R -7.97 -6.68 
S -6.79 -7.05 
 
1 
R -8.09 -7.11 
S -7.50 -7.72 
2 
R -7.35 -6.60 
S -8.39 -7.29 
 
- 
R -8.24 -7.55 
S -7.71 -6.90 
 
- 
R -7.21 -7.50 
S -6.87 -7.38 
 
Table 9 – Ligands that were docked with HDLP Y91E and HDLP Y91R and analysed. *No favourable binding 
free energies greater than 6.00 kcal mol
-1
. 
Methylene-carboxyl derivative 30 also showed promising selectivity and potency (-8.39 vs. -
7.29 kcal mol-1). The dockings were also analysed visually for binding interactions between 
the COOH group of the ligand and the Arg group of the Y91R mutant and between the 
hydroxamic acid and the Zn in the active site. From this analysis 29 was also identified as a 
potential ligand despite not displaying energetic selectivity.  
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Compound HDAC1 Y91R vs. Y91E 
Selectivity (kcal mol-1) 
Visual Binding 
Interactions 
 
-7.71 vs. -6.90 
Zn – NHOH      Good 
Arg – COOH     Good 
 
-8.24 vs. -7.55 
Zn – NHOH      Good 
Arg – COOH     Good 
 
-7.50 vs. -7.72 
Zn – NHOH      Good 
Arg – COOH     Good 
 
-8.39 vs. -7.29 
Zn – NHOH        Ok 
Arg – COOH     Good 
 
-7.97 vs. -6.68 
Zn – NHOH      Good 
Arg – COOH     Good 
 
Table 10 – Table of promising HDAC1 E98R mutant selective inhibitors based on binding energies and 
visual analysis of the interactions.   
Synthetic routes were then designed for 27 and 28 (Fig. 43) and 29 and 30 (Fig. 44) based 
on previous close precedent and ease of synthesis[150]. It was decided not to synthesise 
hydroxamic acid 31 due to the possibility that the synthesised enantiopure compound 
would racemise. 
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Fig. 43 – Retrosynthetic analysis of compounds 27 and 28.   
 
The route for 27 and 28 was designed so that the variable amino acid group of either 
enantiomer could be added in the penultimate step, before deprotection. Adding variability 
in this penultimate step would potentially allow a library of compounds to be made if the 
scaffold was further optimised. The protected hydroxamic acid could then be made from 
the parent dicarboxylic acid in two steps thus allowing a quick and facile synthesis of 27 and 
28.  
 
Fig. 44 – Retrosynthetic analysis of compounds 29 and 30.   
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Retrosynthetic analysis of 29 and 30 was based around introduction of the chiral centre and 
previous precedent for forming this centre with a protected carboxylate[151]. AutoDock 
analysis suggested that the binding would be affected by the stereochemistry at the alpha 
carbon and so a strategy for enantioselective synthesis was formulated whereby 
incorporation of a chiral auxiliary would allow diastereoselective electrophilic addition to 
the enolate[152]. Removal of the chiral auxiliary would then allow access to the 
enantiomerically pure phenylamide. The other end of the molecule could then be 
deprotected and oxidised to form the carboxylic acid, which could be further reacted to 
form the hydroxamic acid Zn-binding group.  
With AutoDock analysis of compounds 27 and 28 showing both the potential for good 
binding and with the potential for library synthesis and subsequent optimisation, it was 
decided to commence synthesis of 27 and 28 first (Scheme 2).  
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Scheme 2 – a) Ac2O, b) MeOH, 60 
o
C, c) H2NOBn, EDCI, HOBt, Et3N, CH2Cl2, d) LiOH, THF/water, e) D-Phe-
OMe, EDCI, HOBt, Et3N, CH2Cl2, f) L-Phe-OMe, EDCI, HOBt, Et3N, CH2Cl2, g) H2, Pd/C. 
 
Monomethylpimelate 32 was synthesised from pimelic acid via the cyclic anhydride in 53% 
yield and then coupled with O-benzyl protected hydroxylamine to give 33 in 99% yield. 
Selective ester hydrolysis with LiOH then provided carboxylic acid 34 with LiOH in 69% yield, 
allowing to either L-Phe-OMe or D-Phe-OMe in quantitative yield. Both enantiomers were 
then divided into two portions and either hydrogenolysis or hydrolysis was performed. O-Bn 
groups were removed from both L and D enantiomers via hydrogenolysis in 56% and 27% 
yields respectively to yield the two compounds 39 and 40. Both products were isolated by 
precipitation from diethyl ether and this step is likely responsible for the disparity in the 
yields of these reactions; this problem could potentially be resolved with further 
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optimisation. Hydroxamic acids 39 and 40 were then set aside for testing as possible 
inhibitors of HDAC1 E98R as it was postulated that the methyl ester may be able to interact 
with the Arg group via hydrogen bonding (albeit with likely lower selectivity due to the 
polar interaction being significantly lower with an ester).  
Hydrolysis of 35 and 36 was then completed in 59% yield for the L-enantiomer and 100% 
yield for the D-enantiomer. The carboxylic acids 37 and 38 were then subjected to 
hydrogenolysis to yield target compounds 27 and 28 in 55% and 50% yield respectively. 
The four synthesised targets (27, 28, 39 and 40) were assayed for activity against w/t 
HDAC1 and the E98R mutant (Fig. 45). Interestingly all the inhibitors appeared to show an 
enhanced ability to inhibit HDAC1 over the E98R mutant. This is the opposite to the desired 
result in terms of engineering selective inhibitor pairs and was possibly due to the arginine 
group interfering having a blocking effect on the inhibitors (including TSA) or some other 
induced conformational change in the active site.  
 
 
Fig. 45 - Relative activity of inhibitors 26, 27, 14 and 15 incubated at 10 μM with HDAC1 or HDAC1(E98R).  
Errors are the standard errors from three separate experiments. 
 
While this selectivity was opposite to that desired it showed the potential for engineered 
selectivity in HDACs. With TSA also showing lower potency for inhibiting the mutant it may 
be that a different ZBG would be required to allow this selectivity to be exploited in a way 
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that was favourable for enhanced inhibition of the mutant. Another interesting discovery 
was also that of 39 and 40 as potentially good inhibitors of HDAC1. This is perhaps not 
surprising as they very closely match the structure of a reported set of HDAC inhibitors, 
which have the same structures as 39 and 40 with the exception of one extra CH2 group in 
the carbon chain[150](Fig. 46). Those reported structures display an IC50 of 800 nM for the S-
enantiomer and 880 nM for the R enantiomer towards inhibiting rat liver HDAC. Thus, an 
interesting future experiment would be to test the selectivity and activity of 27 and 28 
versus their longer chain analogues.  
 
Fig. 46 – Competitive inhibitors with very similar structures to 39 and 40 inhibit rat liver HDAC with high 
nanomolar potency
[150]
. 
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Conclusions and Future Work 
An engineered protein-ligand pair was designed, modelled and synthesised with successful 
expression of an active mutant and demonstrated inhibition of the mutant. The desired 
outcome was to synthesise a mutant-ligand pair that would show selectivity for the mutant 
over the wild-type but it was found that the synthesised inhibitors and the natural product 
TSA showed selective inhibition for the wild-type over the mutant. While this result 
suggested that engineered selectivity was possible, it also highlighted the challenges of 
designing a ligand-receptor pair with desired complementarity. While AutoDock 4.0 is a 
good method for visualising docking interactions for PLE it is limited in that global 
conformational changes induced by mutations, e.g. in the active site, are not considered in 
the model and thus these effects are difficult to predict. The apparent sensitivity of the 
catalytic activity to active site mutation also suggests that this PLE strategy may be difficult 
to exploit to obtain desired selectivity.  
Perhaps a more important question arising from this work is that of the effect of the 
cofactors on catalytic activity in Sf9 cell expressed HDAC1. It is not clear from the literature 
to what extent HDAC is activated in these systems and how this activation occurs. From a 
PLE point of view, protein-protein binding interactions could be engineered to be 
susceptible to a targeted inhibitor but more detail about the nature of these interactions 
would need to be obtained to exploit this possibility. That said, mutations of the putative 
protein binding surface could reveal information about the protein-protein binding 
interactions which, in the absence of a crystal structure of the active complex, could itself 
help elucidate the mechanism of activation.       
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2.2 Synthesis of a novel class of isoform-selective inhibitors  
One of the aims of applying protein-ligand engineering (PLE) to HDACs was to negate the 
challenge of designing isoform-selective inhibitors, which is made difficult by conservation 
in the HDAC active site. Despite this difficulty however, progress has been made towards 
isoform-selective inhibitor synthesis as outlined in Section 1.5. The interest in synthesising 
isoform-selective HDAC inhibitors mainly stems from their potential as clinical ligands[153] 
but they also have the potential to be used for dissecting enzyme function. As mentioned in 
Section 1.3, exposure of certain cell lines to broad HDAC inhibitors has been shown to lead 
to the upregulation as well as down regulation of genes and similar studies with isoform-
selective inhibitors would yield more information about the function of specific enzymes.  
The challenge of finding HDAC inhibitors that significantly inhibit one isoform over others 
(due to conservation in the active site channel) means that any selective inhibitor would 
need to exploit other parts of the HDAC active site in order to exhibit competitive inhibition.    
Chlamydocin (Fig. 47) is a potent irreversible cyclic tetrapeptide inhibitor that selectively 
inhibits HDACs 1-3. The selectivity is thought to arise mainly from interactions of the bulky 
capping tetrapeptide with the entrance to the active site channel. This is supported by 
studies into hydroxamic acid derivatives of cyclic tetrapeptides showing that the 
chlamydocin scaffold confers selectivity over other cyclic tetrapeptides[91].  
 
 
Fig. 47 – The cyclotetrapeptide epoxyketone HDAC inhibitor and antibiotic chlamydocin and the 2-amino 
phenylamide HDAC inhibitor MS-275.   
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By contrast 2-amino-phenyl amides such as MS-275 (Fig. 47) show HDAC 1-3 selectivity 
through the ZBG and this is thought to be due to steric clashes within the active site. With 
these two effects in mind it was postulated that combining the unique specificity of each of 
these groups could lead to new selectivity profiles. Thus, design and synthesis of a library of 
compounds with both the Chlamydocin cyclic tetrapeptide group and a 2-phenylamide ZBG 
was proposed. 
The challenge of combining a cyclic tetrapeptide cap with a 2-amino-phenylamide head 
group lies in allowing the inhibitor to adopt the correct conformation to allow binding 
interactions to take place. With both moieties being relatively bulky it is sensible to propose 
that the linker be as flexible as possible. However, more rigid linkers containing aromatic 
groups or alkenes have been found to increase potency due to π-π interactions with 
aromatic amino acid residues in the active site. With this in mind a cross-metathesis (CM) 
approach was proposed crossing an allylglycine motif incorporated into the tetrapeptide 
with a linker-zinc-binding group incorporating a terminal alkene (Fig. 48). This approach 
seemed conducive to library synthesis with potential linker variation as well as the 
possibility of synthesising sets of targets with either an alkene or alkane in the linker chain.  
 
 
Fig. 48 – Retrosynthetic analysis combining cyclotetrapeptide capping group with 2-amino phenylamide 
zinc-binding group.   
 
The terminal alkene functional group lends itself to a large number of possible 
transformations[154],[155],[156],[157],[158]. Incorporation of this motif into the cyclic tetrapeptide 
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could then facilitate the synthesis of 2-amino-phenylamides with a range of linkers. This 
strategy was further supported by the precedent for cross metathesis of protected 
allylglycine and vinylglycine and ring closing metathesis in the presence of peptides[159],[160]. 
The targets proposed were cyclic tetrapeptide 2-amino-phenyl amides with either a straight 
carbon chain linker (with or without double bond) or an aromatic linker as found in MS-275 
(Fig. 49).  
 
Fig. 49 – Proposed series of 2-amino-phenyl cyclic tetrapeptides.  
 
The cross-metathesis (CM) reaction was also chosen due to its orthogonality to the 
presence of peptide bonds although there are potential disadvantages to this approach 
including the distribution of products. CM precursors can be divided into four types based 
on their susceptibility to undergo CM with the more reactive alkenes generally electron rich 
and sterically unhindered and the least reactive sterically hindered and electron poor.[154] 
Type I precursors are highly reactive and quick to dimerise in the metathesis equilibrium, 
type II precursors are less reactive and subsequently slow to dimerise, type III precursors do 
not undergo homodimerisation and type IV precursors are unreactive. The type of 
precursors used in a CM reaction affects the distribution of products. For instance, reactions 
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between two type I precursors will result in a statistical mixture of products while reaction 
between a type I and type II precursor should favour product formation (Scheme 3). The 
cross mixture found when reacting type I reactants with each other can be manipulated 
however by using an excess of one reagent to push the equilibrium towards favoured 
product formation.  
 
Scheme 3 – Distribution of products from type I + type I and type II + type I CM reactions.  
 
For the purposes of the library synthesis the type one precursor cyclo(-D-Pro-L-Phe-Aib-L-
Agl-) 49 was chosen. This was then to be reacted with either the type II substrates 50 and 
51 or an excess of the type I substrates 52 and 53 in order to push the equilibrium of the 
reaction towards the desired product (Fig. 50). The substrates were classified according the 
rules described by Grubbs[154] with styrenes and acrylamides being type II and isolated 
terminal alkenes being type I.      
 
Fig. 50 – Cross-metathesis (CM) precursors. 
Cyclic tetrapeptides have been prepared by a number of groups with some extensive study 
into optimum cyclisation precursors[161]. For the synthesis of the cyclic tetrapeptide cyclo(-
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D-Pro-L-Phe-Aib-L-Agl-) 49 a protection strategy was devised using a tert-butyl ester as the 
permanent protecting group and benzyl carboxylates as the temporary protecting groups. 
This strategy was chosen due to the availability of the starting D-proline O-tert-butyl ester, 
literature precedent and the need to protect the terminal alkene from hydrogenation 
conditions[162](Scheme 4).  
 
 
Scheme 4 – Synthesis of tripeptide Aib-L-Phe-D-Pro-OBu
t
; a) BnCOCl, 2M NaOH; b) DCC, HOBt, Et3N, DMF; 
c) H2, Pd/C AcOH. 
Initial CBz-protection of L-phenylalanine[163] proceeded in 95% yield to give the protected 
amino acid which was then coupled with D-proline tert-butyl ester in 83% yield. The 
product, dipeptide 54, was then deprotected via hydrogenation over Pd/C to give the L-Phe-
D-Pro-OBut dipeptide 55 in 87% yield. Aminoisobutyric acid was then CBz-protected[164] in 
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64% yield and subsequently coupled to the free dipeptide 55 using DCC and HOBt to give 
the protected tripeptide 56 in 80% yield. Hydrogenolysis over Pd/C then afforded the free 
tripeptide Aib- L-Phe-D-Pro-OBut 57 in 95% yield.  
The next step in the synthesis would involve coupling of tripeptide 57 with L-allylglycine. 
The preparation of enantiopure allylglycine is often achieved by enzymatically resolving the 
racemic mixture using pig kidney acylase although chemical syntheses of L and D allylglycine 
have been reported[165],[166]. Unfortunately preparation of the L-enantiomer of N-Boc 
allylglycine via the enzymatic route requires a number of protection and deprotection steps 
(Fig. 51).  
 
 
Fig. 51 – Protection, resolution, deprotection and reprotection steps towards L-allylglycine. 
 
It was therefore decided to couple the tripeptide Aib-L-Phe-D-Pro-OBut 57 with DL-N-Boc-
allylglycine[160] in the hope that the two diastereomers could be separated (Scheme 5).  DL-
N-Boc-allylglycine was prepared in 81% yield by reacting DL-allylglycine with di-tert-butyl-
dicarbonate. The coupling was then attempted proceeding in 54% yield but the two 
diastereomers 58 were not separable via column chromatography. It was then decided to 
attempt the deprotection followed by cyclisation in the hope that the two cyclised products 
would be separable. The mixture of diastereomers was deprotected with TFA in 
quantitative yield to form the mixture 59.  
 
Scheme 5 – Coupling of tripeptide to DL-allylglycine; a) DCC, HOBt, Et3N; b) TFA.  
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Cyclisation of the free tetrapeptide mixture 59 was attempted at high dilution with the 
coupling reagent 2-(1H-7-azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium 
hexafluorophosphate methanaminium (HATU) (Fig. 52). HATU is an “all-in-one” coupling 
reagent that provides both the uronium group to activate the carboxylate as well as the 
azabenzotriazole group to form the stable intermediate activated ester and was used due to 
previous precedent for tetrapeptide cyclisation reactions[167].    
 
 
Fig. 52 – Coupling reagent HATU.  
 
The reaction yielded what appeared by 1H-NMR to be one diastereomer of the cyclised 
peptide 60 as well as another product which was identified by MS to be the cyclic 
octapeptide product 61 (Scheme 6). 
 
 
Scheme 6 – Cyclisation of DL-Agl-Aib-L-Phe-D-Pro-OH.  
 
Head-to-tail cyclisation of tetrapeptides is known to be problematic due to the restricted 
conformations imposed by cyclisation[168]. However, with precedent for cyclisation of 
tetrapeptides with the L-configuration at the allylglycine centre it was hoped that the 
desired cycle had been formed. To test this, a small sample of enantiopure L-N-Boc-
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allylglycine was obtained commercially and reacted with Aib-L-Phe-D-Pro-OBut 57 and 
cyclised to compare to the product obtained from attempted cyclisation of the mixture. 
H- Aib-L-Phe-D-Pro-OBut was coupled to Boc-L-allylglycine (Agl) in 44% yield and the 
resulting L-N-Boc-Agl-Aib-L-Phe-D-Pro-OBut 62 deprotected with TFA in 87% yield to form H-
L-Agl-Aib-L-Phe-D-Pro-OH.TFA 63. Synthesis of the diastereomerically pure cyclo(-L-Agl-Aib-L-
Phe-D-Pro-) was then carried out with HATU in 80% yield (Scheme 7).  
  
 
Scheme 7 – Cyclisation of H-L-Agl-Aib-L-Phe-D-Pro-OH.TFA. 
 
NMR analysis confirmed the identity of the cyclotetrapeptide from the attempted 
cyclisation of the diastereomeric mixture 60 as cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 49. This also 
suggested that the octopeptide 61 was composed of the D-Agl diastereomer. While the 
diastereoselective cyclisation is interesting it was decided that future syntheses would 
utilise the enantiopure L-allylglycine route as loss of at least half of the material in the final 
coupling step is not economical.  
The four potential metathesis coupling substrates were then synthesised via amine 
protection and coupling via the acid chloride (Scheme 8). Yields for the reactions varied 
from 38–81% but the products were made in sufficient quantity to attempt the subsequent 
cross-metathesis reactions. 
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Scheme 8 – Synthesis of metathesis precursors; a) K2CO3, DCM; b) (ClCO)2. 
 
Initial attempts at cross-metathesis (CM) involved reaction of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 
49, which is a type I substrate and 50, which is a type II substrate. Grubbs II (Scheme 9) was 
the first CM catalyst tried as it is known to be more reactive than the Grubbs I (Fig. 53) 
catalyst at room temperature while still being relatively inexpensive. Under these 
conditions the desired product was obtained in 27% yield exclusively as the E-isomer 
(Scheme 9).  
 
 
Scheme 9 – Cross-metathesis of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 50 and 49. 
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Attempts to optimise this reaction were made before moving on to other substrates.  
Grubbs I and the Grubbs-Hoveyda II catalysts (Fig. 53) were tested. While the Grubbs I 
catalyst showed very low reactivity even upon heating, Grubbs-Hoveyda II, which is known 
to allow CM of highly electron deficient substrates[169] worked well with the product 
obtained in 62% yield as exclusively the E-isomer. 
 
 
Fig. 53 – Grubbs I and Grubbs – Hoveyda II.  
 
Coupling of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 49 with the butenoic acid benzamide precursor 52 
was then attempted using an excess of 52 (4 eq). Initially no desired product formation was 
observed although a white precipitate was visible in the reaction mixture which was 
identified as the homodimer of 52. This was undesirable as formation of this insoluble 
dimer in DCM was removing the excess of 52 from the metathesis equilibrium. In an 
attempt to resolve this problem toluene was added to the reaction mixture to increase the 
solubility of the dimer, thus reintroducing it to the equilibrium. With a toluene/DCM 
mixture the reaction proceeded with formation of the coupled product 65 with the E-
isomer isolated in 37% yield (Scheme 10).  
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Scheme 10 – CM of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 36 with 39. 
 
Synthesis of the pentenoic acid derivative 66 was carried out using the same conditions as 
65. The E-isomer was the major product isolated in a yield of 81% after column 
chromatography (Scheme 11). 
 
 
Scheme 11 – CM of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) 36 with 40. 
 
Reaction of 49 with the type-II substrate 51 was also problematic due to homodimerisation. 
Performing the reaction in a toluene/DCM mixture however, led to formation of the desired 
product 67 in 20% yield (Scheme 12). This was not expected as the p-vinyl-benzoic acid 
derivative was expected to behave like a “Type II” precursor with formation of the dimer 
being slow. However, insolubility may have removed this dimer from the equilibrium thus 
lowering the yield.  
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Scheme 12 – Cross-metathesis to produce the CM product 54. 
 
The cross-metathesis products 64, 65, 66 and 67 were then either Boc-deprotected in 
TFA/DCM (Scheme 14) or hydrogenated in EtOH and then Boc-deprotected (Scheme 13) to 
form the desired inhibitors. 
 
 
Scheme 13 – Synthesis of final compounds; a) H2, Pd/C, EtOH; b) TFA, DCM. 
PhD Thesis – Robert Felstead September 26, 2012 
 
80 
 
 
Scheme 14 – Synthesis of final compounds; a) H2, Pd/C, EtOH; b) TFA, DCM 
All hydrogenation and TFA mediated Boc-deprotections proceeded in good yields producing 
the potential HDAC inhibitors (41 - 48). These inhibitors were then ready to be assayed for 
activity alongside an amide-linked inhibitor (72) that had been synthesised by a co-worker 
alongside 41  - 48 (Scheme 15)[170].  
 
Scheme 15 – Synthesis of the extra target compound 59[170]; a) DCC, HOBt, DIPEA, DMF; b) TFA; c) HBTU, 
DIPEA, DMF; d) Pd/C, H2. 
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The 9 inhibitors were assayed for inhibition against HDAC1 and HDAC2 using the assay 
system developed as described in Section 2.1. Deacetylase active complexes were prepared 
by co-expressing each HDAC with RbAp46, RbAp48 and MTA2-Flag in Sf9 cells and 
purification via IP. Inhibitors were tested for competitive inhibition using the fluorimetric 
assay described in Section 2.1 and levels were compared to control (Fig. 54). 
 
Fig. 54 – HDAC1 or HDAC2 co-expressed with MTA2-Flag, RbAp46 and RbAp48 in Sf9 cells was purified by 
IP. Results are based on the average of two experiments. Fluorimetric substrate was incubated with the 
beads for 30 min at rt in the presence of 10 µM inhibitor or inhibitor free control buffer at 0.1% DMSO. 
TSA was tested at 2 µM in 1% DMSO. Errors are standard error for the two experiments.   
 
The general activity/selectivity profile for all inhibitors was disappointing with activity 
significantly lower than that of Chlamydocin (HDAC1 IC50 0.15 nM)[171]. All inhibitors did 
show an apparent selectivity for HDAC1 over HDAC2 but this is common for most non-
selective inhibitors[171]. These results were obtained using an assay involving addition of the 
acetylated fluorimetric assay substrate shortly after addition of the inhibitor. However, 
studies involving 2-aminophenyl amide inhibitors have shown that their mode of action is 
via a slow binding mechanism[172]. The consequence of this is that these inhibitors do not 
exhibit their full competitive inhibitor properties until they have been incubated with the 
enzyme for 3 hours or more.  Thus to investigate the possibility of slow binding in 
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compounds 41 – 48 and 72 the assay was repeated with the inhibitors pre-incubated with 
HDAC1 and HDAC2 for 3 hours before conducting the assay. The results showed increased 
potency of the inhibitors as well as possible selectivity profiles for some of the compounds 
(Fig. 55). 
 
 
Fig. 55 – All inhibitors were incubated with the purified HDAC1 or HDAC2/RbAp46/RbAp48/MTA2-Flag 
complex for 3 hours at 10 µM prior to assaying for activity. Errors are the standard error for three 
separate experiments.   
 
Amide-linked inhibitor 72 showed an apparent selectivity for HDAC2 while 43, 44, 47, 42 
and 46 showed an apparent good potency for both HDAC1 and HDAC2. As the assay was a 
single point 10 µM measurement of deacetylase activity it is difficult to draw definitive 
conclusions from these results other than the cyclic tetrapeptides synthesised display 
potency weaker than TSA. Due to time and resource constraints it was not possible to 
perform IC50 measurements for these compounds however such information would be 
particularly useful for clarifying the selectivity profiles of these compounds. 
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Conclusions and Future Work 
A class of cyclic tetrapeptide 2-aminophenyl amide inhibitors were designed and 
synthesised via cross-metathesis and tested for deacetylase inhibition activity against 
HDAC1 and HDAC2. Future work could involve obtaining a full selectivity profile of these 
inhibitors to allow determination of structure-activity relationships. This would aid any 
future isoform-selective inhibitor design based on this class as well as give information 
about the viability of these scaffolds as promoters of selectivity and/or potency in future 
HDACI drug leads.    
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2.3 Activity Based Protein Profiling  
Sections 2.1 and 2.2 described attempts to develop methods for the dissection of HDAC 
function by either discovering or simulating isoform-selective inhibition. As described in 
Section 1.8 probe-based protein profiling has great potential for the dissection of enzyme 
function with activity based protein profiling particularly useful for identifying catalytically 
active enzymes.  
To date HDACs have been studied via a range of affinity based protein profiling probes 
(AfBPs) using a chemical probe based on the SAHA inhibitor (Fig. 56)[129]. The simplest of 
these, SAHA-BPYNE, contains an HDAC binding moiety that resembles SAHA but with a 
benzophenone group incorporated to act as a photoactivatable linker and an alkyne group 
to allow attachment of an affinity group or fluorescent tag via click reaction. 
 
 
Fig. 56 – HDAC affinity based probe SAHA-BPYNE. 
 
Incubation of living cells or cell lysates with the probe followed by photo-activation with UV 
light, click reaction with rhodamine-azide and fluorescence measurement of SDS-PAGE gel 
allowed identification of a number of HDACs and cofactors in those cellular systems. 
Interestingly the results for living cells showed stronger bands for SAHA-sensitive targets 
than those for cell lysates (Fig. 57)[129].  
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Fig. 57 – SAHA-BPYNE showed in vivo UV activated binding to several proteins known to bind to HDACs 
themselves (single arrows) as well as identifying new targets (double arrows)
[129]
.  
 
Among the proteins identified using the SAHA-BPYNE probe were HDACs 1 and 2 as well as 
MBD3, a cofactor known to be associated with HDACs. In this case, activation of the 
benzophenone group required between 5 minutes to 1 hour to allow trapping of the 
proteins.  
Development of an activity based probe (ABP) for HDACs is yet to be reported but if 
successful could potentially allow cell lines to be classified by HDAC catalytic activity as well 
as allow investigation of the effect of clinically relevant inhibitors on labelling.  
The basis of most activity based probes is the modification of an irreversible inhibitor of the 
target enzyme. Irreversible inhibitors of HDACs have been reported specifically in the form 
of epoxyketones such as Chlamydocin (Fig. 47). However, attempts to utilise epoxyketones 
as probes have not been successful due to the loss of the probe under denaturing 
conditions[173]. The irreversible inhibition by epoxyketones is attributed to the formation of 
a covalent linkage with a histidine residue in the active site (Fig. 58). This linkage is however 
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vulnerable to attack from the free hydroxyl group produced in the reaction, which may be 
responsible for loss of this linkage under denaturing conditions.  
 
Fig. 58 – Proposed HDAC binding mechanism of epoxyketone inhibitors.  
One way to avoid this problem would be to use an inhibitor with a leaving group. Many 
ABPs contain leaving groups binding a wide range of proteins (Table 5, Section 1.8) and in 
the case of HDAC binding this would solve the problem of reversibility under denaturing 
conditions as no hydroxyl would be present to displace the histidine intramolecularly (Fig. 
59). 
 
 Fig. 59 – Proposed mechanism for binding of HDAC probe.  
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A range of leaving groups was considered including acyloxy, aryloxy and arylthiomethyl 
ketones (Fig. 60) but to test the concept it was decided that a chloromethyl ketone (CMK) 
would be used.  
 
 
Fig. 60 – Potential warheads for HDAC irreversible inhibitors/ABPs. 
   
CMKs are one of the most highly utilised cross-linkers in ABPP probes targeting cysteine and 
serine proteases and although there are no reports of CMKs being used as HDAC inhibitors, 
literature precedent shows that a CMK version of the HDAC inhibitor Chlamydocin 73 does 
have anti-tumour activity and this could well be due to HDAC inhibition activity (Fig. 61) [174].  
 
 
Fig. 61 – Analogue of Chlamydocin shown to have anti-tumour activity.  
Before synthesis of a probe was undertaken it was decided that a simple scaffold containing 
the warhead and HDAC binding moiety would be synthesised and tested for inhibition 
properties. The initial target was a CMK analogue of SAHA 74 (Fig. 62).  
 
 
Fig. 62 – CMK derivative of SAHA. 
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The initial synthetic strategy to form the CMK 74 was via the diazomethyl ketone 75, which 
in turn would be synthesised from the carboxylic acid 76 (Fig. 63). Formation of 76 could 
either be via the monomethylated ester 77 or the cyclic anhydride 78. 
  
 
 
Fig. 63 – Retrosynthetic analysis of 74.  
 
The main advantage of this strategy was that, if successful, a wide variety of potential 
leaving groups as well as chloride could be incorporated in the last step allowing a library of 
inhibitors to be created.  
Synthesis of 74 started with the formation of 8-oxo-8-(phenylamino)octanoic acid 76 in 20% 
yield from suberic acid (Scheme 16)[175].  
 
 
Scheme 16 - a) Ac2O, reflux; b) Aniline, THF, rt. 
 
Initially a one-pot formation of 74 from 76 was attempted involving formation of the acid 
chloride followed by reaction with TMS-CHN2 to form the diazo derivative and then 
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subsequent reaction with aqueous HCl to form the CMK (Scheme 17). While there is 
precedent for such a procedure in one pot[176]; these reactions usually are carried out using 
diazomethane in formation of the diazoketone as opposed to TMS-diazomethane. TMS-
diazomethane was used however due to its convenience as a reagent and precedent for the 
formation of diazoketones[177]. 
 
 
Scheme 17 – Attempted one-pot formation of 74; a) (COCl)2, CH2Cl2, 0 
o
C; b) TMS-CHN2, THF/CH3CN, 0 
o
C; 
c) HCl/H2O, AcOH 0 
o
C -> rt. 
 
The reaction yielded a complex mixture of products and so attempts were then made to 
isolate the diazoketone 75 using a literature procedure which involved formation of the 
diazoketone by reaction of the pre-formed acyl chloride with TMS-diazomethane in a 
THF/acetonitrile mixture[178] (Scheme 18).   
 
 
Scheme 18 – Attempted formation of 75; a) (COCl)2, CHCl3, 0 
oC; b) TMS-CHN2, THF/CH3CN, 0 
o
C -> rt.  
 
The reaction led to the formation of a complex mixture of products but without any trace of 
the desired diazoketone. It was then decided that formation of the diazoketone via 
anhydride formation would be tried, again based on literature precedent[179] (Scheme 19).  
 
 
Scheme 19  – Unintended methylation of carboxylic acid; a) Isobutyl chlorofomate, NMM; b) TMS-CHN2,  
THF/CH3CN, 0 
o
C. 
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Reaction of 76 with isobutyl chloroformate led to formation of the mixed anhydride by TLC 
but after addition of the TMS-diazomethane, only the methyl ester was recovered. 
Formation of this ester suggests that unreacted carboxylic acid was methylated as TMS-
diazomethane is also used to methylate carboxylic acids[180]. Repeated attempts of 
anhydride formation using the ethyl mixed anhydride yielded only the carboxylic acid 
starting material. At this point it was decided to attempt direct formation of the CMK via 
another method not involving the diazoketone intermediate (Fig. 64).  
 
 
Fig. 64 – Alternative retrosynthetic analysis of 61. 
 
The proposed route involved reaction of a Weinreb intermediate 80 with a lithiated 
chloromethane species to form the chloromethylketone 79 followed by amide coupling to 
form 74. While there is precedent for conversion of Weinreb amides to chloromethyl 
ketones[181], there are no reports of this transformation using substrates bearing carboxylic 
acid groups.  However, it was hoped that deprotonation of the carboxylic acid in situ would 
prevent the group from interfering with the transformation.   
Synthesis of the Weinreb amide 80 from the dicarboxylic acid proceeded in 34% yield due to 
formation of bis-amide by-product (Scheme 20).  
 
 
Scheme 20 – Synthesis of 80; a) HNMeOMe.HCl, DCC, HOBt, Et3N, DMF. 
 
PhD Thesis – Robert Felstead September 26, 2012 
 
91 
 
Attempts to chloromethylate the amide 80 were then made by first deprotonating the 
carboxylic acid in situ with 1 eq. of MeLi, followed by addition of 2 eq. of 
chloroiodomethane and finally a further 1.5 eq. of MeLi. It was hoped that this would allow 
the intermediate CH2ClLi species to be formed in situ before reacting with the amide. The 
reaction proceeded yielding a mixture of starting material 80, methyl ketone 81 from amine 
substitution by excess MeLi present in the system and the desired chloromethylated 
product 79 in a 1:3:6 ratio respectively (Scheme 21). 
 
 
Scheme 21 – Initial Attempt to chloromethylate 80; a) 1eq. then 1.5MeLi, 2eq. CH2ICl, THF, - 78 
o
C. 
 
To improve the desired product yield a range of conditions was tried (Table 11). The first of 
these was pre-formation of the CH2ClLi before addition to the deprotonated 80 in an 
attempt to decrease the amount of methyl ketone by-product formed. In situ formation of 
the CH2ClLi in the presence of excess CH2ICl was then attempted to increase the amount 
CH2ClLi present in the reaction mixture. Finally, addition of MeLi to a pre-mixture of the 
starting material and CH2ICl was attempted to minimise the number of addition steps and 
hopefully improve the yield.     
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Conditions 80 81 79 
1 eq. MeLi and 80; then add pre-mixed CH2ICl 
(2 eq) and MeLi (2.5 eq).  
 
Majority Trace None 
1 eq. MeLi and 80; then add CH2ICl (10 eq) 
followed by MeLi (1.5 eq).   
Recovered None None 
1 eq 80 and 3 eq CH2ICl; then add MeLi (2.5 
eq).  
Recovered None None 
Table 11 – Attempted optimisation of chloromethylation reaction.  
With no improvement of the yield of the desired chloromethyl ketone product it was 
decided to try formation of the α-chloroketo acid from 1-nonen-9-ol via an alternative 
three-step synthesis previously performed on a homologue[182].  
Commercially available 1-nonen-9-ol 82 was epoxidised with m-CPBA in quantitative yield 
and the epoxide 83 subsequently selectively opened by addition of LiCl in mildly acidic 
conditions (Scheme 22). Oxidation of both the primary and secondary alcohol of 84 
simultaneously with Jones’ reagent led to formation of the α-keto acid 79 in 41% yield over 
two steps. 
 
 
Scheme 19 – Synthesis of α-keto acid 79; a) m-CPBA, CH2Cl2; b) LiCl, AcOH, THF; c) CrO3, H2SO4, 
Acetone/H2O. 
 
Coupling of the acid to aniline was initially attempted using EDC coupling but this gave a 
complex mixture of products possibly due to side reactions involving the chloroketone such 
as nucleophilic substitution with aniline. To negate this problem coupling via formation of 
the acyl chloride was attempted to exploit the inherent reactivity of the acid chloride over 
the aliphatic chloride and this was successful forming the target 74 in 36% yield (Scheme 
23). 
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Scheme 23 – Synthesis of 74; a) (COCl)2, CH2Cl2; b) Aniline, Et3N, DCM. 
Successful synthesis of 74 meant the viability of the structure as an irreversible HDAC binder 
could be tested. This was done by incubating 74 with the IP purified HDAC1 complexed with 
RbAp46, RbAp48 and MTA2-Flag described in Section 2.1 (page 51) for one hour at a variety 
of concentrations. The complexes were then assayed for deacetylase activity using the 
fluorimetric assay described in Section 2.1 (page 48). The results showed significant 
lowering of the enzyme activity to 40% ± 8% at 100 µM with full activity at 10 µM 
suggesting that 74 had weak inhibition properties (Fig. 65).  
 
 
Fig. 65 – Average enzymatic activity of IP purified HDAC1/RbAp46/RbAp48/MTA2-Flag cf. control levels. 
The value for 100 μM was obtained over 3 separate experiments and 50 and 10 μM over 2 separate 
experiments. Errors are the standard errors over three and two experiments for 100 µM and 10 and 1 µM 
respectively. 
 
With the SAHA-CMK 74 scaffold showing inhibition (albeit at high concentrations) it was 
decided to progress with synthesis of a potential probe 85 based on this scaffold (Fig. 66). 
The linker and alkyne tag design for 85 were based on that of SAHA-BPYNE, the AfBP 
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developed by Cravatt (Fig. 56) in the hope that it would exhibit the favourable active site 
binding properties exhibited by SAHA-BPYNE.  
 
Fig. 66 – Proposed HDAC ABP 85.  
 
Attempted synthesis of 85 was then started with the amide coupling of 1,4-diaminobenzene 
with 5-hexynoic acid to form alkyne 86 (Scheme 24).  
 
 
Scheme 24 – Synthesis of alkyne 86; a) DCC, HOBt, THF/DCM. 
 
Initial attempts to couple 86 with the α-keto acid 79 led to the formation of the di-
substituted product 87 as identified by NMR (Scheme 25).  
 
 
Scheme 25 – Over acylation of 86 with 79; a) (COCl)2, DMF, 0 
o
C; b) Et3N, 86, CH2Cl2. 
 
This was likely due to the HCl salt of 86 being formed in the reaction leaving the desired 
mono-acylated product 85 in solution and available to react with the remaining acid 
chloride. To avoid this, the reaction was repeated with slow addition of the acid chloride to 
a solution containing the amine and base (Scheme 26). 
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Scheme 26 – Synthesis of 85; a) (COCl)2, DMF, CH2Cl2, 0 oC; b) Et3N, 86, THF.  
The low coupling yield was un-optimised at 13% possibly due to continued formation of the 
unwanted di-acylated product. However, with enough of the desired compound 85 to 
perform biochemical experiments it was decided to progress with testing the biological 
activity of 85. 
To test the ability of the probe to bind HDAC1 in a cellular environment 85 was incubated 
with Sf9 cells expressing either HDAC1 or RbAp46 as a negative control. To test another 
probe 88 (Fig. 67), synthesised by a co-worker and designed to target CDC25 phosphatase, 
was also incubated with HDAC1.  
 
Fig. 67 – Irreversible CDC25 phosphatase inhibitor 88. 
 
Both probes were incubated with the Sf9 cells for 2 hours at 200 µM or 100 µM for 85 and 
88 respectively. The cells were then lysed and the copper(I) catalysed Huisgen [3+2] azide-
alkyne cycloaddition or Click reaction with a bi-functional biotinylated TAMRA-azide 89[183] 
performed (Fig. 68).  
 
Fig. 68 – Bi-functionalised biotinylated TAMRA-azide
[183]
.  
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The total protein was precipitated from the reaction mixture without further purification 
and run on SDS-PAGE gel before being measured for fluorescence (Fig. 69).  
 
Fig. 69 – Sf9 cells were infected with baculovirus expressing either RbAp46 or HDAC1-Flag, lysed and then 
incubated with either 85 at 200 µM or 88 at 100 µM for 2 hours. Click reaction with a biotinylated 
TAMRA-azide was then performed and the protein was precipitated from the reaction and subjected to 
SDS-PAGE before being imaged for fluorescence.   
 
Analysis of the gel showed a distinct band around 55 KDa matching that of HDAC1 in the 
cells incubated with 85 compared with 88 suggesting possible HDAC1 selectivity. A lack of 
binding of 85 to RbAp46 as shown by the right hand lane was also further evidence of this 
selectivity for HDAC1 over other proteins.   
This experiment was then repeated in the presence of activating cofactors RbAp46, RbAp48 
and MTA2 and with or without the competitive HDAC inhibitor TSA (Fig. 70). 
The results showed that incubation of 100 µM 85 in the presence of 1 µM TSA had no 
visible impact on the probe binding. Also, the presence of the cofactors appeared to 
decrease the amount of probe that was bound to the HDAC. However, the expression of 
cofactors is likely to reduce HDAC1 expression due to competition between baculoviruses 
during protein expression. Thus, to gain quantitative information on how activity based the 
PhD Thesis – Robert Felstead September 26, 2012 
 
97 
 
probe was in the presence of cofactors, the amount of HDAC1 relative to cofactors would 
need to be quantified and the activating properties of the cofactors on HDAC1 in this 
system established (see Conclusion – Section 2.1).   
 
 
Fig. 70 – Sf9 cells were infected with baculovirus expressing either HDAC1, RbAp46 (control) or 
HDAC1/MTA2/RbAp46/RbAp48 before being incubated with either TSA (1µM) or control buffer and 85 
(100 µM) for 2 h prior to lysis. Click reaction, SDS-PAGE and fluorescence imaging were carried out as 
described in Fig. 69. Arrow identifies HDAC1-Flag band.  
 
To investigate the potency of 85 in vitro, the probe was incubated with HDAC1 expressing 
cell lysates at a range of concentrations to see if the selectivity could be improved (Fig. 71). 
Probe 85 displayed possible binding to HDAC1 down to a concentration of 1 µM although a 
brighter band (labelled in Fig. 71) below the HDAC1 revealed either an interaction with 
another protein or degradation of the HDAC1 protein.  
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Fig. 71 – Sf9 cells were infected with baculovirus expressing HDAC1 or RbAp46 for 72 h and then lysed in 
Click reaction buffer before incubation with probe 85 at a variety of concentrations for 1 h. Click reaction 
with biotinylated TAMRA-azide was then performed followed by SDS-PAGE and Fluorescence imaging. 
Arrow identifies band for degraded HDAC1. 
 
To test these properties in vivo the probe was incubated at a number of concentrations 
with Sf9 cells expressing either HDAC1 (Fig. 72) or HDAC2 (Fig. 73).  
 
 
Fig. 72 – Sf9 cells expressing HDAC1 were incubated with TSA for 1 hour before addition of probe 85 for 2 
hours at the concentrations shown (all in µM). The cells were then lysed and the Click reaction performed 
with biotinylated TAMRA-azide before protein precipitation, SDS-PAGE and fluorescence imaging.   
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Fig. 73 – Sf9 cells expressing HDAC2 were incubated with TSA for 1 hour before addition of probe for 2 
hours at the concentrations shown (all in µM). The cells were then lysed and the Click reaction performed 
with biotinylated TAMRA-azide before protein precipitation, SDS-PAGE and fluorescence imaging.   
 The results showed that probe 85 can bind to HDAC1 at 1 µM and HDAC2 at 10 µM in vivo 
(the weak band at 100 µM in Fig. 72 is an anomaly as previous experiments have shown 
stronger signals at this concentration). The results also showed that in HDAC1 85 at 1 µM 
can be competed out by TSA at 1 µM and in HDAC2 85 at 10 µM could be competed out by 
TSA at 10 µM. Interestingly, at 10 µM 85 could not be competed out by TSA at 10 µM in 
HDAC1 expressing cells as it had done in HDAC2 expressing cells. These results suggest that 
the probe has greater affinity for HDAC1 than HDAC2, which would be in keeping with the 
inhibitor profile of SAHA upon which the probe is based. This result could, however, also be 
a result of lower expression levels for HDAC2 vs. HDAC1 in the system and so quantification 
of the protein amounts as well as quantification of the fluorescence signal would allow this 
to be investigated further.  
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Conclusion and Future Work    
A probe that targets HDAC1 and HDAC2 has been successfully designed and synthesised.  
Further investigations are required to confirm the ability of 85 to specifically target active 
HDACs including, as outlined in Section 3, Conclusion biotin pull-down and further 
identification by either Western Blot or mass spectrometry. Experiments in natural systems 
are also required to see if 85 is potent enough to target HDACs in these environments. 
However, the out-competition by TSA suggests that the probe is binding to HDACs via the 
enzyme active site and thus provides strong evidence that it is a useful scaffold for 
developing ABPs for HDACs.  
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3 Conclusion 
The development of chemical tools to investigate histone deacetylase enzymes will allow 
the dissection of active enzyme function as well as provide in vivo assays that can identify 
the mode of action of therapeutic inhibitors. Here progress has been made towards the 
development of three methodologies, protein-ligand engineering, isoform-selective 
inhibitor design and activity based protein profiling.  
A protein-ligand receptor pair exploiting the arginine-carboxylate interaction was designed 
and modelled. A system expressing an HDAC1 E98R mutant was then developed and 
optimised with expression of a cofactor activated E98R mutant that could be assayed for 
deacetylase activity. The mutant showed good deacetylase activity comparable to w/t and 
along with the HDAC1 wild-type could facilitate testing of a series of ligands. A number of 
ligands were rationally designed and visualised using AutoDock 4.0 and the most promising 
two synthesised along with two methylated analogues. These inhibitors alongside the broad 
range HDAC inhibitor TSA were tested for inhibition activity against w/t HDAC1 and the 
E98R mutant. The assay results showed a preference for all of the inhibitors including TSA 
to inhibit the w/t over the mutant. They also identified the methylated analogues as 
potentially good inhibitors of HDACs. What would be interesting to investigate further is 
whether preferential inhibition of the w/t over the mutant is specific to hydroxamic acid 
inhibitors or more general. This would allow the effect of the mutation to be more closely 
probed and any potential routes to engineered ligand selectivity to be identified.    
In attempting to discover isoform-selective inhibitors a series of cyclic tetrapeptide 2-
aminophenyl amides was rationally designed and synthesised via ruthenium catalysed 
cross-metathesis reaction. The design was based on combining the Class I selectivity of the 
cyclotetrapeptide capping group and the 2-aminophenyl amide zinc-binding group to 
hopefully confer further selectivity. The inhibitors were tested for inhibition activity against 
cofactor-activated HDAC1 and HDAC2 expressed in Sf9 cells. Simultaneous incubation of the 
inhibitors with the assay substrate showed weak competitive inhibition activity while pre-
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incubation of the inhibitors for 3 hours prior to substrate inhibition showed a much higher 
inhibition of both HDAC1 and HDAC2. A number of the inhibitors showed possible 
selectivity and reasonable potency comparable to TSA but within the confines of the 
experiments carried out it is difficult to be certain of these relationships. Ascertaining the 
selectivity profiles of the most potent compounds against HDACs across a range of classes 
would certainly be a desirable experiment to carry out as it would allow structure activity 
relationships of this compound class to be identified.  
In an attempt to probe HDACs via activity based protein profiling a probe was designed 
using a reactive chloromethyl ketone head group and a linker and scaffold based on the 
affinity based probe SAHABPYNE. The probe was incubated with HDAC1, HDAC2 or a non-
HDAC control in Sf9 cells at a range of probe concentrations. The probe showed selective 
binding to HDAC1 and HDAC2, which could subsequently be competed out by addition of 
the competitive HDAC inhibitor TSA. While this suggested that the probes could bind to 
HDACs it did not identify if the binding was correlated to catalytically active HDAC activity. 
Thus further optimisation of a quantifiable active HDAC system and subsequent probe 
binding ability would further identify it as a viable activity-based probe. Furthermore testing 
in native systems would be necessary to ascertain the probe’s activity in the presence of 
lower concentrations of HDAC. The bi-functionalised tag could potentially allow biotin 
purification and subsequent identification by Western Blot in native systems thus providing 
more information about selectivity. This said, the probe is based on a very simple scaffold 
and a number of scaffolds have been optimised with affinity-based probes[184]. Therefore it 
seems logical that optimisation of the probe scaffold would be possible increasing both 
HDAC selectivity and probe potency.  
The three approaches described herein have had varying success in providing the most 
viable route to chemical dissection of histone deacetylase function. The protein-ligand 
engineering route has identified the challenges of applying the methodology to such a 
system where active site modification has such a dramatic effect on enzyme function and 
thus perhaps has limited scope to this end. The development of isoform-selective inhibitors 
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is in itself a worthy endeavour in terms of providing potential therapeutic scaffolds as well 
as allowing the effect of chemical inhibition to be investigated. To this end, the series 
investigated here offers promise that such selectivity can be rationally designed but further 
evidence is required to identify the usefulness of such inhibitors. Finally - the activity based 
probing route has arguably shown the most promise in terms of dissection of function and 
also has the potential to gather the most relevant information on the function of HDACs 
and the effect of HDAC inhibitors in a range of cellular systems. While there is clearly work 
to be done in terms of ligand optimisation and in determining finer points around activity it 
is possible that this simple scaffold could be the key to dissecting the function of histone 
deacetylases in a variety of systems.    
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4 Experimental 
4.1 Biochemistry – Materials and Methods 
Buffers, Solutions and Media 
All chemicals were obtained from commercial sources and were of a high quality. All 
solutions were made up in ultrapure water unless otherwise stated. 
Solutions and Media Composition 
Solution I 50 mM L-glucose, 10mM EDTA, 25mM Tris-
HCl, pH 8.0  
Solution II 0.2 M NaOH, 1% (w/v) SDS 
Solution III 2.5 M potassium acetate/acetic acid, pH 5.0 
Ampicillin – stock solution (1000x) 50 mg/mL  
Click Reaction Buffer 1% (v/v) NP-40, 1% (v/v) sodium 
deoxycholate, 0.1% (w/v) SDS,  50 mM Tris-
HCl pH 7.4, 150 mM NaCl.  
Coomassie Brilliant Blue Staining Solution 10% (v/v) acetic acid, 10% (v/v) MeOH, 0.4% 
(w/v) Coomassie brilliant blue R-250  
DNA loading buffer (5x) 50% (v/v) Type II loading dye, 10% (v/v) TAE 
(50x) (+ 1% RNase A for crude DNA)   
Electrophoresis transfer buffer (ETB) 39 mM glycine, 48 mM tris-base, 0.037% 
SDS, 10% (v/v) MeOH 
Gene clean wash solution 50 mM NaCl, 10 mM Tris-HCl (pH 7.5), 50% 
(v/v) EtOH 
GST elution buffer I 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
DTT, 5% glycerol.  
GST elution buffer II 20 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 
20 mM glutathione, 5% glycerol, pH 7.4 
HDAC Assay Buffer 50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 
mM KCl, 1 mM 
MgCl2 
IP Buffer I 20 mM Tris, pH 8; 150 mM NaCl; 0.2 mM 
EDTA, 10 mM b-ME, 10% glycerol; 0.5% 
Triton X-100 
KOD Buffer 1.2 M Tris-HCl, 100 mM KCl, 60 mM 
(NH4)2SO4, 1% (v/v) Triton X-100, 0.01% (w/v) 
BSA, pH 8.0 
Luria Broth (LB) medium 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% 
(w/v) bactoyeast extract pH 7 
NETN lysis buffer 100 mM NaCl, 20 mM Tris-Cl (pH 8.0), 0.5 
mM EDTA, 0.5 % (v/v) Nonidet P-40 (NP-40) 
Phosphate buffered saline (PBS) 140 mM NaCl, 3 mM KCl, 2 mM KH2PO4, 10 
mM Na2PO4  
PBST 0.1 % (v/v) Tween-20 in PBS 
SDS – PAGE loading buffer (2x) 64 mM Tris pH 6.8, 10% (v/v) glycerol, 2% 
(w/v) SDS, 0.72% (v/v) 2-mercaptoethanol, 
dash of bromophenol blue  
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SDS – PAGE resolving gel 0.2% (v/v) SDS, 10% acrylamide solution 
(30% acrylamide, 0.8% bisacrylamide), 0.4 M 
Tris-HCl pH 8.8 
SDS – PAGE running buffer 0.25 M Tris base, 1.92 M glycine, 35 mM SDS 
SDS – PAGE stacking gel 0.1% (v/v) SDS, 5% acrylamide solution (30% 
acrylamide, 0.8% bisacrylamide), 0.1 M Tris-
HCl pH 6.8 
T4 DNA ligation buffer (10x) 400 mM Tris-HCl, 100 mM MgCl2, 100 mM 
DTT, 5 mM ATP (pH 7.8) 
Tris-Acetate-EDTA (TAE) buffer (50x) 2 M Tris-HCl, 1 M acetic acid, 50 mM EDTA 
(pH 8.0) 
 
Plasmids 
All plasmids were constructed using standard molecular biology techniques as outlined 
below and nucleotide sequences of plasmids were verified by sequencing. 
The following constructs were used: 
HDAC1-prSETA[131], HDAC1-pBacPAK-Strep-tag II[132], HDAC1(L271A)-pBacPAK-Strep-tag 
II[132], HDAC1(F150A)-pBacPAK-Strep-tag II[132], HDAC1-pAcG2T, HDAC1(L271A)-pAcG2T, 
HDAC1(E98A)-pAcG2T, HDAC1(E98R)-pAcG2T, C-V5-cdk6(T177A)-pcDNA3[185], C-FLAG-
HDAC1-pcDNA3, C-FLAG-HDAC1(L271A)-pcDNA3, C-FLAG-HDAC1(E98A)-pcDNA3, C-FLAG-
HDAC1(E98R)-pcDNA3, pFastBac1.  
 
HDAC1-pAcG2T was created by subcloning the HDAC1 fragment from HDAC1-pBacPAK-
Strep-tag II into HDAC1-pAcG2T using BamHI and EcoRI. 
 
HDAC1(L271A)-pAcG2T was created by subcloning the HDAC1 fragment from 
HDAC1(L271A)-pBacPAK-Strep-tag II into HDAC1-pAcG2T using BamHI and EcoRI. 
 
 HDAC1(E98A)-pAcG2T was created by two-step site directed mutagenesis of HDAC1-
prSETA. The sense strand was generated using sense primer 5' – 
CCGCGGATCCATGGCGCAGACGCAGGACC – 3’ and antisense mutagenic primer 3' – 
GAATACTGGACAGTCGGCGCCAACGTTGAATCTC – 5’ and the antisense strand was generated 
using mutagenic sense primer 5' – GAGATTCAACGTTGGCGCCGACTGTCCAGTATTC – 3’ and 
antisense primer 3' – GCGCGAATTCAGGCCAACTTGACCTCCTCCTTGACC – 5’. Amplification of 
these two strands was carried out using the sense and antisense primers and the resulting 
PCR product was subcloned into HDAC1-pAcG2T using BamHI and EcoRI.  
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HDAC1(E98R)-pAcG2T was created by subcloning a 517bp fragment containing the E98R 
mutation from C-FLAG-HDAC1(E98R)-pcDNA3 into HDAC1(E98A)-pAcG2T using BamHI and 
BsrGI.  
C-FLAG-HDAC1-pcDNA3 was created by subcloning a 425bp fragment containing wild-type 
sequence from HDAC1-prSETA into C-FLAG-HDAC1(E98R)-pcDNA3 using BamHI and BsgI.  
 
C-FLAG-HDAC1(L271A)-pcDNA3 was created by PCR amplification of HDAC1(L271A)-
pBacPAK-Strep-tag II using the primers 5' – CCGCGGATCCATGGCGCAGACGCAGGACC – 3’ 
and 3' – GCGCTCGAGGGCCAACTTGACCTCCTCCTTGACC – 5’, removing the stop codon and 
introducing a XhoI site at the 3’ end. The PCR product was subcloned into C-V5-
cdk6(T177A)-pcDNA3 using BamHI and XhoI.   
 
C-FLAG-HDAC1(E98A)-pcDNA3 was created by subcloning a 517bp fragment containing the 
E98A mutation from HDAC1(E98A)-pAcG2T into C-FLAG-HDAC1(E98R)-pcDNA3 using BamHI 
and BsrGI. 
 
C-FLAG-HDAC1(E98R)-pcDNA3 was created by two-step site directed mutagenesis of 
HDAC1-prSETA. The sense strand was generated using sense primer 5' – 
CCGCGGATCCATGGCGCAGACGCAGGACC – 3’ and antisense mutagenic primer 3' – 
GAATACTGGACAGTCGCGACCAACGTTGAATCTC – 5’ and the antisense strand was generated 
using antisense mutagenic primer 3' – GCGCTCGAGGGCCAACTTGACCTCCTCCTTGACC – 5’, 
removing the stop codon and introducing a XhoI site at the 3’ end and mutagenic  sense 
primer 5' - GAGATTCAACGTTGGTCGCGACTGTCCAGTATTC – 3’. Amplification of these two 
strands was carried out using the sense and antisense primers and the resulting PCR 
product was subcloned into C-V5-cdk6(T177A)-pcDNA3 using BamHI and XhoI.   
 
HDAC1(E98R)-pFastBac1 was created by subcloning a 1453bp fragment containing the 
HDAC1(E98R) from HDAC1(E98R)-pAcG2T into pFastBac1 using BamHI and EcoRI.  
 
HDAC1(wt)-pFastBac1 was created by subcloning a 1453bp fragment containing HDAC1(wt) 
from HDAC1-pBacPAK-Strep-tag II into pFastBac1 using BamHI and EcoRI.  
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Antibodies 
GST B14 (mouse, monoclonal, Santa Cruz), StrepMAB-Classic (IBA), Anti-Flag M2 (mouse, 
monoclonal, Aldrich) and Anti-mouse IgG-HRP secondary antibody (Millipore) were used in 
this research.  
 
Protein expression in Sf9 Cells 
Sf9 cells (derived from Spodoptera frugiperda) were maintained at 27° C in Grace’s 
Complete Insect Medium (GCIM, Gibco BRL) supplemented with 10 % (vlv) FBS. The culture 
of Sf9 cells was set up in six-well dishes (Nunc), each well containing approximately 5.8 x 105 
cells (determined using a Neubeur haemocytometer) in 3 mL of medium. 2 µL of linearized 
recombinant Autographa calfornica nuclear polyhedrosis virus (AcNPV) (Pharmingen — 
BaculoGold system) and 5 ng of plasmid DNA or 1 µg Bacmid DNA were added to 100 µL 
Grace’s medium and added to 20 µL of lipofectin in 100 µL of Grace’s medium.  After 10 – 
15 min at room temperature 1 mL of Grace’s medium was added to the mixture and the 
mixture added to the relevant wells (after aspiration of the medium and washing with 
Grace’s medium). The wells were left O/N at 27 oC and then the medium replaced with 
Grace’s medium containing 10% (v/v) FBS. After 7 days the virus was harvested from the 
medium and 0.5 mL added to a 6 cm dish containing 3 mL of medium and 2.3 x 106 cells. 
After 7 more days the medium was removed and 0.5 mL added to a 9 cm dish containing 8 
mL of medium and 5.8 x 106 cells. After another 7 days the medium was removed and 0.5 
mL added to a 75 cm3 flask containing 15 mL of medium and 5.8 x 106 cells. After a further 7 
days the medium was retained and 1 mL added to a 175 cm3 flask containing 1.3 x 107 cells 
for the final round of amplification. After 7 days the 50 mL of viral medium was kept for test 
infections and large scale expression. Expression was afforded by adding between 10 µL and 
500 µL of viral titer per 5.8 x 105, 5.8 x 106 or 1.3 x 107 cells at 70% confluency.   
FastBac Bacmid preparation: 
pFastBac vectors were heat-shock transformed into DH10Bac™ competent E. coli cells and 
plated on LB agar medium supplemented with 50 μg/ml kanamycin, 7 μg/ml gentamicin, 10 
μg/ml tetracycline, 100 μg/ml Bluo-gal and 40 μg/ml IPTG. The plates were incubated for 48 
hours and white colonies picked and re-streaked onto agar plates supplemented as above 
and incubated O/N. White colonies were picked and inoculated in 2 ml LB medium 
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containing 50 μg/ml kanamycin, 7 μg/ml gentamicin, and 10 μg/ml tetracycline. Bacmid 
DNA was isolated by mini-preparation. 
 
Transformation of Bacterial Cells by Electroporation  
Plasmid DNA (1 µL) was mixed with E. coli DH5α cells and electroporation was carried out 
using a BioRad Gene Pulser set to 2.2-2.3 kV. LB medium (1 mL) was added, the resulting 
solution centrifuged (13 krpm, 1 s) and 800 µL removed. The pellet was resuspended in the 
remaining solution and the cells plated onto LB agar medium supplemented with 50 µg/ml 
of ampicillin. The agar dishes were incubated overnight at 37°C. 
 
Enzymatic digestion of DNA  
DNA restriction digests were carried out at 20 µL volume in the appropriate buffer using 1-5 
µg of DNA and restriction enzyme/s compromising no more than 10% of the total volume. 
Samples were incubated at 37°C for one hour. TAE loading buffer was added and samples 
run on a 1 % (w/v) agarose gel.  
 
Agarose gel electrophoresis 
1% (w/v) agarose gels were made up with 1x TAE buffer containing 1 µg/mL of Ethidium 
Bromide. Samples were subject to electrophoresis by applying 60 - 120 mA of constant 
current through the gel. Digested DNA was visualized by Ethidium Bromide staining under 
UV-A radiation and the required DNA band excised. 
 
GeneClean DNA purification 
The sample was incubated with an equal volume of 6M Nal at 60°C for 5 min. Glassmilk 
(Bio-101 Systems) was added to the sample and incubated on ice for 5 min to allow the DNA 
bind to the Glassmilk. The salt was removed from the sample by washing three times in 500 
µL gene clean wash solution. The pellet was re-suspended in 20 µL water and incubated at 
65°C for 5 min. After centrifugation for 1 min at 13000 rpm, an aliquot of the supernatant 
solution was used for ligation. 
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DNA ligation 
Ligation was performed at 20 µL volume in T4 DNA ligase buffer. 1 µL of digested vector and 
16 µL of digested insert (both from gene clean purification) were incubated at room 
temperature for between 1 and 60 hours with 1 µL of T4 DNA ligase (Fermentas). 
 
PCR Reaction 
DNA template(s) (0.02 µg), primer (0.125 nmol) and mutagenic primer (0.125 nmol) were 
added to dNTPs (5 nmol), MgCl2 (25 nmol), 10x KOD buffer (2.5 µL) and made up to 24.75 µL 
with sterile water. KOD polymerase (0.25 µL, 1U/µL, Novagen) was added, the mixture 
heated (98 oC, 5 min), the PCR reaction run (98 oC, 15 s; 55 oC, 2 s; 72 oC, 20s; 25 cycles) and 
the resulting mixtures separated on a 1% agarose gel followed by gene clean DNA 
purification of the excised DNA.  
 
Annealing of Oligonucleotides 
Oligonucleotides (1 µg of each) and 10x KOD buffer (2 µL) in a 20 µL reaction were heated 
(98 oC, 1 min) before being cooled over 30 min to 4 oC.  
 
Sample preparation for DNA sequencing 
DNA sequencing was performed through outsourcing to Beckman Coulter Genomics. 
 
Small scale preparation of plasmid DNA (mini-prep) 
Single colonies were grown in 2 ml of LB containing 50 µg/mL of ampicillin overnight at 37°C 
with shaking. 1.5 mL of culture was transferred to a fresh microcentrifuge tube and pelleted 
by microcentrifugation (13000rpm for 10 seconds). The supernatant solution was removed 
and the pellet was re-suspended in 100 µL of Solution I. 200 µL of Solution II was added and 
tubes were mixed by inversion. 150 µL of Solution III was added and the samples were 
centrifuged at 13000 rpm for 5 min. The supernatant solution was transferred to a fresh 
tube and 1 mL of absolute ethanol was added followed by centrifugation at 13000 rpm for 5 
min. The DNA pellet was re-suspended in 50 µL of water. 
 
Large scale preparation of plasmid DNA (maxi-prep) 
The remaining 0.5 mL of culture from the miniprep was inoculated into 200 mL of LB 
containing 50 µg/mL ampicillin and was grown overnight at 37°C with shaking. The bacteria 
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were harvested by centrifugation at 5000 rpm, 4°C for 5 min. The supernatant solution was 
decanted and the pellet was re-suspended in Solution I, Solution II (10 mL) was added and 
the tubes mixed by inversion. Bacterial DNA and protein were precipitated by adding 15 mL 
of Solution III. The precipitate was pelleted by centrifugation at 9,000 rpm, 4°C for 5 min 
and the supernatant solution was filtered through gauze to remove any loose precipitate. 
Plasmid DNA was precipitated from the filtrate by adding isopropanol (45 mL) and 
centrifuged at 9,000 rpm, 4°C for 5 min. The pellet was re-suspended in 3 mL of water and 4 
mL of 5 M LiCl (pre-cooled to –20 Co) was added. The solution was incubated on ice for 5 
min followed by centrifugation at 13000 rpm for 5 min. The supernatant solution was 
collected and 1 mL of ethanol were added followed by centrifugation at 5000 rpm for 5 min. 
The pellet was re-suspended in 500 µL of water and 10 µL RNase A (10 mg/mL) was added. 
The sample was incubated at 37°C for 15 min followed by the addition of 600 µL of 20% 
(w/v) PEG8000/2.5 M NaCI, incubation on ice for 5 min and centrifugation at 13000 rpm for 
5 min. The pellet was re-suspended in 500 µL of water and an equal volume of 1:1 (v/v) 
phenol-chloroform was added, the sample mixed via vortex and centrifuged at 13000 rpm 
for 5 min. The aqueous top phase was transferred to a fresh microcentrifuge tube and 
mixed via vortex with an equal volume of chloroform. The top aqueous phase was 
transferred to a fresh microcentrifuge tube and 1 mL of ethanol was added together with 
50 µL of 3 M sodium acetate (pH 5.2). The sample was centrifuged at 13000 for 5 min and 
the DNA pellet was re-suspended in 100 – 300 µL of water. The plasmid DNA sample was 
then stored at -20°C. 
 
SDS-Polyacrylamide gel electrophoresis[186] 
Cultured cells were lysed with appropriate amount of 2x SDS-PAGE buffer according to 
experimental design. Samples were loaded onto a 10% gel and subjected to electrophoresis 
at 200V for approximately 1 hour.  
 
Detection of protein by Coomassie Blue staining of SDS-PAGE gels 
SDS-PAGE gels were incubated in Coomassie Blue staining solution at room temperature 
with gentle rocking for 30 – 45 min. 
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Immunoblotting (Western Blotting) 
Polyacrylamide gel with resolved samples was equilibrated in ETB for 30 min and 
transferred onto Protran® nitrocellulose membrane (Schuster & Schuell) via 
electrophoresis. The transfer was performed for 35 min at 400mA. The membrane was then 
incubated overnight with primary antibodies in 5 % (w/v) milk solution in PBST with shaking 
at 4°C. Subsequently, the membrane was washed three times for 10 min in PBST then Horse 
radish peroxidase (HRP)-conjugated secondary antibody was incubated with PBST/milk for 
45 min followed by three 10 min washes in PBST and two rinses in PBS. The mix of 
Amersham enhanced chemiluminescence (ECL) solutions were applied to the membrane for 
1 min, after which it was visualized using the LAS-3000 imaging system (Fujifilm). 
Affinity Purification using Glutathione Sepharose 
The supernatant was added to glutathione Sepharose beads (50 or 250 µL, GE Healthcare), 
pre-equilibrated by washing with NETN (1 or 10 mL). The solution was tumbled (4 oC, 1h) 
before being centrifuged (2krpm, 4 oC, 1 min) and washed with NETN (3 x 1 or 10 mL). The 
protein was either assayed on the beads, eluted immediately or the volume reduced to 150 
µL, an equal volume of glycerol added, the solution kept on ice for 30 min and then 
subsequently stored at –20 oC.  
 
Elution from Glutathione Sepharose Beads 
The beads were washed with GST elution buffer I and the protein eluted with elution buffer 
II (3 x 200 µL, rt, 5 min) before centrifugation (5 krpm, rt, 1 min). 
 
Immunoprecipitation for Protein Purification 
Sf9 cells were collected 72 h post-infection, centrifuged at 2000 rpm for 2 mins and washed 
with ice cold PBS. Cells were lysed on ice for 10 minutes in 150 µL of IP Buffer I with 
occasional vortexing. After centrifugation for 5 min at 14000 rpm, 2 µL of Anti-Flag M2 
antibody and 25 µL of pre-equilibrated protein G-Sepharose beads were added and mixed 
incubate for 2 h at 4 oC. Beads were subsequently washed three times with IP Buffer I at 4 
oC and then 2 times with HDAC Assay Buffer.  
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HDAC Assays 
Recombinant protein beads or eluent (1 – 5 µL) were incubated with Fluor de LysTM HDAC 
substrate (Biomol International) at 50 µM concentration in HDAC assay buffer diluted to 50 
µL final volume for 20 min at rt either in half volume 96-well plates or tumbling in a 
microfuge tube.  Fluor de LysTM HDAC developer (Biomol International) diluted to 2x stock in 
50 µL containing TSA (1 µM) was then added and the mixture incubated at rt for 15 min. 
Fluroescence generated was monitored at wavelengths 360 nm (excitation) and 460 nm 
(emission) using a Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies). 
 
Click Reaction 
Sf9 cells were lysed in Click Reaction Buffer (150 µL) on ice for 10 min and then centrifuged 
for 10 min at 14000 rpm at 4 oC. The protein concentration was adjusted to 1 mg/mL with 
buffer. The Click reaction mixture was prepared and added to 100 µL of the mixture (final 
concentrations: 100 µM 76 and 1 mM CuSO4 vortexed followed by 1mM TCEP vortexed, left 
for 2 min and then 100 µM TBTA added). The mixture was shaken for 1 h at rt and then 
EDTA added to a final concentration of 10mM. Protein was precipitated by; addition of 400 
µL of ice-cold methanol followed by vortexing, 100 µL of chloroform followed by vortexing 
and 300 µL water; vortexing followed by 2 min centrifuge at 14000 rpm and removal of the 
top layer; addition of 400 µL methanol followed by vortexing and 2 min centrifuge at 14000 
rpm; and removal of the methanol followed by evaporation to dryness. Protein was then 
ready for SDS-PAGE analysis. 
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4.2 Molecular Docking 
The crystal structure of HDLP complexed to TSA (PDB code: 13CR) was imported into 
Chimera[142] and hydrogen atoms added. Y91E and Y91R mutations were also implemented 
at this stage. The AutoDockTools (ADT) package was employed to create the docking input 
files and analyse docking results. Autogrid4 was used to prepare the grid parameter file and 
the docking was run using AutoDock 4.0. A grid size of 60 x 60 x 60 points with a grid 
spacing of 0.375Å was implemented and centred on the active site. A rigid docking surface 
was used with the exception of the Y91X mutation around which active torsions of the 
single bonds were permitted. All single bonds in the ligands apart from amide bonds were 
treated as active torsional bonds. 50 docked structures were generated by using Lamarckian 
genetic algorithm searches. A default protocol was applied with an initial population of 150 
randomly placed individuals, a maximum number of 2.5 x 107 energy evaluations and a 
maximum number of 2.7 x 104 generations. A mutation rate of 0.02 and a crossover rate of 
0.8 were used.      
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4.3 Chemistry Experimental 
General Experimental 
All reactions were conducted under an inert argon atmosphere. All reagents were used as 
purchased from commercial sources. Thin layer chromatography was performed on Merck 
silica gel glass plates (60 F254) using UV light or potassium permanganate and heat to 
visualise compounds. Flash column chromatography was performed using silica gel (particle 
size 33 – 70 μm). 
Melting points were collected on a Reichert melting point apparatus. IR spectra were 
recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer. NMR spectra were recorded 
at room temperature unless otherwise stated on Bruker DRX 400 machines. When mixtures 
of two rotamers are present in the NMR spectra these are quoted as Hmaj and Hmin and the 
ratio stated. Mixtures of unassigned diastereomers are referred to as a and b and where 
absolute stereochemistry is known by the appropriate configuration. Mass spectra were 
recorded on Micromass Autospec Premier spectrometers. Optical rotations were recorded 
on a Perkin-Elmer 241 polarimeter at 589 nm (Na D-line) with a path length of 1 dm. 
Concentrations (c) are quoted in g/100 mL and specific rotations, [α]20D   , are quoted in units 
of 10-1degcm2g-1 at the specified temperature, T.  
 
Purification of laboratory solvents 
All solvents were distilled before use. Anhydrous solvents and reagents were obtained as 
follows: 
DMF – Stirred over MgSO4 for 24 h, filtered and distilled under reduced pressure and stored 
over molecular sieves (4Å) under argon. 
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Experimental 
Monomethyl pimelate[187] 32 
 
Pimelic acid (1.60 g, 10 mmol) was heated under reflux in acetic anhydride (4 mL) for 1 h. 
Excess acetic anhydride was removed under reduced pressure and the resulting cloudy oil 
dissolved in methanol (10 mL) and acetonitrile (5 mL) and stirred for 16 h at rt. The solvent 
was removed and reduced pressure and the residue dissolved in methanol (7 mL) and 
heated under reflux for 2 h. The solvent was removed under reduced pressure and the 
crude product was purified by silica gel chromatography using a mixture of ethyl 
acetate/hexane (30%) to yield Monomethyl pimelate 32 as a clear oil (930 mg, 53%), Rf = 
0.25 (SiO2; 70:30 hexane/ethyl acetate); δH (400 MHz; CDCl3) 3.70 (3H, s, CH3), 2.39 (2H, t 
J 7.5, CH2-CO), 2.35 (2H, t J 7.5, CH2-CO), 1.68 (4H, q J 8.0, -CH2-CH2-CH2-CH2-CO), 1.45 – 
1.36 (2H, m, CH2-CH2-CH2-). Data are in agreement with the literature
[187].  
 
6-Trityloxycarbamoyl-hexanoic acid methyl ester 33 
 
 
 
Triethylamine (0.567 mL, 4.1 mmol) was added to a solution of monomethyl pimelate 32 
(697 mg, 4.0 mmol) in DCM (20 mL) and the mixture cooled to 0 oC. Hydroxybenzotriazole 
(645 mg, 4.2 mmol), triethylamine (0.567 mL, 4.1 mmol) and EDCI.HCl (805 mg, 4.2 mmol) 
were then added and the mixture stirred for 10 minutes at 0 oC. N-Benzyl hydroxylamine 
hydrochloride (638 mg, 4.0 mmol) and triethylamine (0.567 mL, 4.1 mmol) were then added 
and the mixture stirred for a further 2 h at rt. The reaction mixture was then diluted into 
ethyl acetate (50 mL) and washed with sat. aq. sodium bicarbonate (25 mL), hydrochloric 
acid (2M, 25 mL), water (25 mL) and brine (25 mL) before being dried over sodium sulfate. 
The solvent was removed under reduced pressure and the crude product purified by silica 
gel chromatography using a mixture of ethyl acetate/hexane (1:1) to yield 33 as a clear oil 
(1.11 g, 99%), Rf = 0.15 (SiO2; 70:30 hexane/ethyl acetate); νmax/cm
-1 1740 (C=O, ester), 1658 
(C=O, amide); δH (400 MHz; CDCl3) 7.44 – 7.40 (5H, m, ArH), 5.00 – 4.81 (2H, m, CH2-Ph ), 
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3.68 (3H, s, CH3), 2.36 – 2.01 (4H, m, 2 x CH2-CO), 1.72 – 1.56 (4H, m, -CH2-CH2-CH2-), 
1.41 – 1.31 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.1, 129.2, 128.7, 51.5, 33.8, 
32.9, 28.5, 24.9, 24.4; m/z (ES) 280 ([M + H]+, 20%), (Found: [M + H]+, 280.1558. C15H22NO4 
requires 280.1549; ∆3.2 ppm). 
 
6-Trityloxycarbamoylhexanoic acid 34 
 
 
 
Lithium hydroxide (1M, 4.5 mL, 4.5 mmol) was added to a solution of methyl ester 33 (978 
mg, 3.5 mmol) dissolved in THF (3.5 mL) and the mixture stirred for 4 h at rt. Sodium 
hydroxide (0.5 M, 10 mL) was then added to the reaction mixture and washed with ethyl 
acetate (50 mL). The aqueous layer was acidified to pH 3 with 2M hydrochloric acid and 
extracted into ethyl acetate (3 x 50 mL). The combined organic extracts were then dried 
over sodium sulfate and the solvent removed under reduced pressure to yield 34 as a waxy 
solid (642 mg, 69%), νmax/cm
-1 1727 (C=O, acid), 1659 (C=O, amide); δH (400 MHz; CDCl3) 
7.44 – 7.39 (5H, m, ArH), 7.34 (3H, m, Ar3,5H + NH), 4.99 – 4.81 (2H, m, CH2-Ph ), 2.40 – 
2.04 (4H, m, 2 x CH2-CO), 1.71 – 1.59 (4H, m, -CH2-CH2-CH2-), 1.41 – 1.33 (2H, m, CH2-
CH2-CH2-); δC (101 MHz; CDCl3) 178.4, 129.3, 128.7, 33.6, 28.4, 24.2; m/z (ES) 266 ([M + H]
+, 
91%), (Found: [M + H]+, 266.1394. C15H22NO4 requires 266.1392; ∆0.8 ppm). 
 
(S)-2-(6-Benzyloxycarbamoyl-hexanoylamino)-3-phenylpropionic Acid Methyl Ester 35 
 
 
Triethylamine (0.144 mL, 1.03 mmol) was added to a solution of carboxylic acid 34 (265 mg, 
1.0 mmol) in DCM (5 mL) and the mixture cooled to 0 oC. Hydroxybenzotriazole (169 mg, 1.1 
mmol), triethylamine (0.144 mL, 1.03 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (211 mg, 1.1 mmol) were then added and 
the mixture stirred for 10 minutes at 0 oC. L-Phe-OMe.HCl (216 mg, 1.0 mmol) and 
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triethylamine (0.144 mL, 1.03 mmol) were then added and the mixture stirred for a further 
20 h at rt. The reaction mixture was reduced in volume under reduced pressure, then 
diluted into ethyl acetate (25 mL) and washed with sat. aq. sodium bicarbonate (3 x 25 mL), 
water (25 mL), hydrochloric acid (2M, 25 mL), water (25 mL) and brine (25 mL) before being 
dried over sodium sulfate. The solvent was removed under reduced pressure to yield 35 as 
a clear gum (426 mg, 100%), νmax/cm
-1 1740 (C=O, ester), 1654 (C=O, amide); δH (400 MHz; 
CDCl3) 7.45 – 7.38 (5H, m, ArH), 7.34 – 7.25 (3H, m, ArH), 7.13 – 7.09 (2H, m, ArH), 5.92 
(1H, bs, NH),  4.99 – 4.81 (3H, m, CH2-Ph + CHN), 3.70 (3H, s, -Me),   3.21 – 3.06 (2H, m, 
CH2-Ph), 2.22 – 2.01 (4H, m, 2 x CH2-CO), 1.73 – 1.55 (4H, m, -CH2-CH2-CH2-), 1.37 – 1.25 
(2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 172.5, 172.2, 135.9, 129.3, 128.6, 127.2, 52.9, 
52.4, 37.9, 36.0, 24.7; m/z (ES) 427 ([M + H]+, 21%), (Found: [M + H]+, 427.2222. C24H31N2O5 
requires 427.2233; ∆2.6 ppm). 
 
(R)-2-(6-Benzyloxycarbamoyl-hexanoylamino)-3-phenylpropionic Acid Methyl Ester 36 
 
 
Triethylamine (0.144 mL, 1.03 mmol) was added to a solution of carboxylic acid 34 (265 mg, 
1.0 mmol) in DCM (5 mL) and the mixture cooled to 0 oC. Hydroxybenzotriazole (169 mg, 1.1 
mmol), triethylamine (0.144 mL, 1.03 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (211 mg, 1.1 mmol) were then added and 
the mixture stirred for 10 minutes at 0 oC. D-Phe-OMe.HCl (216 mg, 1.0 mmol) and 
triethylamine (0.144 mL, 1.03 mmol) were then added and the mixture stirred for a further 
20 h at rt. The reaction mixture was reduced in volume under reduced pressure, then 
diluted into ethyl acetate (25 mL) and washed with sat. aq. sodium bicarbonate (3 x 25 mL), 
water (25 mL), hydrochloric acid (2M, 25 mL), water (25 mL) and brine (25 mL) before being 
dried over sodium sulfate. The solvent was removed under reduced pressure to yield 36 as 
a clear gum (426 mg, 100%), νmax/cm
-1 1740 (C=O, ester), 1654 (C=O, amide); δH (400 MHz; 
CDCl3) 7.45 – 7.38 (5H, m, ArH), 7.34 – 7.25 (3H, m, ArH), 7.13 – 7.09 (2H, m, ArH), 5.92 
(1H, bs, NH),  4.99 – 4.81 (3H, m, CH2-Ph + CHN), 3.70 (3H, s, -Me),   3.21 – 3.06 (2H, m, 
CH2-Ph), 2.22 – 2.01 (4H, m, 2 x CH2-CO), 1.73 – 1.55 (4H, m, -CH2-CH2-CH2-), 1.37 – 1.25 
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(2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 172.5, 172.2, 135.9, 129.3, 128.6, 127.2, 52.9, 
52.4, 37.9, 36.0, 24.7; m/z (ES) 427 ([M + H]+, 21%), (Found: [M + H]+, 427.2220. C24H31N2O5 
requires 427.2233; ∆3.0 ppm). 
 
 (S)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenylpropionic Acid 37 
 
 
Lithium hydroxide (0.5M, 2 mL, 1.0 mmol) was added to a solution of methyl ester 35 (213 
mg, 0.5 mmol) dissolved in THF (2 mL) and the mixture stirred for 16 h at rt. The mixture 
was then diluted into water (20 mL) and ethyl acetate (40 mL). The aqueous layer was 
acidified to pH 3 with 2M hydrochloric acid and extracted into ethyl acetate (3 x 50 mL). The 
combined organic extracts were then washed with water (25 mL), brine (25 mL) and dried 
over sodium sulfate. The solvent removed under reduced pressure to yield 37 as a clear 
gum (121 mg, 59%), νmax/cm
-1 1710 (C=O, acid), 1667 (C=O, amide); δH (400 MHz; CD3OD) 
7.46 – 7.21 (10H, m, ArH), 4.86 (2H, bs, CH2-Ph), 4.73 – 4.67 (1H, m, CHN) 3.28 – 2.90 
(2H, m, CH2-Ph), 2.19 – 2.12 (2H, m, CH2-CO), 2.06 – 1.98 (2H, m, CH2-CO), 1.60 – 1.45 
(4H, m, -CH2-CH2-CH2-), 1.25 – 1.12 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.5, 
173.4, 171.4, 137.2, 135.6, 129.0, 128.8, 128.2, 128.1, 128.0, 126.4, 77.5, 53.5, 37.0, 35.0, 
32.1, 27.9, 24.9, 24.8; m/z (ES) 413 ([M + H]+, 100%), (Found: [M + H]+, 413.2066. C23H29N2O5 
requires 413.2076; ∆2.4 ppm). 
 
(R)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenylpropionic Acid 38 
 
 
Lithium hydroxide (0.5M, 2 mL, 1.0 mmol) was added to a solution of methyl ester 36 (213 
mg, 0.5 mmol) dissolved in THF (2 mL) and the mixture stirred for 16 h at rt. The mixture 
was then diluted into water (20 mL) and ethyl acetate (40 mL). The aqueous layer was 
acidified to pH 3 with 2M HCl and extracted into ethyl acetate (3 x 50 mL). The combined 
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organic extracts were then washed with water (25 mL), brine (25 mL) and dried over sodium 
sulfate. The solvent removed under reduced pressure to yield 38 as a clear gum (206 mg, 
100%), νmax/cm
-1 1710 (C=O, acid), 1667 (C=O, amide); δH (400 MHz; CD3OD) 7.46 – 7.21 
(10H, m, ArH), 4.86 (2H, bs, CH2-Ph), 4.73 – 4.67 (1H, m, CHN) 3.28 – 2.90 (2H, m, CH2-
Ph), 2.19 – 2.12 (2H, m, CH2-CO), 2.06 – 1.98 (2H, m, CH2-CO), 1.60 – 1.45 (4H, m, -CH2-
CH2-CH2-), 1.25 – 1.12 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.5, 173.4, 171.4, 
137.2, 135.6, 129.0, 128.8, 128.2, 128.1, 128.0, 126.4, 77.5, 53.5, 37.0, 35.0, 32.1, 27.9, 
24.9, 24.8; m/z (ES) 413 ([M + H]+, 100%), (Found: [M + H]+, 413.2073. C23H29N2O5 requires 
413.2076; ∆0.7 ppm). 
 
(S)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenylpropionic acid methyl ester 39 
 
 
Pd/C (10% wt., 28 mg) was added to a solution of methyl ester 35 (107 mg, 0.25 mmol) in 
methanol (2.5 mL) and the mixture stirred at rt under hydrogen atmosphere for 24 h. The 
reaction mixture was filtered through celite and the solvent removed under reduced 
pressure. The crude residue was triturated with diethyl ether to yield 39 as a white solid (47 
mg, 56%), m.p. 105 oC; νmax/cm
-1 1741 (C=O, ester), 1645 (C=O, amide); δH (400 MHz; 
CD3OD) 7.34 – 7.20 (5H, m, ArH)  4.74 – 4.67 (1H, m, CHN), 3.71 (3H, s, -Me), 3.22 – 2.92 
(2H, m, CH2-Ph), 2.18 (2H, t J 7.0, CH2-CO), 2.07 (2H, t J 7.0, CH2-CO), 1.63 – 1.49 (4H, m, 
-CH2-CH2-CH2-), 1.31 – 1.21 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.6, 172.3, 
171.5, 136.9, 128.8, 128.1, 126.5, 53.7, 51.3, 36.9, 35.0, 32.1, 28.0, 25.0, 24.9; m/z (ES) 337 
([M + H]+, 100%), (Found: [M + H]+, 337.1750. C17H25N2O5 requires 337.1763; ∆3.9 ppm). 
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(R)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenylpropionic acid methyl ester 40 
 
 
Pd/C (10% wt., 28 mg) was added to a solution of methyl ester 36 (107 mg, 0.25 mmol) in 
methanol (2.5 mL) and the mixture stirred at rt under hydrogen atmosphere for 24 h. The 
reaction mixture was filtered through celite and the solvent removed under reduced 
pressure. The crude residue was triturated with diethyl ether to yield 40 as a white solid (23 
mg, 27%), m.p. 105 oC; νmax/cm
-1 1741 (C=O, ester), 1645 (C=O, amide); δH (400 MHz; 
CD3OD) 7.34 – 7.20 (5H, m, ArH)  4.74 – 4.67 (1H, m, CHN), 3.71 (3H, s, -Me), 3.22 – 2.92 
(2H, m, CH2-Ph), 2.18 (2H, t J 7.0, CH2-CO), 2.07 (2H, t J 7.0, CH2-CO), 1.63 – 1.49 (4H, m, 
-CH2-CH2-CH2-), 1.31 – 1.21 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.6, 172.3, 
171.5, 136.9, 128.8, 128.1, 126.5, 53.7, 51.3, 36.9, 35.0, 32.1, 28.0, 25.0, 24.9; m/z (ES) 337 
([M + H]+, 100%), (Found: [M + H]+, 337.1751. C17H25N2O5 requires 337.1763; ∆3.6 ppm). 
 
(S)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenyl-propionic Acid 27 
 
 
Pd/C (10% wt., 20 mg) was added to a solution of carboxylic acid 37 (103 mg, 0.25 mmol) in 
methanol (2.5 mL) and the mixture stirred at rt under hydrogen atmosphere for 3.5 h. The 
reaction mixture was filtered through celite and the solvent removed under reduced 
pressure. The crude residue was triturated with diethyl ether to 27 as a white solid (44 mg, 
55%), m.p. 124 oC; νmax/cm
-1 1722 (C=O, acid), 1631 (C=O, amide); δH (400 MHz; CD3OD) 
7.32 – 7.19 (5H, m, ArH)  4.73 – 4.67 (1H, m, CHN), 3.27 – 2.91 (2H, m, CH2-Ph), 2.18 (2H, 
t J 8.0, CH2-CO), 2.07 (2H, t J 7.0, CH2-CO), 1.63 – 1.48 (4H, m, -CH2-CH2-CH2-), 1.30 – 
1.19 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.5, 173.6, 171.5, 137.2, 128.9, 128.0, 
126.4, 53.6, 37.0, 35.1, 32.2, 28.0, 25.0, 24.9; m/z (ES) 323 ([M + H]+, 48%), (Found: [M + H]+, 
323.1612. C16H23N2O5 requires 323.1607; ∆1.5 ppm). 
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(R)-2-(6-Hydroxycarbamoyl-hexanoylamino)-3-phenyl-propionic Acid 28 
 
 
Pd/C (10% wt., 20 mg) was added to a solution of carboxylic acid 38 (103 mg, 0.25 mmol) in 
methanol (2.5 mL) and the mixture stirred at rt under hydrogen atmosphere for 3.5 h. The 
reaction mixture was filtered through celite and the solvent removed under reduced 
pressure. The crude residue was triturated with diethyl ether to yield 28 as a white solid (40 
mg, 50%), m.p. 124 oC; νmax/cm
-1 1722 (C=O, acid), 1631 (C=O, amide); δH (400 MHz; 
CD3OD) 7.32 – 7.19 (5H, m, ArH)  4.73 – 4.67 (1H, m, CHN), 3.27 – 2.91 (2H, m, CH2-Ph), 
2.18 (2H, t J 8.0, CH2-CO), 2.07 (2H, t J 7.0, CH2-CO), 1.63 – 1.48 (4H, m, -CH2-CH2-CH2-), 
1.30 – 1.19 (2H, m, CH2-CH2-CH2-); δC (101 MHz; CDCl3) 174.5, 173.6, 171.5, 137.2, 128.9, 
128.0, 126.4, 53.6, 37.0, 35.1, 32.2, 28.0, 25.0, 24.9; m/z (ES) 323 ([M + H]+, 50%), (Found: 
[M + H]+, 323.1600. C16H23N2O5 requires 323.1607; ∆2.2 ppm). 
 
N-Benzyloxycarbonyl-L-phenylalanine, Z-L-Phe-OH[163]   
 
 
To a solution of L-phenylalanine (4.96 g, 30 mmol) in 2M sodium hydroxide (15 mL) at 0 oC 
was added dropwise benzyl chloroformate (4.28 mL, 30 mmol). After 1 h 1M sodium 
hydrogen carbonate (40 mL) was added and the mixture stirred for a further 20 h at room 
temperature. The reaction mixture was then washed with diethyl ether (50 mL) and the 
aqueous layer acidified with 2M HCl (50 mL) and the organic products extracted into ethyl 
acetate (3 x 50 mL). The combined organic extracts were washed in brine (50 mL) and dried 
over magnesium sulfate. The solvent was removed under reduced pressure to yield Z-L-
Phenylalanine (8.57g, 95%) as a white solid, m.p. 87 oC [Lit.[163], m.p. 88 oC]; [α]20D   + 5.3 (c. 
1.0 in MeOH); δH (400 MHz; CDCl3) 7.42 – 7.14 (10H, m, Ar-H), 5.23 – 5.08 (3H, m, Ar-
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CH2-O + NH), 4.69 (1H, m, CH), 3.22 – 3.05 (2H, m, Ar-CH2-C). Data are in agreement 
with the literature[163]. 
 
N-Benzyloxycarbonyl-L-phenylalaninyl-O-tert-butyloxycarbonyl-D-Proline, Z-L-Phe-D-Pro-
OtBu[162] 54  
 
 
To a solution of H-D-Pro-OtBu.HCl (4.99 g, 24.0 mmol) and Z-L-Phe-OH (7.18 g, 24.0 mmol) in 
DMF (50 mL) at 0 oC were added hydroxybenzotriazole (3.24 g, 24.0 mmol), dicyclohexyl 
carbodiimide (5.94 g, 28.8 mmol) and triethylamine (3.35 mL, 24.0 mmol) and the mixture 
stirred at rt for 8 h. The reaction mixture was filtered, DMF removed under reduced 
pressure and the resulting residue dissolved in ethyl acetate (100 mL), washed with 10% 
citric acid (100 mL), 4% sodium bicarbonate (100mL), brine (50 mL) and dried over 
anhydrous magnesium sulfate. Ethyl acetate was removed under reduced pressure and the 
resulting residue purified by silica gel chromatography using a mixture of dichloromethane 
and methanol (99:1) to yield 54 as a colourless oil (9.03 g, 83%), (4:1 mixture of rotamers), 
Rf = 0.65 (SiO2; 97:3 dichloromethane/methanol); [α]20D   + 70 (c. 0.1 in MeOH); νmax/cm
-1 
1719 (C=O, ester), 1640 (C=O, amide) ;δH (400 MHz; CDCl3) 7.42 – 7.17 (10H, m, Ar-H), 
5.67 (1H, m, NH), 5.18 – 4.96 (2H, m, Ar-CH2-O), 4.71 (1H
maj, m, CH(Phe)maj), 4.55 (1Hmin, 
m, CH(Phe)min), 4.20 (1Hmaj, m, CH(Pro)maj, 3.70 – 3.37 (1Hmaj + 2Hmin, m, N-CHH + 
CH(Pro)min), 3.20 – 2.82 (2H, m, Ar-CH2-C), 2.65 (1H
maj, m, N-CHHmaj), 2.35 – 2.15 (2Hmin, 
m, N-CHHmin + N-CH2-CH2-CHH
min), 2.02 – 1.55 (4Hmaj + 3Hmin, m, N-CH2-CH2-CHH
min, N-
CH2-CH2- CH2
maj), 1.52 (9Hmin, s, OtBumin), 1.45 (9Hmaj, s, OtBumaj); δC (101 MHz; CDCl3, 55 
oC) 170.7, 169.7, 155.6, 136.9, 136.6, 136.5, 129.5, 128.5, 128.4, 128.0, 127.9, 126.9, 126.7, 
82.3, 81.2, 66.8, 59.8, 54.1, 46.8, 46.6, 38.1, 34.0, 31.4, 28.9, 28.0, 25.7, 24.9, 24.3, 22.3; 
m/z (ES) 475 ([M + Na]+, 100%), (Found: [M + H]+, 453.2379. C26H33N2O5 requires 453.2389; 
∆2.2ppm). 
 
 
PhD Thesis – Robert Felstead September 26, 2012 
 
123 
 
L-phenylalaninyl-O-tert-butyloxycarbonyl-D-Proline, H-L-Phe-D-Pro-OtBu[162] 55 
 
 
Z-L-Phe-D-Pro-OtBu (6.34 g, 14.0 mmol) was dissolved in acetic acid (30 mL) and Pd/C (10% 
wt., 0.85 g) added. The mixture was stirred at rt under hydrogen atmosphere for 15 h. The 
reaction mixture was filtered, acetic acid removed under reduced pressure and the 
resulting residue dissolved in ethyl acetate (100 mL), washed with saturated sodium 
bicarbonate (50mL) and dried over anhydrous magnesium sulfate. Ethyl acetate was 
removed under pressure to yield 55 as a colourless oil (3.88 g, 87%), [α]20D   + 10 (c. 0.1 in 
MeOH); νmax/cm
-1 1737 (C=O, ester), 1642 (C=O, amide); δH (400 MHz; CDCl3) 7.39 – 7.19 
(5H, m, Ar-H), 4.29 – 4.12 (1H, m, CH(Phe)), 3.83 – 3.47 (2H, m, CH(Pro) + N-CHH), 3.15 – 
2.62 (3H, m, Ar-CH2-C + N-CHH), 2.30 – 1.55 (6H, m, N-CH2-CH2-CH2 + NH2), 1.55 – 1.42 
(9H, m, OtBu); δC (101 MHz; CDCl3, 55 
oC) 173.6, 171.3, 138.1, 129.9, 129.5, 129.3, 128.8, 
128.5, 128.4, 127.5, 126.6, 81.1, 60.1, 59.6, 59.3, 57.8, 55.1, 46.5, 45.2, 42.4, 41.8, 40.6, 
34.0, 31.5, 31.3, 28.9, 28.0, 24.5, 22.3, 21.7; m/z (ES) 319 ([M + H]+, 100%) (Found: [M + H]+, 
319.2011. C18H27N2O3 requires 319.2022; ∆3.4ppm). 
 
N-(Benzyloxycarbonyl)aminoisobutyric acid, Z-Aib-OH[164]  
 
 
To a solution of aminoisobutyric acid (3.09 g, 30 mmol) in 2M sodium hydroxide (15 mL) at 
0 oC was added dropwise benzyl chloroformate (4.28 mL, 30 mmol). After 1 h 1M sodium 
hydrogen carbonate (40 mL) was added and the mixture stirred for a further 20 h at room 
temperature. The reaction mixture was then washed with diethyl ether (50 mL) and the 
aqueous layer acidified with 2M hydrochloric acid (50 mL) and the organic products 
extracted into ethyl acetate (3 x 50 mL). The combined organic extracts were washed in 
brine (50 mL) and dried over magnesium sulfate. The solvent was removed under reduced 
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pressure to yield Z-Aib-OH (4.54g, 64%) as a white solid, m.p. 83 – 84 oC [Lit.,[164] 84 – 85  
oC]; δH (400 MHz; CDCl3) 7.45 – 7.30 (5H, m, Ar-H), 5.39 (1H, bs, NH), 5.12 (2H, s, Ar-CH2-
O), 1.58 (6H, s, 2 x Me). Data are in agreement with the literature[164]. 
 
N-Benzyloxycarbonyl-aminoisobutyryl-L-phenylalaninyl-O-tert-butyloxycarbonyl-D-
Proline, Z-Aib-L-Phe-D-Pro-OtBu[162] 56  
 
 
To a solution of H-L-Phe-D-Pro-OtBu (3.82 g, 12.0 mmol) and Z-Aib-OH (2.84 g, 12.0 mmol) in 
DMF (25 mL) at 0 oC were added hydroxybenzotriazole (1.62 g, 12.0 mmol), dicyclohexyl 
carbodiimide (2.97 g, 14.4 mmol) and triethylamine (1.67 mL, 12.0 mmol) and the mixture 
stirred at rt for 14 h. The reaction mixture was filtered, DMF removed under reduced 
pressure and the resulting residue dissolved in ethyl acetate (50 mL), washed with 10% 
citric acid (50 mL), 4% sodium bicarbonate (50mL), brine (50 mL) and dried over anhydrous 
magnesium sulfate. Ethyl acetate was removed under reduced pressure and the resulting 
residue purified by silica gel chromatography using a mixture of dichloromethane and 
methanol (99:1) to yield 56 as a white foam (5.14 g, 80%), (4:1 mixture of rotamers), m.p. 
54 - 56 oC; Rf = 0.60 (SiO2; 97:3 dichloromethane/methanol); [α]20D   + 40 (c. 0.1 in MeOH);  
νmax/cm
-1 1730 (C=O, ester), 1636 (C=O, amide); δH (400 MHz; CDCl3) 7.40 – 7.17 (10H, m, 
Ar-H), 6.85 (1H, m, NH), 5.48 – 4.72 (4H, m, CH(Phe) + Ar-CH2-O + NH), 4.23 (1H
maj, m, 
CH(Pro)maj, 3.67 – 3.49 (1Hmaj + 2Hmin, m, N-CHH + CH(Pro)min), 3.27 – 2.89 (2H, m, Ar-
CH2-C), 2.73 (1H
maj, m, N-CHHmaj), 2.35 – 2.15 (2Hmin, m, N-CHHmin + N-CH2-CH2-CHH
min), 
2.00 – 1.70 (4Hmaj + 3Hmin, m, N-CH2-CH2-CHH
min, N-CH2-CH2- CH2
maj), 1.65 – 1.30 (15H, 
m, 2 x Me + OtBu); δC (101 MHz; CDCl3, 55 
oC) 173.7, 170.7, 169.6, 154.8, 136.6, 129.6, 
128.5, 128.3, 128.0, 127.9, 126.9, 126.6, 81.1, 66.6, 56.9, 51.8, 46.6, 39.4, 37.7, 34.0, 31.3, 
28.9, 28.0, 25.8, 25.3, 25.1, 24.3, 22.3 ; m/z (ES) 560 ([M + Na]+, 100%), (Found: [M + H]+, 
538.2906. C30H40N3O6 requires 538.2917; ∆2.0ppm). 
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Aminoisobutyryl-L-phenylalaninyl-O-tert-butyloxycarbonyl-D-Proline, H-Aib-L-Phe-D-Pro-
OtBu[162] 57 
 
 
Z-Aib-L-Phe-D-Pro-OtBu (5.11 g, 9.5 mmol) was dissolved in acetic acid (20 mL) and Pd/C 
(10% wt., 0.60 g) added. The mixture was stirred at rt under hydrogen atmosphere for 22 h. 
The reaction mixture was filtered, acetic acid removed under reduced pressure and the 
resulting residue dissolved in ethyl acetate (40 mL), washed with saturated sodium 
bicarbonate (20mL) and dried over anhydrous magnesium sulfate. Ethyl acetate was 
removed under pressure to yield 57 as a white foam (3.83 g, 100%), (2.5:1 mixture of 
rotamers), m.p. 76 oC; [α]20D   + 50 (c. 0.1 in MeOH); νmax/cm
-1 1740 (C=O, ester), 1644 (C=O, 
amide); δH (400 MHz; CDCl3) 8.15 (1H
maj , m, NHmaj), 8.00 (1Hmin , m, NHmin), 7.32 – 7.18 
(5H, m, Ar-H), 5.04 (1Hmin, m, CH(Phe)min), 4.90 (1Hmaj, m, CH(Phe)maj), 4.69 (1Hmin, m, 
CH(Pro)min), 4.23 (1Hmaj, m, CH(Pro)maj), 3.68 – 3.53 (1H , m, N-CHH), 3.23 – 2.95 (2H, m, 
Ar-CH2-C), 2.80 (1H
maj, m, N-CHHmaj), 2.35 – 2.18 (2Hmin, m, N-CHHmin + N-CH2-CH2-
CHHmin), 2.00 – 1.51 (4Hmaj + 12Hmin, m, OtBumin + N-CH2-CH2-CHH
min + N-CH2-CH2- 
CH2
maj), 1.46 (9Hmaj, s, OtBumaj), 1.36 (3Hmaj, s, Memaj), 1.31 (3Hmaj, s, Memaj), 1.27 (3Hmin, 
s, Memin), 1.05 (3Hmin, s, Memin); δC (101 MHz; CDCl3, 55 
oC) 177.0, 170.9, 169.9, 136.9, 
129.6, 129.3, 128.3, 128.2, 126.8, 126.5, 81.0, 60.2, 59.8, 51.5, 46.6, 39.5, 37.9, 28.0, 24.4, 
22.4; m/z (ES) 426 ([M + Na]+, 100%), (Found: [M + H]+, 404.2542. C22H34N3O4 requires 
404.2549; ∆1.7ppm). 
 
 
N-tert-Butyloxycarbonyl-DL-allylglycine, Boc-DL-Agl-OH[188]  
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DL-allylglycine (2.30 g, 20.0 mmol) and NaOH (0.90 g, 24.0 mmol) were dissolved in a 
mixture of 1:1 H2O/dioxane (150 mL) and cooled to 0 
oC. Di-tert-butyl-dicarbonate at 25 oC 
(5.51 mL, 24.0 mmol) was added dropwise and the reaction mixture stirred for 24 h. 
Dioxane was removed under reduced pressure and the aqueous layer washed with Et2O 
(100 ml) and acidified to pH3 with 10% KHSO4. The organic product was extracted into ethyl 
acetate (3 x 100 mL), washed with 0.001M KHSO4 and dried over magnesium sulfate. The 
solvent was removed under reduced pressure to yield Boc-DL-Agl-OH (3.50g, 81%) as a 
colourless oil,  δH (400 MHz; CDCl3) 5.83 – 5.60 (1H, m, CH=CH2), 5.23 – 5.15 (2H, m, 
CH=CH2), 5.05 (1H, m, NH), 4.42 (1H, m, N-CH), 2.60 (2H, m, CH2-CH=CH2), 1.49 (9H, s, 
OtBu). Data are in agreement with the literature[188]. 
 
N-tert-Butyloxycarbonyl-DL-allylglycinyl-aminoisobutyryl-L-phenylalaninyl-O-tert-
butyloxycarbonyl-D-Proline, Boc-DL-Agl-Aib-L-Phe-D-Pro-OtBu 58 
 
 
To a solution of H-Aib-L-Phe-D-Pro-OtBu (3.83 g, 9.5 mmol) and Boc-DL-Agl-OH (2.05 g, 9.5 
mmol) in DMF (20 mL) at 0 oC were added hydroxybenzotriazole (1.28 g, 9.5 mmol), 
dicyclohexyl carbodiimide (2.35 g, 11.4 mmol) and triethylamine (1.32 mL, 9.5 mmol) and 
the mixture stirred at rt for 8 h. The reaction mixture was filtered, DMF removed under 
reduced pressure and the resulting residue dissolved in ethyl acetate (100 mL), washed with 
10% citric acid (100 mL), 4% sodium bicarbonate (100mL), brine (50 mL) and dried over 
anhydrous MgSO4. Ethyl acetate was removed under reduced pressure and the resulting 
residue purified by silica gel chromatography using a mixture of dichloromethane and 
methanol (99:1) to yield 58 as a white foam (3.07 g, 54%), m.p. 70 - 72 oC; Rf = 0.45 (SiO2; 
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97:3 dichloromethane/methanol); [α]20D   + 30 (c. 0.1 in MeOH); νmax/cm
-1 1738 (C=O, ester), 
1642 (C=O, amide); δH (400 MHz; CDCl3) 7.30 – 7.16 (5H, m, Ar-H), 6.88 – 6.60 (2H, m, 2 x 
NH), 5.80 (1H, m, CH=CH2), 5.17 (2H, CH=CH2), 4.96 – 4.72 (1H, m, CH(Phe)), 4.25 – 3.96 
(2H, m, CH(Pro) + NH), 3.59 (1H, m, N-CHH), 3.23 – 2.17 (5H, m, CH2-Ar + CH2-CH=CH2 + 
N-CHH),  2.00 – 1.28 (28H, m, N-CH2-CH2-CH2 + 2 x O
tBu + 2 x Me); δC (101 MHz; CDCl3, 55 
oC) 173.6, 170.9, 170.7, 169.6, 169.5, 136.7, 136.6, 133.5, 133.4, 126.6, 118.8, 118.6, 82.2, 
81.2, 80.3, 59.8, 57.1, 54.5, 52.7, 52.6, 46.6, 39.2, 36.1, 31.3, 29.0, 28.3, 28.0, 25.2, 25.1, 
25.0, 24.7, 24.3, 22.3; m/z (ES) 623 ([M + Na]+, 100%), (Found: [M + H]+, 601.3589. 
C32H49N4O7 requires 601.3601; ∆2.0ppm). 
 
DL-allylglycinyl-aminoisobutyryl-L-phenylalaninyl-D-Proline.TFA, H-DL-Agl-Aib-L-Phe-D-Pro-
OH.TFA 59 
 
 
Boc-DL-Agl-Aib-L-Phe-OH-D-Pro-OtBu (601 mg, 1.0 mmol) was dissolved in TFA (3 mL) and 
the mixture stirred at rt for 3 h. The TFA was removed under reduced pressure and the 
resulting residue triturated with diethyl ether to yield 59 as a white solid (559 mg, 100%) 
(1:1 mixture of diastereomers assigned based on diastereomerically pure H-L-Agl-Aib-L-Phe-
OH-D-Pro-OH.TFA, data not shown), m.p. 126 - 128 oC; [α]20D   + 30 (c. 0.1 in MeOH); νmax/cm
-
1 1722 (C=O, carboxylic acid), 1631 (C=O, amide),  δH (400 MHz; CDCl3) 8.55 – 7.43 (m, 
COOH + NH2 + NH), 7.33 – 7.15 (5H, m, Ar-H), 5.73 (1H, m, CH=CH2), 5.28 (2H, m, 
CH=CH2), 4.99 – 4.70 (1H, m, CH(Phe)), 4.48 – 4.10 (2H, m, CH(Pro) + CH(Agl)), 3.87 – 
3.68 (2H, m, NH + N-CHH), 3.15 – 2.87 (3H, m, CH2-Ar + N-CHH), 2.70 (2H
L, m, CH2-
CH=CH2
L), 2.61 (2HD, m, CH2-CH=CH2
D), 2.11 – 1.60 (4H, m, N-CH2-CH2-CH2), 1.52 (3H
L, s, 
MeL), 1.41 (3HD, s, MeD), 1.35 (3HL, s, MeL), 1.28 (3HD, s, MeD); δC (101 MHz; CDCl3, 55 
oC) 
174.4, 174.3, 168.5, 136.2, 136.0, 127.1, 121.3, 121.2, 59.6, 57.9, 57.8, 52.5, 47.3, 38.3, 
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35.6, 35.3, 28.7, 26.7, 25.1, 24.6, 24.5; m/z (ES) 445 ([M – TFA + H]+, 100%), (Found: [M – 
TFA + H]+, 445.2443. C23H33N4O5 requires 445.2451; ∆1.8ppm). 
 
 
Cyclo(L-allylglycinyl-aminoisobutyryl-L-phenylalaninyl-D-Proline), Cyclo(-L-Agl-Aib-L-Phe-D-
Pro-) 49 
 
 
H-L-Agl-Aib-L-Phe-OH-D-Pro-OH.TFA (559 mg, 1.0 mmol) was dissolved in DMF (100 mL) and 
HATU (456 mg, 1.2 mmol) and DIEA (0.56 mL, 3.2 mmol) added in 5 aliquots at 20 minute 
intervals. The reaction was stirred for a further 1 h and DMF removed under reduced 
pressure. The resulting residue was dissolved in ethyl acetate (50 mL), washed with 10% 
citric acid (50 mL), 4% sodium bicarbonate (50mL), brine (25 mL) and dried over anhydrous 
magnesium sulfate. Ethyl acetate was removed under reduced pressure and the resulting 
residue purified by silica gel chromatography using a mixture of dichloromethane and 
methanol (99:1) to yield 49 as a white solid (137 mg, 32%), m.p. 183 - 185 oC; Rf = 0.55 (SiO2; 
97:3 dichloromethane/methanol); [α]20D   - 40 (c. 0.1 in MeOH); νmax/cm
-1 1685 (C=O), 1656 
(C=O), 1639 (C=O), δH (400 MHz; CDCl3) 7.50 (1H, d, J 10.5, NH), 7.31 – 7.20 (5H, m, ArH), 
7.17 (1H, d, J 10.0, NH), 5.91 (1H, s, NH), 5.75 (1H, ddt, J 10 and 7.0 and 7.0, CH=CH2), 
5.16 (3H, m, CH (Phe) + CH=CH2), 4.69 (1H, m, CH(Pro)), 3.28 (2H, m, CH2-Ar), 2.99 (1H, 
m, N-CHH), 2.70 (2H, m, CH2-CH=CH2), 2.27 (2H, m, N-CH2-CHH), 1.83 – 1.65 (5H, m, Me 
+ N-CH2-CH2-CH2) 4.30 (1H, m, CH(Agl)), 3.89 (1H, m, N-CHH), 3.28 (2H, m, CH2-Ar), 2.98 
(1H, m, N-CHH), 2.69 – 2.15 (4H, m, CH2-CH=CH2+ N-CH2-CHH), 1.85 – 1.72 ((5H, m, Me + 
N-CH2-CH2-CH2), 1.43 (3H, s, Me); δC (101 MHz; CDCl3) 175.6, 173.8, 172.8, 171.8, 137.1, 
132.8, 129.1, 126.7, 118.4, 58.9, 57.8, 53.5, 47.0, 35.8, 33.2, 26.5, 25.0, 24.8, 23.5; m/z (ES) 
449 ([M + Na]+, 100%), (Found: [M + H]+, 427.2332. C23H31N4O4 requires 427.2345; 
∆3.0ppm). 
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(2-Amino-phenyl)-carbamic acid tert-butyl ester[189] 
 
1,2-phenylenediamine (5.43 g, 50.0 mmol) was ground to a powder and heated to 30 oC. 
Sulfamic acid (243 mg, 2.5 mmol) was added to the powder followed by Di-tert-butyl-
dicarbonate (12.06 mL, 52.5 mmol) and the mixture stirred vigorously for 5 minutes. The 
reaction mixture was dissolved in ethyl acetate (100 mL), washed with water (2 x 100 mL) 
and brine (100 mL) and dried over magnesium sulfate. Ethyl acetate was removed under 
reduced pressure and the resulting residue purified by silica gel chromatography using a 
mixture of dichloromethane and methanol (99:1) to yield (2-amino-phenyl)-carbamic acid 
tert-butyl ester (5.77 g, 55%) as an off-white solid, m.p. 113 oC [Lit[190] ,114 oC]; δH (400 
MHz; CDCl3) 7.33 – 7.27 (1H, m, Ar-H), 7.06 – 7.00 (1H, m, Ar-H), 6.86 – 6.79 (2H, m, Ar-
H), 6.23 (1H, bs, NH), 3.82 (2H, bs, NH2), 1.53 (9H, s, OBu
t). Data are in agreement with 
the literature[190]. 
 
N-tert-Butyloxycarbonyl-L-allylglycine, Boc-L-Agl-OH[188]   
 
 
L-Allylglycine (985 mg, 6.5 mmol) and sodium hydroxide (572 mg, 14.3 mmol) were 
dissolved in a mixture of 1:1 H2O/dioxane (50 mL) and cooled to 0 
oC. Di-tert-butyl-
dicarbonate at 25 oC (2.09 mL, 9.1 mmol) was added dropwise and the reaction mixture 
stirred for 24 h. Dioxane was removed under reduced pressure and the aqueous layer 
washed with Et2O (50 ml) and acidified to pH3 with 10% KHSO4. The organic product was 
extracted into ethyl acetate (3 x 50 mL), washed with 0.001M KHSO4 (5 x 50 mL) and dried 
over magnesium sulfate. The solvent was removed under reduced pressure to yield Boc-L-
Agl-OH (1.15g, 82%) as a colourless oil, [α]20D   + 15 (c. 1.0 in CHCl3); δH (400 MHz; CDCl3) 
5.83 – 5.60 (1H, m, CH=CH2), 5.23 – 5.15 (2H, m, CH=CH2), 5.05 (1H, m, NH), 4.42 (1H, m, 
N-CH), 2.60 (2H, m, CH2-CH=CH2), 1.49 (9H, s, O
tBu). Data are in agreement with the 
literature[191]. 
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L-Allylglycinyl-aminoisobutyryl-L-phenylalaninyl-D-Proline.TFA, H-L-Agl-Aib-L-Phe-D-Pro-
OH.TFA 63   
 
 
To a solution of H-Aib-L-Phe-D-Pro-OtBu (2.16 g, 5.35 mmol) and Boc-L-Agl-OH (1.15 g, 5.35 
mmol) in DMF (20 mL) at 0 oC were added hydroxybenzotriazole (723 mg, 5.35 mmol), 
dicyclohexyl carbodiimide (1.33 g, 6.42 mmol) and triethylamine (0.934 mL, 5.35 mmol) and 
the mixture stirred at rt for 16 h. The reaction mixture was filtered, DMF removed under 
reduced pressure and the resulting residue dissolved in ethyl acetate (50 mL), washed with 
10% citric acid (50 mL), 4% sodium bicarbonate (50mL), brine (50 mL) and dried over 
anhydrous magnesium sulfate. Ethyl acetate was removed under reduced pressure and the 
resulting residue purified by silica gel chromatography using a mixture of dichloromethane 
and methanol (99:1) to yield Boc-L-Agl-Aib-L-Phe-OH-D-Pro-OtBu (1.40 g, 44%) as a white 
foam, which was subsequently dissolved in TFA (8 mL) and the mixture stirred at rt for 3 h. 
The TFA was removed under reduced pressure and the resulting residue triturated with 
diethyl ether to yield 63 as a white solid (1086 mg, 85%), m.p. 126 - 128 oC; [α]20D   + 40 (c. 
0.1 in MeOH); νmax/cm
-1 1722 (C=O, carboxylic acid), 1631 (C=O, amide),  δH (400 MHz; 
CDCl3) 8.55 – 7.43 (m, COOH + NH2 + NH), 7.33 – 7.15 (5H, m, Ar-H), 5.73 (1H, m, 
CH=CH2), 5.28 (2H, m, CH=CH2), 4.99 – 4.80 (1H, m, CH(Phe)), 4.41 – 4.15 (2H, m, 
CH(Pro) + CH(Agl)), 3.86 – 3.61 (2H, m, NH + N-CHH), 3.15 – 2.87 (3H, m, CH2-Ar + N-
CHH), 2.75 – 2.58 (2H, m, CH2-CH=CH2), 2.09 – 1.60 (4H, m, N-CH2-CH2-CH2), 1.53 – 1.23 
(6H, m, 2Me); δC (101 MHz; CDCl3) 175.0, 174.4, 174.3, 171.4, 170.9, 168.4, 136.0, 130.7, 
130.0, 129.3, 128.6, 128.5, 127.2, 121.3, 121.1, 59.4, 57.6, 57.4, 53.0, 47.4, 38.3, 35.6, 28.8, 
27.1, 25.0, 24.4, 22.6; m/z (ES) 445 ([M – TFA + H]+, 100%), (Found: [M – TFA + H]+, 
445.2451. C23H33N4O5 requires 445.2451; ∆0.0 ppm). 
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N-(N-Boc-2-aminophenyl)-2-propenamide 50 
 
 
To a solution of N-Boc-1,2-diaminobenzene (417 mg, 2 mmol) in DCM (5 mL) at 0 oC was 
added K2CO3 (304 mg, 2.2 mmol) followed by dropwise addition of acryloyl chloride (0.178 
mL, 2.2 mmol). The mixture was then allowed to warm to rt and stirred vigorously for 22 h. 
The reaction mixture was then cooled to 0 oC and water (10 mL) added. The organic layer 
was then diluted to in DCM (20 mL), washed with sat. aq. NaHCO3 (25 mL), water (25 mL) 
and brine (25 mL) before being dried over MgSO4. The solvent was removed under reduced 
pressure and the resulting residue purified by silica gel chromatography using a mixture of 
ethyl acetate/hexane (10% - 30%) to yield 50 (394 mg, 75%) as a white solid, m.p. 125 - 127 
oC; Rf = 0.20 (SiO2; 8:2 hexane/ethyl acetate); νmax/cm
-1 1730 (C=O, amide), 1656 (C=O, Boc); 
δH (400 MHz; CDCl3) 8.55 (1H, bs, NH), 7.52 (1H, m, Ar-H), 7.34 (1H, m, Ar-H), 7.13 (2H, 
m, Ar-H), 7.02 (1H, m, NH), 6.41 (1H, d, J 17.0, trans CH=CHH), 6.25 (1H, dd, J 17.0, 10.0, 
CH=CHH), 5.76 (1H, d, J 10.0, cis CH=CHH), 1.53 (9H, s, OtBu); δC (101 MHz; CDCl3) 164.3, 
154.4, 131.1, 130.5, 129.9, 127.6, 126.2, 125.4, 124.4, 81.1, 28.3; m/z (ES) 285 ([M + Na]+, 
100%), (Found: [M + Na]+, 285.1221. C14H18N2O3Na requires 285.1215; ∆2.1 ppm). 
 
 
N-(N-Boc-2-aminophenyl)-3-butenamide 52 
 
 
To a solution of 3-butenoic acid (0.188 mL, 2.2 mmol) in DCM (5 mL) at 0 oC was added 
oxalyl chloride (0.192 mL, 2.2 mmol) and a drop of DMF. The mixture was left stirring at rt 
for 2.5 h. The reaction mixture was then cooled to 0 oC and K2CO3 (608 mg, 4.4 mmol) 
added followed by N-Boc-1,2-diaminobenzene (417 mg, 2 mmol). The mixture was then 
allowed to warm to rt and stirred vigorously for 22 h. The reaction mixture was then cooled 
to 0 oC and water (10 mL) added. The organic layer was then diluted to in ethyl acetate (25 
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mL), washed with sat. aq. sodium hydrogen carbonate (25 mL), water (25 mL) and brine (25 
mL) before being dried over magnesium sulfate. The solvent was removed under reduced 
pressure and the resulting residue purified by silica gel chromatography using a mixture of 
ethyl acetate/hexane (10% - 30%) to yield 52 (449 mg, 81%) as a white solid, m.p. 84 - 85 oC; 
Rf = 0.20 (SiO2; 8:2 hexane/ethyl acetate); νmax/cm
-1 1733 (C=O, amide), 1653 (C=O, Boc); δH 
(400 MHz; CDCl3) 8.19 (1H, bs, NH), 7.51 (1H, m, Ar-H), 7.35 (1H, m, Ar-H), 7.17 (2H, m, 
Ar-H), 6.84 (1H, m, NH), 6.04 (1H, ddt, J 17.0, 10.0, 7.0, CH=CHH), 5.33 (1H, d, J 10.0, 
trans CH=CHH), 5.32 (1H, d, J 10.0, cis CH=CHH), 3.19 (2H, d, J 7.0, -CH2-), 1.53 (9H, s, 
OtBu); δC (101 MHz; CDCl3) 169.7, 154.4, 154.2, 130.8, 130.4, 126.2, 125.6, 125.4, 124.6, 
120.2, 81.0, 42.3 28.3; m/z (ES) 299 ([M + Na]+, 100%), (Found: [M + Na]+, 299.1372. 
C15H20N2O3Na requires 299.1372; ∆0.0 ppm). 
 
N-(N-Boc-2-aminophenyl)-4-pentenamide 53  
 
 
To a solution of 4-pentenoic acid (0.255 mL, 2.2 mmol) in DCM (5 mL) at 0 oC was added 
oxalyl chloride (0.192 mL, 2.2 mmol) and a drop of DMF. The mixture was left stirring at rt 
for 2.5 h. The reaction mixture was then cooled to 0 oC and K2CO3 (608 mg, 4.4 mmol) 
added followed by N-Boc-1,2-diaminobenzene (417 mg, 2 mmol). The mixture was then 
allowed to warm to rt and stirred vigorously for 23 h. The reaction mixture was then cooled 
to 0 oC and water (10 mL) added. The organic layer was then diluted to in ethyl acetate (25 
mL), washed with sat. aq. NaHCO3 (25 mL), water (25 mL) and brine (25 mL) before being 
dried over magnesium sulfate. The solvent was removed under reduced pressure and the 
resulting residue purified by silica gel chromatography using a mixture of ethyl 
acetate/hexane (10% - 30%) to yield 53 (218 mg, 38%) as a white solid, m.p. 131 - 133 oC; Rf 
= 0.25 (SiO2; 8:2 hexane/ethyl acetate); νmax/cm
-1 1726 (C=O, amide), 1646 (C=O, Boc); δH 
(400 MHz; CDCl3) 8.14 (1H, bs, NH), 7.39 (2H, m, Ar-H), 7.14 (2H, m, Ar-H), 6.96 (1H, m, 
NH), 5.88 (1H, m, CH=CHH), 5.14 (1H, d, J 10.0, trans CH=CHH), 5.07 (1H, d, J 10.0, cis 
CH=CHH), 2.46 (4H, m, -CH2-CH2-), 1.53 (9H, s, O
tBu); δC (101 MHz; CDCl3) 171.6, 154.2, 
131.0, 129.7, 126.3, 126.2, 125.5, 125.2, 124.3, 120.2, 116.0, 80.9, 36.4, 29.6, 28.3; m/z (ES) 
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313 ([M + Na]+, 100%), (Found: [M + Na]+, 313.1534. C16H22N2O3Na requires 313.1528; ∆1.9 
ppm). 
 
N-(N-Boc-2-aminophenyl)-4-vinyl benzamide 51 
 
 
To a solution of 4-vinyl benzoic acid (326 mg, 2.2 mmol) in DCM (5 mL) at 0 oC was added 
oxalyl chloride (0.192 mL, 2.2 mmol) and a drop of DMF. The mixture was left stirring at rt 
for 2.5 h. The reaction mixture was then cooled to 0 oC and K2CO3 (608 mg, 4.4 mmol) 
added followed by N-Boc-1,2-diaminobenzene (417 mg, 2 mmol). The mixture was then 
allowed to warm to rt and stirred vigorously for 24 h. The reaction mixture was then cooled 
to 0 oC and water (10 mL) added. The organic layer was then diluted to in ethyl acetate (25 
mL), washed with sat. aq. NaHCO3 (25 mL), water (25 mL) and brine (25 mL) before being 
dried over magnesium sulfate. The solvent was removed under reduced pressure and the 
resulting residue purified by silica gel chromatography using a mixture of ethyl 
acetate/hexane (10% - 30%) to yield 51 (252 mg, 39%) as a white solid, m.p. 118 - 119 oC; Rf 
= 0.15 (SiO2; 8:2 hexane/ethyl acetate); νmax/cm
-1 1698 (C=O, amide), 1653 (C=O, Boc); δH 
(400 MHz; CDCl3) 9.30 (1H, bs, NH), 7.94 (2H, m, Ar-H), 7.70 (1H, m, Ar-H), 7.47 (2H, m, 
Ar-H), 7.26 (1H, m, Ar-H), 7.14 (2H, m, Ar-H), 6.78 (1H, dd, J 18.0, 11.0, CH=CHH), 5.88 
(1H, d, J 18.0, trans CH=CHH), 5.40 (1H, d, J 10.0, cis CH=CHH), 1.53 (9H, s, OtBu); δC (101 
MHz; CDCl3) 165.5, 154.7, 141.0, 136.0, 133.3, 130.7, 130.2, 127.8, 126.3, 125.8, 125.7, 
125.3, 124.5, 124.3, 116.2, 81.2, 28.3; m/z (ES) 313 ([M + Na]+, 100%), (Found: [M + Na]+, 
313.1534. C16H22N2O3Na requires 313.1528; ∆1.9 ppm). 
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Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amido E-hex-4-enoic acid)-Aib-L-Phe-D-Pro-) 
64 
 
 
To a solution of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) (42.7 mg, 0.1 mmol) and N-(N-Boc-2-
aminophenyl)2-propenamide (26.2 mg, 0.1 mmol) in DCM (1 mL) was added Grubbs-
Hoveyda II (3.1 mg, 0.05 mmol). The mixture was left stirring at rt for 24 h. A further portion 
of Grubbs-Hoveyda II (6.2 mg, 0.1 mmol) was then added and the mixture stirred for a 
further 40 h. The reaction mixture was purified by silica gel chromatography using a mixture 
of methanol/DCM (0.5% - 3%) and then the product residue dissolved in DCM (10 mL), 
washed for 1 h at 0 oC with 30% aq. H2O2 (5mL) followed by 10% aq. sodium sulfite (10 mL) 
and then dried over MgSO4. The solvent was the removed under reduced pressure to yield 
64  (34 mg, 52%) as a white solid, m.p. 134 - 135 oC; [α]20D   - 31 (c. 1.0 in CHCl3); Rf = 0.25 
(SiO2; 98:2 DCM/methanol); νmax/cm
-1 1666 (C=C); δH (400 MHz; CDCl3) 8.45 (1H, s, NH), 
7.50 – 7.09 (9H, m, ArH), 6.85 (1H, dt, J 16.5 8.0, -CH=CHCO), 6.19 (1H, s, NH), 6.07 (1H, 
d, J 16.5, -CH=CHCO), 5.19 (1H, m, CH(Phe)), 4.67 (1H, m, CH(Pro)), 4.51 (1H, m, CH), 
3.88 (1H, m, N-CHH), 3.25 (2H, m, CH2-Ar), 2.97 (1H, m, N-CHH), 2.69 (2H, m, CH2-
CH=CH2), 2.24 (2H, m, N-CH2-CHH), 1.86 – 1.67 (5H, m, Me + N-CH2-CH2-CH2), 1.53 (9H, s, 
OtBu), 1.31 (3H, s, Me); δC (101 MHz; CDCl3) 175.5, 173.4, 173.0, 171.7, 164.0, 154.5, 139.9, 
136.9, 130.8, 129.1, 129.0, 128.7, 126.8, 126.7, 126.3, 125.4, 125.1, 124.6, 81.0, 58.9, 57.9, 
53.5, 53.0, 47.0, 35.9, 31.7, 28.3, 26.3, 25.0, 24.8, 23.5; m/z (ES) 683 ([M + Na]+, 100%), 
(Found: [M + H]+, 661.3343. C35H45N6O7 requires 661.3350; ∆1.1 ppm). 
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Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amido E-oct-4-enoic acid)-Aib-L-Phe-D-Pro-) 
66 
 
 
To a solution of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) (32.0 mg, 0.075 mmol) and N-(N-Boc-2-
aminophenyl)-2-pentenamide (87.0 mg, 0.30 mmol) in DCM (1 mL) was added Grubbs-
Hoveyda II (7.0 mg, 0.011 mmol). The mixture was left stirring at rt for 24 h. A further 
portion of Grubbs-Hoveyda II (7.0 mg, 0.011 mmol) was then added and the mixture stirred 
for a further 66 h. The reaction mixture was purified by silica gel chromatography using a 
mixture of methanol/DCM (0.5% - 3%) and then the product residue dissolved in DCM (10 
mL), washed for 1 h at 0 oC with 30% aq. H2O2 (5mL) followed by 10% aq. sodium sulfite (10 
mL) and then dried over magnesium sulfate. The solvent was the removed under reduced 
pressure to yield 66 (19 mg, 37%) as a white solid, m.p. 98 - 99 oC; [α]20D   - 32 (c. 1.0 in 
CHCl3); Rf = 0.25 (SiO2; 98:2 DCM/methanol); νmax/cm
-1 1669 (C=O, amide); δH (400 MHz; 
CDCl3) 8.29 (1H, s, NH), 7.50 – 7.13 (9H, m, ArH), 5.96 (1H, s, NH), 5.56 (2H, m, CH=CH), 
5.17 (1H, m, CH(Phe)), 4.53 (1H, m, CH(Pro)), 4.23 (1H, m, CH), 3.84 (1H, m, N-CHH), 
3.24 (2H, m, CH2-Ar), 2.96 (1H, m, N-CHH), 2.61-2.08 (8H, m, N-CH2-CHH + -CH2-CH2-CH2-
CH=CH), 1.82 – 1.60 (5H, m, Me + N-CH2-CH2-CH2), 1.53 (9H, s, O
tBu), 1.29 (3H, s, Me); δC 
(101 MHz; CDCl3) 175.6, 174.0, 172.9, 171.9, 171.3, 154.3, 137.0, 132.2, 130.6, 130.3, 130.0, 
129.0, 128.6, 126.8, 126.3, 126.1, 125.6, 125.4, 124.7, 81.0, 58.8, 57.8, 54.3, 53.4, 47.0, 
35.8, 32.1, 28.6, 28.4, 26.3, 25.0, 24.7, 23.5; m/z (ES) 711 ([M + Na]+, 100%), (Found: [M + 
H]+, 689.3671. C32H49N6O7 requires 689.3663; ∆1.2 ppm). 
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Cyclo(-L-(5-para-(2-amino-6-(N-(N-Boc-2-aminophenyl)benzamido) E-pent-4-enoic acid)-
Aib-L-Phe-D-Pro-)  67   
 
 
To a solution of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) (32.0 mg, 0.075 mmol) and N-(N-Boc-2-
aminophenyl)-4-vinyl benzamide (25.4 mg, 0.075 mmol) in DCM (1 mL) was added Grubbs-
Hoveyda II (7.0 mg, 0.011 mmol). The mixture was left stirring at rt for 24 h. A further 
portion of Grubbs-Hoveyda II (7.0 mg, 0.011 mmol) and toluene (1 mL) was then added and 
the mixture stirred for a further 96 h. The reaction mixture was purified by silica gel 
chromatography using a mixture of methanol/DCM (0.5% - 3%) and the product 67 (11 mg, 
20%) isolated as a white solid, m.p. 124 - 125 oC; [α]20D   - 48 (c. 1.0 in CHCl3); Rf = 0.20 (SiO2; 
98:2 DCM/methanol); νmax/cm
-1 1669 (C=O, amide); δH (400 MHz; CDCl3) 9.14 (1H, s, NH), 
7.50 – 7.15 (13H, m, ArH), 6.78 (1H, s, NH), 6.57 (1H, d, J 17.0,CH=CHAr), 6.23 (1H, dt, J 
17.0, 7.0 CH=CHAr), 5.96 (1H, s, NH), 5.20 (1H, m, CH(Phe)), 4.69 (1H, m, CH(Pro)), 4.40 
(1H, m, CH), 3.90 (1H, m, N-CHH), 3.28 (2H, m, CH2-Ar), 2.99 (1H, m, N-CHH), 2.70 (2H, 
m, CH2-CH=CH2), 2.27 (2H, m, N-CH2-CHH), 1.83 – 1.65 (5H, m, Me + N-CH2-CH2-CH2), 
1.54 (9H, s, OtBu), 1.36 (3H, s, Me); δC (101 MHz; CDCl3) 175.6, 175.6, 173.7, 172.9, 171.9, 
154.6, 140.5, 137.0, 133.0, 132.7, 131.1,  129.8, 129.0, 128.7, 126.8, 126.7, 126.3, 126.1, 
125.9, 125.8, 124.5, 115.5, 81.5, 59.0, 57.8, 54.0, 53.5, 47.1, 35.8, 32.7, 28.3, 26.5, 25.0, 
24.8, 23.5; m/z (ES) 759 ([M + Na]+, 100%), (Found: [M + H]+, 737.3674. C41H49N6O7 requires 
737.3663; ∆1.5 ppm). 
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Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amido hexanoic acid)-Aib-L-Phe-D-Pro-) 68  
 
 
To a solution of 64 (16.7 mg, 0.025 mmol) in EtOH (1 mL) was added Pd/C (10% wt., 4 mg). 
The mixture was stirred under H2 atmosphere at rt for 18 h. The reaction mixture was 
filtered through celite and the solvent removed under reduced pressure to yield 68  (16.7 
mg, 100%) as a white solid, m.p. 114 - 115 oC; [α]20D   - 30 (c. 1.0 in CHCl3); Rf = 0.25 (SiO2; 
98:2 DCM/methanol); νmax/cm
-1 1666 (C=O, amide); δH (400 MHz; CDCl3) 8.39 (1H, s, NH), 
7.52 – 7.06 (9H, m, ArH), 6.21 (1H, s, NH), 5.18 (1H, m, CH(Phe)), 4.68 (1H, m, CH(Pro)), 
4.34 (1H, m, CH), 3.88 (1H, m, N-CHH), 3.25 (2H, m, CH2-Ar), 2.97 (1H, m, N-CHH), 2.49 – 
2.11 (4H, m, -CH2-CH2-CH2-), 1.95 – 1.62 (7H, m, Me + -CH2-CH2-CH2 + N-CH2-CH2-CH2), 
1.54 (9H, s, OtBu), 1.32 (5H, m, Me + N-CH2-CH2-CH2); δC (101 MHz; CDCl3) 175.5, 174.2, 
172.9, 171.9, 171.4, 154.2, 137.0, 130.6, 130.1, 129.0, 128.6, 126.8, 126.2, 125.5, 125.1, 
124.7, 80.9, 58.8, 57.9, 54.1, 53.4, 47.0, 36.2, 36.0, 28.3, 26.2, 25.0, 24.7, 23.6, 21.5; m/z 
(ES) 685 ([M + Na]+, 100%), (Found: [M + H]+, 663.3502. C35H47N6O7 requires 663.3506; ∆0.6 
ppm). 
 
Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amido octanoic acid)-Aib-L-Phe-D-Pro-) 70  
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To a solution of 66 (10.0 mg, 0.0145 mmol) in EtOH (1 mL) was added Pd/C (10% wt., 4 mg). 
The mixture was stirred under H2 atmosphere at rt for 16 h. The reaction mixture was 
filtered through celite and the solvent removed under reduced pressure to yield 70 (10.0 
mg, 100%) as a white solid, m.p. 90 - 92 oC; [α]20D   - 29 (c. 1.0 in CHCl3); Rf = 0.25 (SiO2; 98:2 
DCM/methanol); νmax/cm
-1 1670 (C=O, amide); δH (400 MHz; CDCl3) 8.16 (1H, bs, NH), 7.40 
– 7.07 (9H, m, Ar-H), 5.18 (1H, m, CH(Phe)), 4.68 (1H, m, CH(Pro)), 4.24 (1H, m, CH), 3.87 
(1H, m, N-CHH), 3.25 (2H, m, CH2-Ar), 2.97 (1H, m, N-CHH), 2.44 – 2.13 (4H, m, -CH2-CH2-
CH2-CH2-), 1.86 – 1.66 (7H, m, Me + -CH2-CH2-CH2-CH2 + N-CH2-CH2-CH2), 1.54 (9H, s, 
OtBu), 1.49 -1.30 (5H, s, Me + -CH2-CH2-CH2-CH2 δC (101 MHz; CDCl3) 175.6, 174.4, 174.3, 
172.9, 172.1, 154.3, 137.0, 130.5, 129.0, 128.6, 126.7, 126.1, 125.7, 125.5, 124.8, 81.0, 58.8, 
57.8, 54.2, 53.4, 46.9, 37.1, 35.9, 28.7, 28.3, 26.4, 25.4, 25.1, 25.0, 24.9, 24.7, 23.6;  m/z (ES) 
713 ([M + Na]+, 100%), (Found: [M + Na]+, 713.3651. C37H50N6O7Na requires 713.3639; ∆1.7 
ppm). 
 
Cyclo(-L-(5-para-(2-amino-6-(N-(N-Boc-2-aminophenyl)benzamido) pentanoic acid)-Aib-L-
Phe-D-Pro-)   71 
 
 
To a solution of 67 (6.0 mg, 0.0081 mmol) in EtOH (1 mL) was added Pd/C (10% wt., 3 mg). 
The mixture was stirred under H2 atmosphere at rt for 16 h. The reaction mixture was 
filtered through celite and the solvent removed under reduced pressure to yield 71 (6.0 mg, 
100%) as a white solid, m.p. 113 - 114 oC; [α]20D   - 31 (c. 1.0 in CHCl3); Rf = 0.20 (SiO2; 98:2 
DCM/methanol); νmax/cm
-1 1663 (C=O, amide); δH (400 MHz; CDCl3) 7.33 – 7.14 (13H, m, 
Ar-H), 5.18 (1H, m, CH(Phe)), 4.67 (1H, m, CH(Pro)), 4.23 (1H, m, CH), 3.88 (1H, m, N -
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CHH), 3.26 (2H, m, -CH2-Ar), 2.97 (1H, m, N-CHH), 2.72 (2H, m, -CH2-CH2-Ar), 2.38 – 2.13 
(2H, m, -CH2-CH2-CH2-Ar), 1.90 – 1.61 (7H, m, Me + -CH2-CH2-CH2 + N-CH2-CH2-CH2), 1.54 
(9H, s, OtBu), 1.35 (3H, s, Me); δC (101 MHz; CDCl3) 175.6, 174.2, 174.3, 172.9, 171.9, 
165.5, 154.5, 146.1, 137.0, 132.1, 131.0, 129.9, 129.0, 128.6, 128.6,  127.5, 126.1, 126.1, 
125.9, 125.7, 124.5, 81.4, 58.8, 57.8, 54.3, 53.4, 47.0, 35.8, 28.6, 28.3, 27.1, 26.5, 25.0, 24.7, 
23.5; m/z (ES) 761 ([M + Na]+, 100%), (Found: [M + H]+, 739.3826. C41H51N6O7 requires 
739.3819; ∆0.9 ppm).  
 
Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amido E-hept-4-enoic acid)-Aib-L-Phe-D-
Pro-) 65  
 
 
To a solution of cyclo(-L-Agl-Aib-L-Phe-D-Pro-) (32 mg, 0.075 mmol) and N-(N-Boc-2-
aminophenyl)3-butenamide (83 mg, 0.30 mmol) in a 1:1 mixture of DCM/Toluene (2 mL) 
was added Grubbs-Hoveyda II (14 mg, 0.02 mmol). The mixture was left stirring at rt for 72 
h. A further portion of Grubbs-Hoveyda II (7 mg, 0.1 mmol) was then added and the mixture 
stirred for a further 7 d. The reaction mixture was purified by silica gel chromatography 
using a mixture of methanol/DCM (0.5% - 3%) and the solvent removed under reduced 
pressure to yield 65 (18.5 mg, 37%) as a white solid, m.p. 98 - 99 oC; [α]20D   - 32 (c. 1.0 in 
CHCl3); Rf = 0.25 (SiO2; 98:2 DCM/methanol); νmax/cm
-1 1660 (amide); δH (400 MHz; CDCl3) 
7.68 – 7.09 (9H, m, ArH), 5.96 – 5.51 (2H, m, alkene-CH), 5.18 (1H, m, CH(Phe)), 4.71 
(1H, m, CH(Pro)), 4.44 (1H, m, CH), 3.86 (1H, m, N-CHH), 3.20 (4H, m, CH2-Ar + CH2-
C=CH-CH2), 2.97 (1H, m, N-CHH), 2.62 – 2.03 (4H, m, CH2-C=CH-CH2 + N-CH2-CH2-CH2), 
1.85 – 1.26 (17H, m, 2 x Me + OtBu + -CH2-CH2-CH2); δC (101 MHz; CDCl3) 175.4, 174.1, 
174.0, 173.3, 173.0, 169.7, 154.3, 136.9, 130.4, 129.0, 128.6, 128.5, 127.8, 126.8, 126.2, 
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125.6, 125.2, 124.7, 81.0, 59.0, 58.6, 57.8, 57.7,  53.5, 53.3, 47.0, 46.8, 41.5, 40.6, 36.6, 
36.1, 35.9, 32.6, 28.3, 28.2, 26.3, 26.0, 25.0, 24.8, 24.6, 23.6, 23.4; m/z (ES) 697 ([M + Na]+, 
100%), (Found: [M + H]+, 675.3497. C36H47N6O7 requires 675.3506; ∆1.3 ppm). 
 
Cyclo(-L-(2-amino-6-(N-(N-Boc-2-aminophenyl)amidoheptanoic acid)-Aib-L-Phe-D-Pro-) 69 
 
 
To a solution of 65 (9.5 mg, 0.014 mmol) in EtOH (1 mL) was added Pd/C (10% wt., 5 mg). 
The mixture was stirred under H2 atmosphere at rt for 16 h. The reaction mixture was 
filtered through celite and the solvent removed under reduced pressure to yield 69 (7.0 mg, 
74%) as a white solid, m.p. 105 - 106 oC; [α]20D   - 24 (c. 1.0 in CHCl3); Rf = 0.25 (SiO2; 98:2 
DCM/methanol); νmax/cm
-1 1677 (C=O, amide); δH (400 MHz; CDCl3) 7.60 – 7.11 (9H, m, Ar-
H), 6.00 (1H, bs, NH), 5.18 (1H, m, CH(Phe)), 4.66 (1H, m, CH(Pro)), 4.24 (1H, m, CH), 
3.87 (1H, m, N-CHH), 3.26 (2H, m, CH2-Ar), 2.97 (1H, m, N-CHH), 2.49 – 2.12 (4H, m, -
CH2-CH2-CH2-), 1.97 – 1.61 (7H, m, Me + -CH2-CH2-CH2 + N-CH2-CH2-CH2), 1.57 – 1.51 (9H, 
m, OtBu), 1.36 (3H, s, Me); δC (101 MHz; CDCl3) 175.6, 174.3, 172.9, 171.9, 171.8, 154.3, 
137.0, 130.5, 129.0, 128.6, 126.8, 126.1, 125.7, 125.5, 124.7, 81.0, 58.8, 57.8, 54.3, 53.4, 
47.0, 36.8, 35.8, 28.5, 28.3, 26.4, 25.1, 25.0, 24.8, 24.7, 23.4;  m/z (ES) 699 ([M + Na]+, 
100%), (Found: [M + H]+, 677.3668 C36H49N6O7 requires 677.3663; ∆0.7 ppm). 
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Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido hexanoic acid)-Aib-L-Phe-D-Pro-) 45 
 
 
A solution of N-Boc-protected 2-amino phenylamide 68 (17 mg, 0.025 mmol) in DCM (1 mL) 
was cooled to 0 oC and TFA (0.2 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 45 as a white solid (12 mg, 83%), m.p. 131 - 
132 oC; [α]20D   - 10 (c. 0.1 in DMSO); Rf = 0.30 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1670 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.76 – 6.55 (9H, m, ArH), 5.00 – 4.11 (3H, 
m, CH(Phe) + CH(Pro) + CH), 3.61 – 2.83 (4H, m, N-CH2 + CH2-Ar), 2.42 – 1.17 (16H, m, 2 
x Me + -CH2-CH2-CH2- + N-CH2-CH2-CH2); δC (101 MHz; DMSO) 174.4, 173.9, 172.2, 171.9, 
170.8, 170.5, 167.6, 167.0, 137.4, 137.1, 131.6, 129.0, 128.7, 128.3, 126.5, 126.4, 124.4, 
116.1, 67. 4, 58.2, 57.4, 57.3, 57.1, 52.1, 45.6, 38.1, 35.9, 29.8, 29.0, 28.3, 28.0, 26.4, 25.9, 
25.2, 24.9, 24.2, 24.0, 23.8, 23.2, 23.1, 22.4, 20.8, 13.9, 10.8; m/z (ES) 563 ([M + H]+, 27%), 
(Found: [M + H]+, 563.2985. C30H39N6O5 requires 563.2982; ∆0.5 ppm). 
 
Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido E-hex-4-enoic acid)-Aib-L-Phe-D-Pro-) 41  
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A solution of N-Boc-protected 2-amino phenylamide 64 (17 mg, 0.026 mmol) in DCM (2 mL) 
was cooled to 0 oC and TFA (0.2 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 41  as a white solid (14 mg, 99%), m.p. 149 - 
150 oC; [α]20D   +10 (c. 0.1 in DMSO); Rf = 0.30 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1670 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.36 – 6.88 (9H, m, ArH), 6.72 (1H, m, 
CH=CH-CO), 6.29 (1H, m, CH=CH-CO),  5.02 – 4.33 (3H, m, CH(Phe) + CH(Pro) + CH), 3.66 
– 2.54 (4H, m, N-CH2 + CH2-Ar), 2.40 – 1.11 (12H, m, 2 x Me + -CH2-CH=CH- + N-CH2-CH2-
CH2); δC (101 MHz; DMSO) 174.4, 174.1, 173.2, 172.4, 171.8, 163.5, 158.5, 158.1, 140.1, 
137.4, 137.0, 129.0, 128.5, 128.4, 128.3, 126.5, 126.4, 126.3, 126.2, 125.2, 59.4, 58.3, 57.4, 
57.3, 57.2, 54.9, 53.6, 52.1, 48.7, 45.7, 35.9, 32.5, 26.4, 24.9, 24.3, 24.1, 20.9; m/z (ES) 561 
([M + H]+, 100%), (Found: [M + H]+, 561.2819. C30H37N6O5 requires 561.2825; ∆1.1 ppm). 
 
Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido E-hept-4-enoic acid)-Aib-L-Phe-D-Pro-) 42 
 
 
A solution of N-Boc-protected 2-amino phenylamide 65 (9 mg, 0.013 mmol) in DCM (1 mL) 
was cooled to 0 oC and TFA (0.1 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 42 as a white solid (7 mg, 99%), m.p. 137 - 138 
oC; [α]20D   + 30 (c. 0.1 in DMSO); Rf = 0.25 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1667 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.33 – 6.76 (9H, m, ArH), 5.73 (1H, m, 
CH=CH-CH2), 5.49 (1H, m, CH=CH-CH2), 5.00 – 4.25 (3H, m, CH(Phe) + CH(Pro) + CH), 3.60 
– 2.82 (4H, m, N-CH2 + CH2-Ar), 2.46 – 1.07 (14H, m, 2 x Me + -CH2-CH=CH-CH2- + N-CH2-
CH2-CH2); δC (101 MHz; (CD3)2SO) 174.5, 173.6, 172.3, 171.6, 169.7, 169.5, 158.1, 157.9, 
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137.5, 137.0, 129.1, 128.5, 128.4, 128.3, 127.9, 127.0, 126.9, 126.6, 126.4, 126.1, 125.7, 
125.4, 118.2, 113.8, 64.9, 59.4, 58.3, 57.2, 57.1, 54.1, 52.2, 52.1,  48.8, 45.7, 35.9, 35.1, 
32.8, 32.5, 26.4, 24.9, 24.5, 24.2, 24.1, 23.9, 21., 15.2; m/z (ES) 575 ([M + H]+, 100%), 
(Found: [M + H]+, 575.2990. C31H39N6O5 requires 575.2982; ∆1.1 ppm). 
 
Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido heptanoic acid)-Aib-L-Phe-D-Pro-) 46 
 
 
A solution of N-Boc-protected 2-amino phenylamide 69 (7 mg, 0.010 mmol) in DCM (1 mL) 
was cooled to 0 oC and TFA (0.1 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 46 as a white solid (5 mg, 84%), m.p. 128 - 129 
oC; [α]20D   + 20 (c. 0.1 in DMSO); Rf = 0.30 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1667 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.33 – 6.75 (9H, m, ArH), 5.01 – 4.21 (3H, 
m, CH(Phe) + CH(Pro) + CH), 3.60 – 2.81 (4H, m, N-CH2 + CH2-Ar), 2.43 – 1.07 (18H, m, 2 
x Me + -CH2-CH2-CH2-CH2- + N-CH2-CH2-CH2); δC (101 MHz; (CD3)2SO) 174.8, 174.5, 174.2, 
172.3, 171.8, 171.3, 170.2, 167.3, 158.0, 137.5, 137.0, 129.0, 128.5, 128.4, 128.3, 126.6, 
126.4, 126.0, 125.3, 118.0, 113.8, 64.9, 58.3, 57.2, 57.1, 55.1, 54.4, 52.1, 48.8, 45.7, 35.9, 
35.5, 35.3, 35.4, 29.3, 26.4, 25.0, 25.0, 24.9, 24.9, 24.8, 24.3, 24.1, 23.9, 21.0, 15.2; m/z (ES) 
577 ([M + Na]+, 100%), (Found: [M + H]+, 577.3141. C31H41N6O5 requires 577.3138; ∆1.1 
ppm). 
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Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido E-oct-4-enoic acid)-Aib-L-Phe-D-Pro-) 43  
 
A solution of N-Boc-protected 2-amino phenylamide 66 (9 mg, 0.013 mmol) in DCM (1 mL) 
was cooled to 0 oC and TFA (0.1 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 43 as a white solid (7 mg, 93%), m.p. 140 - 141 
oC; [α]20D   - 10 (c. 0.1 in DMSO); Rf = 0.30 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1667 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.76 – 6.55 (9H, m, ArH), 5.70 – 5.31 
(2H, m, CH=CH), 5.00 – 4.11 (3H, m, CH(Phe) + CH(Pro) + CH), 3.69 – 2.81 (4H, m, N-CH2 
+ CH2-Ar), 2.42 – 1.15 (12H, m, 2 x Me + -CH2-HC=CH- + N-CH2-CH2-CH2); δC (101 MHz; 
(CD3)2SO;) 174.8, 174.5, 174.3, 173.7, 172.3, 171.6, 170.5, 169.9, 153.8, 137.5, 137.1, 132.3, 
131.9, 129.1, 128.6, 128.4, 128.3, 126.5, 126.4, 125.8, 125.5, 124.9, 123.8, 116.7, 116.2, 
113.9, 58.3, 57.3, 57.2, 52.2, 48.7, 45.6, 35.9, 35.5, 32.5, 28.3, 28.1, 26.5, 26.3, 25.0, 24.3, 
24.2, 23.8, 21.0; m/z (ES) 589 ([M + Na]+, 71%), (Found: [M + H]+, 589.3125. C32H41N6O5 
requires 589.3138; ∆2.2 ppm). 
 
Cyclo(-L-(2-amino-6-(N-(2-aminophenyl)amido octanoic acid)-Aib-L-Phe-D-Pro-) 47  
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A solution of N-Boc-protected 2-amino phenylamide 70 (10 mg, 0.014 mmol) in DCM (1 mL) 
was cooled to 0 oC and TFA (0.1 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 47 as a white solid (8 mg, 96%), m.p. 122 - 123 
oC; [α]20D   + 30 (c. 0.1 in DMSO); Rf = 0.30 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1674 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.32 – 6.86 (9H, m, ArH), 5.00 – 4.12 (3H, 
m, CH(Phe) + CH(Pro) + CH), 3.99 – 2.82 (4H, m, N-CH2 + CH2-Ar), 2.39 – 1.10 (20H, m, 2 
x Me + 5 x -CH2- + N-CH2-CH2-CH2); δC (101 MHz; (CD3)2SO;) 174.5, 174.3, 174.2, 171.8, 
171.6, 158.4, 158.0, 154.5, 137.1, 137.0, 130.8, 129.0, 128.5, 128.4, 128.3, 126.5, 126.4, 
126.0, 125.5, 113.7, 59.4, 58.3, 57.3, 57.1, 52.1, 45.6, 35.9, 35.6, 32.5, 28.2, 26.3, 26.2, 26.0, 
25.0, 24.7, 24.3, 24.1, 23.8, 21.0; m/z (ES) 591 ([M + H]+, 100%), (Found: [M + H]+, 591.3275. 
C32H43N6O5 requires 591.3295; ∆3.4 ppm). 
 
Cyclo(-L-(5-para-(2-amino-6-(N-(2-aminophenyl)benzamido) E-pent-4-enoic acid)-Aib-L-
Phe-D-Pro-) 44 
 
 
A solution of N-Boc-protected 2-amino phenylamide 67 (5 mg, 0.007 mmol) in DCM (0.5 mL) 
was cooled to 0 oC and TFA (0.05 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 44 as a white solid (4 mg, 93%), m.p. 172 - 173 
oC; [α]20D   + 20 (c. 0.1 in DMSO); Rf = 0.25 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1667 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.99 – 6.87 (13H, m, ArH), 6.68 (1H, m, 
CH=CH-Ar), 6.34 (1H, m, CH=CH-Ar),  5.02 – 4.39 (3H, m, CH(Phe) + CH(Pro) + CH), 3.62 – 
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2.54 (4H, m, N-CH2 + CH2-Ar), 2.37 – 1.19 (12H, m, 2 x Me + -CH2-CH=CH- + N-CH2-CH2-
CH2); δC (101 MHz; DMSO)174.4, 174.3, 173.4, 172.3, 171.7, 165.0, 137.5, 137.0, 131.5, 
131.2, 129.0, 128.5, 128.4, 128.3, 127.9, 126.7, 126.5, 126.4, 125.9, 125.7, 117.0, 58.3, 57.3, 
57.2, 54.2, 52.2, 48.8, 45.7, 35.9, 28.0, 26.6, 25.0, 24.3, 24.1; m/z (ES) 637 ([M + H]+, 100%), 
(Found: [M + H]+, 637.3133. C36H41N6O5 requires 637.3138; ∆0.8 ppm). 
 
Cyclo(-L-(5-para-(2-amino-6-(N-(2-aminophenyl)benzamido) pentanoic acid)-Aib-L-Phe-D-
Pro-) 48    
 
 
A solution of N-Boc-protected 2-amino phenylamide 71 (6 mg, 0.008 mmol) in DCM (0.5 mL) 
was cooled to 0 oC and TFA (0.05 mL) added. The mixture was stirred at 0 oC for 3 h. The 
solvent and TFA were removed under reduced pressure and the remaining residue 
triturated with diethyl ether (10 mL) to yield 48 as a white solid (5 mg, 100%), m.p. 137 - 
138 oC; [α]20D   + 10 (c. 0.1 in DMSO); Rf = 0.25 (SiO2; 95:5 DCM/methanol); νmax/cm
-1 1667 
(amide); δH (400 MHz; (CD3)2SO; D2O exchange) 7.97 – 6.89 (13H, m, ArH), 5.02 – 4.12 
(3H, m, CH(Phe) + CH(Pro) + CH), 3.59 – 2.66 (4H, m, N-CH2 + CH2-Ar), 2.36 – 0.83 (16H, 
m, 2 x Me + 3 x -CH2- + N-CH2-CH2-CH2); δC (101 MHz; DMSO)174.9, 174.5, 174.2, 172.3, 
171.9, 170.1, 167.2, 165.5, 158.2, 157.9, 146.0, 137.4, 137.0, 131.7, 129.0, 128.5, 128.4, 
128.3, 128.3, 128.0, 126.8, 126.6, 126.5, 126.4, 57.3, 57.3, 57.1, 54.3, 52.1, 45.6, 35.9, 34.3, 
34.2, 28.9, 27.0, 26.9, 26.5, 25.1, 24.3, 24.0, 23.9, 23.2, 22.4, 13.9; m/z (ES) 639 ([M + H]+, 
25%), (Found: [M + H]+, 639.3275. C36H43N6O5 requires 639.3295; ∆3.1 ppm). 
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8-Oxo-8-(phenylamino)octanoic acid 76[192]  
 
 
A solution of suberic acid (2 g, 11.48 mmol) in acetic anhydride (4 mL) was heated under 
reflux for 1 h. The mixture was allowed to cool and the excess acetic anhydride and acetic 
acid removed under reduced pressure. The resulting yellow residue was dissolved in THF 
(10 mL) and aniline (0.988 mL, 11.48 mmol) added. The mixture was stirred at rt for 30 min. 
The resulting white suspension was diluted into water (20 mL) and the solid product filtered 
off and recrystallised from water/acetonitrile to yield carboxylic acid 76  as a white solid 
(391 mg, 14%), m.p. 123 – 124 oC [Lit.[192],122 – 123 oC]; [δH (400 MHz; DMSO-d6) 9.87 (1H, 
s, NH), 7.59 (2H, d J 8.0, Ar2,6H), 7.29 (2H, t J 8.0, Ar3,5H), 7.03, (1H, t J 8.0, Ar4H), 2.31 
(2H, t J 7.5, CH2- COOH), 2.21 (2H, t J 7.0, CH2- CONHPh), 1.58 (4H, m, C3,6H2), 1.30 (4H, 
m, C4,5H2);.Data are in agreement with the literature
[192]. 
 
8-Oxo-8-(N-methoxy-N-methylamino)octanoic acid 80 
 
 
A solution of suberic acid (1 g, 5.74 mmol) in DMF (10 mL) was cooled to 0 Co and 
hydroxybenzotriazole (776 mg, 5.74 mmol) followed by dicyclohexyl carbodiimide (1.42 g, 
6.89 mmol) added. To this mixture was then added a premixed solution of 
dimethylhydroxylamine hydrochloride (672 mg, 6.89 mmol) and triethylamine (0.96 mL, 
6.89 mmol) in DMF (5 mL) and the reaction mixture stirred O/N at rt. DMF was removed 
under reduced pressure and the resulting white residue dissolved in ethyl acetate (50 mL) 
and filtered. The filtrate was then washed with hydrochloric acid (2M, 20 mL) and then 
sodium bicarbonate (1M, 15 mL). The organic layer was then removed and the aqueous 
layer acidified to pH 2.0 with 2M HCl before extraction into ethyl acetate (3 x 50 mL). The 
organic layer was washed with brine (50 mL), dried over magnesium sulfate and the solvent 
removed under reduced pressure. The resulting crude product was then purified by silica 
gel chromatography using a mixture of methanol/DCM (2% - 5%)  to yield carboxylic acid 80 
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as a clear oil (423 mg, 34%), Rf = 0.20 (SiO2; 1:1 hexane/ethyl acetate); νmax/cm
-1 1733 (C=O, 
amide), 1712 (C=O, acid); δH (400 MHz; CDCl3) 3.70 (3H, s, O-Me), 3.20 (3H, s, N-Me), 2.44 
(2H, t J 7.5, CH2-CON), 2.37 (2H, t J 7.5, CH2-COO), 1.66 (4H, m, C3,6H2), 1.39 (4H, m, 
C4,5H2); δC (101 MHz; CDCl3) 179.2, 179.2, 61.2, 34.0, 32.2, 31.7, 29.0, 28.8, 24.5, 24.4; m/z 
(ES) 218 ([M + H]+, 92%), (Found: [M + H]+, 218.1390. C10H20NO4 218.1392; ∆0.9 ppm). 
 
7-(Oxiran-2-yl)heptanol-1-ol 83[193]  
 
 
A solution of 8-nonen-1-ol (0.837 mL, 5.0 mmol) in DCM (25 mL) was cooled to 0 Co and a 
solution of m-CPBA (949 mg, 5.5 mmol) in DCM (15 mL) added. The mixture was then 
stirred at rt for 6 h and a further portion of mCPBA (259 mg, 1.5 mol) added before being 
left to stir O/N. The mixture was quench with sat. aq. sodium sulfite (20 mL) and the organic 
layer washed with sodium bicarbonate (1M, 20 mL) before being dried over magnesium 
sulfate.  The solvent was removed under reduced pressure to yield epoxide 83 as a clear oil. 
(791 mg, 100%), [δH (400 MHz; CDCl3) 3.66 (2H, t, J 6.5, CH2OH), 2.93 (1H, m, CHH-CHO-), 
2.76 (1H, m, CHH-CHO-), 2.49 1H, m, CHH-CHO-), 1.67 – 1.32 (12H, m, 6 x -CH2-), 1.28 
(1H, bs, -OH);. Data are in agreement with the literature[193]. 
 
9-Chloro-8-oxo-nonenoic acid 84  
 
 
To a solution of 7-(oxiran-2-yl)heptanol-1-ol 83 (791 mg, 5.0 mmol) in THF (50 mL) was 
added acetic acid (1.43 mL, 25.0 mmol) and anhydrous lithium chloride (848 mg, 20.0 
mmol) and the mixture left stirring for 72 h. The reaction mixture was then diluted into 
water (50 mL) and the organic layer extracted into diethyl ether (3 x 40 mL) before being 
dried over magnesium sulfate. The solvent was removed under reduced pressure and the 
crude clear oil dissolved in acetone (7 mL) and cooled to 0 oC. To it was added dropwise a 
solution of Chromium trioxide (1.59 g, 15.9 mmol) and concentrated sulfuric acid (1.39 mL, 
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26.0 mmol) in water (12 mL). The mixture was stirred at rt for 5 h before being re-cooled to 
0 oC. Saturated sodium sulfite (25 mL) was then added and the mixture extracted into 
diethyl ether (3 x 25 mL). The combined organic extract were washed in water (50 mL), 
brine (50 mL) and dried over magnesium sulfate before the solvent was removed under 
reduced pressure. The crude product was recrystallised from diethyl ether/hexane to yield 
alpha keto acid 84 as a white solid (423 mg, 41%), Rf = 0.40 (SiO2; 95:5 DCM/methanol); 
m.p. 59 – 60 oC; νmax/cm
-1 1722 (C=O, ketone), 1691 (C=O, acid δH (400 MHz; CDCl3) 4.10 
(2H, s, CH2Cl), 2.61 (2H, t J 7.0, CH2-COCH2Cl), 2.37 (2H, t J 7.5, CH2-COOH), 1.65 (4H, m, 
C3,6H2), 1.36 (4H, m, C4,5H2); δC (101 MHz; CDCl3) 202.7, 179.8, 48.2, 39.6, 33.9, 28.8, 28.7, 
24.4, 23.3; m/z (ES) 224 ([M + NH4]
+, 100%), (Found: [M + NH4]
+, 224.1064. C9H19NO3Cl 
requires 224.1053; ∆4.9 ppm). 
 
9-Chloro-1,8-dioxo-1-(phenylamino)nonane 74   
 
 
To a solution of 9-chloro-8-oxo-nonenoic acid 4 (51.7 mg, 0.25 mmol) in DCM (2 mL) cooled 
to 0 Co was added oxalyl chloride (22 µL, 0.25 mmol) followed by DMF (2 µL) and the 
mixture left stirring for 30 minutes. Aniline (22 µL, 0.25 mmol) followed by triethylamine 
(52.5 µL, 0.375 mmol) were then added and the mixture stirred at room temperature for 16 
h. The reaction mixture was then diluted into DCM (10 mL) and washed with HCl (0.1M, 10 
mL), sodium bicarbonate (0.1M, 10 mL) and dried over magnesium sulfate before the 
solvent was removed under reduced pressure. The crude product was by silica gel 
chromatography using a mixture of methanol/DCM (1% - 2%)   to yield phenyl amide 74 as a 
white solid (25 mg, 36%), Rf = 0.75 (SiO2; 95:5 DCM/methanol); m.p. 95 – 96 
oC; νmax/cm
-1 
1722 (C=O, ketone), 1684 (C=O, amide); δH (400 MHz; CDCl3) 7.55 (2H, d, J 8.0, Ar2,6H), 
7.34 (3H, m, Ar3,5H + NH), 7.12 (1H, t J 8.0, Ar4H), 4.10 (2H, s, CH2Cl), 2.61 (2H, t J 7.0, 
CH2-COCH2Cl), 2.37 (2H, t J 7.5, CH2-CONHPh), 1.79 – 1.67 (4H, m, C3,6H2), 1.38 (4H, m, 
C4,5H2); δC (101 MHz; CDCl3) 202.8, 171.3, 138.0, 129.0, 124.2, 119.8, 48.4, 39.6, 37.6, 28.8, 
28.7, 25.3, 23.3; m/z (ES) 282 ([M + H]+, 50%), (Found: [M + H]+, 282.1259. C15H21NO2Cl 
requires 282.1261; ∆0.7 ppm). 
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N-(4-Amino-phenyl)-5-hexynamide 86  
 
 
To a solution of 5-hexynoic acid (0.55 mL, 10.0 mmol) and hydroxybenzotriazole (1.00 g, 6.5 
mmol) in 1:1 DCM/THF (30 mL) was added dicyclohexyl carbodiimide (1.34 g, 6.5 mmol) and 
the mixture left stirring for 5 min. A solution of 1,4-diaminobenzene (2.70 g, 25 mmol) in 1:1 
DCM/THF (30 mL) was added and the mixture left stirring at rt for 20 h. The reaction 
mixture was then diluted into DCM (60 mL), washed with water (2 x 50 mL) and dried over 
magnesium sulfate before the solvent was removed under reduced pressure. The crude 
product dissolved in acetonitrile and DCC-urea filtered off before being purified by silica gel 
chromatography using a mixture of methanol/DCM (2% - 4%)  to yield 86 as an off-white 
solid (627 mg, 59%), Rf = 0.30 (SiO2; 95:5 DCM/methanol); m.p. 60  
oC; νmax/cm
-1 2162 (CC, 
alkyne), 1658 (C=O, amide); δH (400 MHz; CDCl3) 7.29 (2H, d, J 8.0, Ar3,5H), 7.08 (1H, bs, 
NH), 6.67 (2H, d, J 8.0, Ar2,6H), 3.62 (2H, bs, NH2), 2.50 (2H, t J 7.0, CH2-CON), 2.35 (2H, 
td J 7.0 2.0, -CH2-CCH), 2.03 (1H, t J 2.0, CCH), 1.97 (2H, q, CH2-CH2-CH2); δC (101 MHz; 
CDCl3) 170.3, 143.3, 129.2, 122.1, 115.4, 83.6, 69.3, 35.8, 24.1, 17.8; m/z (ES) 203 ([M + H]
+, 
97%), (Found: [M + H]+, 203.1174. C12H15N2O requires 203.1179; ∆2.5 ppm). 
 
9-Chloro-1,8-dioxo-1-(4-(5-hexynamido)phenylamino)nonane 85  
  
 
To a solution of 9-chloro-8-oxononenoic acid 71 (38.0 mg, 0.18 mmol) in DCM (1 mL) cooled 
to 0 Co was added oxalyl chloride (16 µL, 0.18 mmol) followed by DMF (2 µL) and the 
mixture left stirring for 1 h. DCM and excess oxalyl chloride were then removed under 
reduced pressure and the residue re-dissolved in DCM (1 mL) and slowly added to a solution 
of amine 86 (37 mg, 0.18 mmol) and triethylamine (25 µL, 0.18 mmol) in DCM (1 mL). The 
mixture was stirred at room temperature for 16 h. The reaction mixture was then diluted 
into DCM (10 mL) and washed with HCl (0.1M, 10 mL), sodium bicarbonate (0.1M, 10 mL) 
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and dried over magnesium sulfate before the solvent was removed under reduced pressure. 
The mixture was then recrystallised twice from MeOH to yield 85 as a white solid (9 mg, 
13%), Rf = 0.45 (SiO2; 96:4 DCM/methanol); m.p. 144 – 145 
oC; νmax/cm
-1 2368 (CC, alkyne), 
1727 (C=O, amide); δH (400 MHz; ; (CD3)2SO) 9.89 (1H, s, NH), 9.83 (1H, s, NH), 7.48 (4H, 
s, ArH), 4.49 (2H, s, CH2Cl),  2.38 (2H, t J 7.0, CH2-CO), 2.28 – 2.18 (4H, m, 2 x CH2-CO), 
1.74 (2H, q J 7.0, CH2), 1.61 – 1.43 (4H, m, 2 x CH2), 1.32 – 1.10 (4H, m, 2 x CH2);  δC (128 
MHz; (CD3)2SO) 202.5, 171.2, 170.5, 134.7, 134.5, 132.7, 131.8, 131.1, 128.7, 123.2, 119.6, 
84.3, 71.7, 49.2, 36.4, 35.1, 34.9, 28.6, 28.4, 25.2, 25.2, 24.2, 23.1, 17.5; m/z (ES) 391 ([M + 
H]+, 8%), (Found: [M + H]+, 391.1771. C21H28N2O3Cl requires 391.1788; ∆4.3 ppm). 
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